<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="HB0D401F8F2C14820999962B65E3819AF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 7667 RH: Food and Drug Amendments of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-06-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code><calendar display="yes">Union Calendar No. 262</calendar><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7667</legis-num><associated-doc role="report" display="yes">[Report No. 117–348]</associated-doc><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220506">May 6, 2022</action-date><action-desc><sponsor name-id="E000215">Ms. Eshoo</sponsor> (for herself, <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, <cosponsor name-id="P000034">Mr. Pallone</cosponsor>, and <cosponsor name-id="M001159">Mrs. Rodgers of Washington</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><action display="yes"><action-date date="20220607">June 7, 2022</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc><action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction><action-instruction>For text of introduced bill, see copy of bill as introduced on May 6, 2022</action-instruction></action><action><action-desc><pagebreak></pagebreak></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.<pagebreak></pagebreak></official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H829D1483B59145548FA147ADD4A0BA23"><section id="H78D3C581278E4AD080ACE2FAD470A223" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Food and Drug Amendments of 2022</short-title></quote>.</text></section><section id="H36B4820D3CEC4C41B559878893756B33"><enum>2.</enum><header>Table of contents</header><text display-inline="no-display-inline">The table of contents of this Act is as follows:</text><toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded" changed="added" reported-display-style="italic" committee-id="HIF00"><toc-entry idref="H78D3C581278E4AD080ACE2FAD470A223" level="section">Sec. 1. Short title.</toc-entry><toc-entry idref="H36B4820D3CEC4C41B559878893756B33" level="section">Sec. 2. Table of contents.</toc-entry><toc-entry idref="H21839353A62147609C50E1F6753BBECF" level="title">Title I—Fees Relating to Drugs</toc-entry><toc-entry idref="HDEC2F6AC12C146D3A6EEC90A2C2378EF" level="section">Sec. 101. Short title; finding.</toc-entry><toc-entry idref="H886CAFAA9F444918B85BCF433B518AEC" level="section">Sec. 102. Definitions.</toc-entry><toc-entry idref="H3F855C4DBB5545D3B7324C7FA1D9DBAC" level="section">Sec. 103. Authority to assess and use drug fees.</toc-entry><toc-entry idref="H500DD3C854784DD0BDB8AE863BC1972D" level="section">Sec. 104. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="HE20CA73844DD44CABD30D75DAF32BEDC" level="section">Sec. 105. Sunset dates.</toc-entry><toc-entry idref="HBE8F00717E4B4D9487AFF58B08D13C6E" level="section">Sec. 106. Effective date.</toc-entry><toc-entry idref="HE4FB5FF4EB1C4585BFE0915A942B736E" level="section">Sec. 107. Savings clause.</toc-entry><toc-entry idref="H2D5599075AEE495BBB018D32321641FA" level="title">Title II—Fees Relating to Devices</toc-entry><toc-entry idref="H4452879561D24053BEB33334933AE1DC" level="section">Sec. 201. Short title; finding.</toc-entry><toc-entry idref="H6959EFF9915740C8AF55F818A9CC7793" level="section">Sec. 202. Definitions.</toc-entry><toc-entry idref="H4A60DA195ECF48209CA8E51465C31AA9" level="section">Sec. 203. Authority to assess and use device fees.</toc-entry><toc-entry idref="H52AD4A75B44E47E7BAD689C2E43B4EEA" level="section">Sec. 204. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="HBBBD199A5F4D4B42A610C70A941EF51D" level="section">Sec. 205. Conformity assessment pilot program.</toc-entry><toc-entry idref="H16847F1979084A75863108DD8A93A52B" level="section">Sec. 206. Reauthorization of third-party review program.</toc-entry><toc-entry idref="HA6FA1A5ADD7B46FAB07388E6CE2F7520" level="section">Sec. 207. Sunset dates.</toc-entry><toc-entry idref="H621E5894A0E24E9F837A72E620A47C18" level="section">Sec. 208. Effective date.</toc-entry><toc-entry idref="H3225257D64944189B070A696370AFEB2" level="section">Sec. 209. Savings clause.</toc-entry><toc-entry idref="HB889EDDAC5A541ECAC8FDCAC8405422E" level="title">Title III—Fees Relating to Generic Drugs</toc-entry><toc-entry idref="HE8CC4BE31C334B13A5B7334F05512569" level="section">Sec. 301. Short title; finding.</toc-entry><toc-entry idref="HA6B613AB0AE941D48929EA6921AEE704" level="section">Sec. 302. Authority to assess and use human generic drug fees.</toc-entry><toc-entry idref="H8A8A5A89C1CB40929D7846D12AACD36A" level="section">Sec. 303. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="H99CCD043C24047ADA3ACD50C04E1D83F" level="section">Sec. 304. Sunset dates.</toc-entry><toc-entry idref="HD28F2B14A75B40CBB8DDCA4F04195455" level="section">Sec. 305. Effective date.</toc-entry><toc-entry idref="H50EE0E5185BA4E0C9A54F68596A08C89" level="section">Sec. 306. Savings clause.</toc-entry><toc-entry idref="H8A083C08C3024165B6DA0E256C96CAA8" level="title">Title IV—Fees Relating to Biosimilar Biological Products</toc-entry><toc-entry idref="HC4E8959FC18B4DFC8536EED95F3D7A1B" level="section">Sec. 401. Short title; finding.</toc-entry><toc-entry idref="H771DDFD488BC44B28F8EF0FFD8836B5A" level="section">Sec. 402. Definitions.</toc-entry><toc-entry idref="H5545B12E326D4EB193FA3D727FEABAA6" level="section">Sec. 403. Authority to assess and use biosimilar fees.</toc-entry><toc-entry idref="H963D13AC7E0B4CB49FD0EB59B775ACC9" level="section">Sec. 404. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="H6EBE95544E254D03931F0E9B9649268B" level="section">Sec. 405. Sunset dates.</toc-entry><toc-entry idref="H785D2A1E68CE40858D95C82061C24D0E" level="section">Sec. 406. Effective date.</toc-entry><toc-entry idref="HDA3F7267B974441C833ED89CC3016538" level="section">Sec. 407. Savings clause.</toc-entry><toc-entry idref="HA944948E00CF456283F345820122510D" level="title">Title V—Improving Diversity in Clinical Studies</toc-entry><toc-entry idref="H8A34873E0D9B4C79BD792FDDBEEAAD8B" level="section">Sec. 501. Diversity action plans for clinical studies.</toc-entry><toc-entry idref="H17D65F79003F42349880E185B8F94214" level="section">Sec. 502. Evaluation of the need for FDA authority to mandate postapproval studies or postmarket surveillance due to insufficient demographic subgroup data.</toc-entry><toc-entry idref="H309A4F99880D4C03A6285A7569ABB85B" level="section">Sec. 503. Public workshops to enhance clinical study diversity.</toc-entry><toc-entry idref="H73B6DB6BF902412596526CF00835BB1E" level="section">Sec. 504. Annual summary report on progress to increase diversity in clinical studies.</toc-entry><toc-entry idref="HA92CEC138E7E4352B323EC50B90D8C51" level="section">Sec. 505. Public meeting on clinical study flexibilities initiated in response to COVID–19 pandemic.</toc-entry><toc-entry idref="HEA1808DBFF024224AB21B524AD275CBC" level="section">Sec. 506. Decentralized clinical studies.</toc-entry><toc-entry idref="H984DF19901B946BA9FEA79ABF8C8B448" level="title">Title VI—Generic Drug Competition</toc-entry><toc-entry idref="H1FE480473C3D4CDCB0F219E9B7939D6C" level="section">Sec. 601. Increasing transparency in generic drug applications.</toc-entry><toc-entry idref="HAFF266E7780E4F09A144ED64E73DA079" level="section">Sec. 602. Enhancing access to affordable medicines.</toc-entry><toc-entry idref="H30FF2E12D1A145C8BA81B0482C83D682" level="title">Title VII—Research, Development, and Supply Chain Improvements</toc-entry><toc-entry idref="H3D9A08D3E0D74BEABD088DD283366129" level="subtitle">Subtitle A—In General</toc-entry><toc-entry idref="HDB7EA72398B64012BD2720134684F03C" level="section">Sec. 701. Animal testing alternatives.</toc-entry><toc-entry idref="H7CE1EFF637CA4572A5588E7D70FB6234" level="section">Sec. 702. Emerging technology program.</toc-entry><toc-entry idref="H10AEA6EC1DC54C498BDE78E1DE955A43" level="section">Sec. 703. Improving the treatment of rare diseases and conditions.</toc-entry><toc-entry idref="HF147978FC8E041BCBCBAACA867AB0AD8" level="section">Sec. 704. Antifungal research and development.</toc-entry><toc-entry idref="HCC6B5A4E475049C58E92E9CA47BAD0C8" level="section">Sec. 705. Advancing qualified infectious disease product innovation.</toc-entry><toc-entry idref="HE70950D1BA4E425FB7BBCF2B938CF571" level="section">Sec. 706. Advanced manufacturing technologies designation pilot program.</toc-entry><toc-entry idref="H64C0E97BCFFF4396BAE66613143D5E12" level="section">Sec. 707. Public workshop on cell therapies.</toc-entry><toc-entry idref="HABD915002E794862AD8A5895F550518B" level="section">Sec. 708. Reauthorization of best pharmaceuticals for children.</toc-entry><toc-entry idref="HA140D3A4D44041C3B0B71690343C3A55" level="section">Sec. 709. Reauthorization for humanitarian device exemption and demonstration grants for improving pediatric availability.</toc-entry><toc-entry idref="H5E6BB07EBE86451FA18F2488A8956579" level="section">Sec. 710. Reauthorization of provision related to exclusivity of certain drugs containing single enantiomers.</toc-entry><toc-entry idref="H035F88099C7742AA8C337CCE1BFCED46" level="section">Sec. 711. Reauthorization of the critical path public-private partnership program.</toc-entry><toc-entry idref="HA7AF67BB67984F45B9469273B4941043" level="section">Sec. 712. Reauthorization of orphan drug grants.</toc-entry><toc-entry idref="HF74DA43AE1A746EBB5AA62E5208ABB1D" level="section">Sec. 713. Research into pediatric uses of drugs; additional authorities of Food and Drug Administration regarding molecularly targeted cancer drugs.</toc-entry><toc-entry idref="HF2F48029B55D4E008F34E2B5C6D06E0C" level="subtitle">Subtitle B—Inspections</toc-entry><toc-entry idref="H569DD81C83FF405FAE69BFFC51018F74" level="section">Sec. 721. Factory inspection.</toc-entry><toc-entry idref="H36C8801954F842C39647B52B81F47CEC" level="section">Sec. 722. Uses of certain evidence.</toc-entry><toc-entry idref="H2368E585D5B34A78A23968974B2446B9" level="section">Sec. 723. Improving FDA inspections.</toc-entry><toc-entry idref="H8E609FE61BA444B1A9A788FB58C52DD3" level="section">Sec. 724. GAO report on inspections of foreign establishments manufacturing drugs.</toc-entry><toc-entry idref="H9EE8CE03CB004998B3DDD85301CA1048" level="section">Sec. 725. Unannounced foreign facility inspections pilot program.</toc-entry><toc-entry idref="H4A2EE50C31EE467F846A732FA54D4DBF" level="section">Sec. 726. Reauthorization of inspection program.</toc-entry><toc-entry idref="H87C14AD17C38431B8541D9AB482A8660" level="section">Sec. 727. Enhancing intra-agency coordination and public health assessment with regard to compliance activities.</toc-entry><toc-entry idref="H5468090BDB114C90AC31EA5D7B516E7B" level="section">Sec. 728. Reporting of mutual recognition agreements for inspections and review activities.</toc-entry><toc-entry idref="H0C4C499339A944098476348C0CF1AEC7" level="section">Sec. 729. Enhancing transparency of drug facility inspection timelines.</toc-entry><toc-entry idref="HE4A7D6CCC1254A76A0762ACE00FD0125" level="title">Title VIII—Transparency, Program Integrity, and Regulatory Improvements</toc-entry><toc-entry idref="H61BEF6B1F9534AACA831F868DE408CD8" level="section">Sec. 801. Prompt reports of marketing status by holders of approved applications for biological products.</toc-entry><toc-entry idref="H79C6319CF4C04B6BBCDCAF35C52A85B5" level="section">Sec. 802. Encouraging blood donation.</toc-entry><toc-entry idref="H8391A71A16E74FE88DCCAFF3BE78AC05" level="section">Sec. 803. Regulation of certain products as drugs.</toc-entry><toc-entry idref="H46FADEFD8DD649D08ABEE803AFA1E6BB" level="section">Sec. 804. Postapproval studies and program integrity for accelerated approval drugs.</toc-entry><toc-entry idref="H5D9A9876CADE479ABC84D59B061BAD7D" level="section">Sec. 805. Facilitating the use of real world evidence.</toc-entry><toc-entry idref="H38E5D9571ADA4A99A921184A9C2246E3" level="section">Sec. 806. Dual Submission for Certain Devices.</toc-entry><toc-entry idref="H6D4F2FBAF95D4CC5966F53BED0C30064" level="section">Sec. 807. Medical Devices Advisory Committee meetings.</toc-entry><toc-entry idref="HF3FE18236476478081B2C7BC2BC7E50E" level="section">Sec. 808. Ensuring cybersecurity of medical devices.</toc-entry><toc-entry idref="H8DB61ECB6AC946279DA9893C31E8FF01" level="section">Sec. 809. Public docket on proposed changes to third-party vendors.</toc-entry><toc-entry idref="H41CF6BEABCA24425BC731014C2E3B022" level="section">Sec. 810. Facilitating exchange of product information prior to approval.</toc-entry><toc-entry idref="HDD334399F0F84A71980FBDE306A667CE" level="section">Sec. 811. Bans of devices for one or more intended uses.</toc-entry><toc-entry idref="H33CC9FE097634ECEAE2E602951102FEA" level="section">Sec. 812. Clarifying application of exclusive approval, certification, or licensure for drugs designated for rare diseases or conditions.</toc-entry><toc-entry idref="H8DAEBA3C1DDB4130919C271E2EEE5599" level="section">Sec. 813. GAO report on third-party review.</toc-entry><toc-entry idref="H14DA16CF3AE642FFB9AE628AC6806CCB" level="section">Sec. 814. Reporting on pending generic drug applications and priority review applications.</toc-entry><toc-entry idref="H4D5095118BD24C83A7A3288FC3B96454" level="section">Sec. 815. FDA Workforce Improvements.</toc-entry></toc></section><title id="H21839353A62147609C50E1F6753BBECF"><enum>I</enum><header>Fees Relating to Drugs</header><section id="HDEC2F6AC12C146D3A6EEC90A2C2378EF"><enum>101.</enum><header>Short title; finding</header><subsection id="H2D2223F0A5564504908C84B451CA34D1"><enum>(a)</enum><header>Short Title</header><text>This title may be cited as the <quote><short-title>Prescription Drug User Fee Amendments of 2022</short-title></quote>.</text></subsection><subsection id="H4BEDF1CC0FEC4C5AAC34DF7B68968998"><enum>(b)</enum><header>Finding</header><text>The Congress finds that the fees authorized by the amendments made by this title will be dedicated toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities, as set forth in the goals identified for purposes of part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.</text></subsection></section><section id="H886CAFAA9F444918B85BCF433B518AEC"><enum>102.</enum><header>Definitions</header><subsection id="H906B50E9D38D48A29F7846238943AE41"><enum>(a)</enum><header>Human drug application</header><text display-inline="yes-display-inline">Section 735(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g(1)</external-xref>) is amended by striking <quote>an allergenic extract product, or</quote> and inserting <quote>does not include an application with respect to an allergenic extract product licensed before October 1, 2022, does not include an application with respect to a standardized allergenic extract product submitted pursuant to a notification to the applicant from the Secretary regarding the existence of a potency test that measures the allergenic activity of an allergenic extract product licensed by the applicant before October 1, 2022, does not include an application with respect to</quote>.</text></subsection><subsection id="H5BDB6BF612DC4B00A5B43894D3EC2B23"><enum>(b)</enum><header>Prescription drug product</header><text display-inline="yes-display-inline">Section 735(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g(3)</external-xref>) is amended—</text><paragraph id="H93CC48A047FC4007BC831B9141190CA1"><enum>(1)</enum><text>by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively;</text></paragraph><paragraph id="H2E08863C36044D079A797C0A6F43D545"><enum>(2)</enum><text>by striking <quote>(3) The term</quote> and inserting <quote>(3)(A) The term</quote>;</text></paragraph><paragraph id="HA79778711A0B4FFC94AB230E77031511"><enum>(3)</enum><text>by striking <quote>Such term does not include whole blood</quote> and inserting the following: </text><quoted-block style="OLC" id="H1CD6FB0EA7AA4AF2A3E99D6A5E699B0A" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H425F29F2BE3241F0957B270B99F7DB3D" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Such term does not include whole blood</text></subparagraph><after-quoted-block>;</after-quoted-block></quoted-block></paragraph><paragraph id="H321885A4AFC24477BABA168A7F486DCC"><enum>(4)</enum><text>by striking <quote>an allergenic extract product,</quote> and inserting <quote>an allergenic extract product licensed before October 1, 2022, a standardized allergenic extract product submitted pursuant to a notification to the applicant from the Secretary regarding the existence of a potency test that measures the allergenic activity of an allergenic extract product licensed by the applicant before October 1, 2022,</quote><italic></italic>; and</text></paragraph><paragraph id="HEF0D76B38FCB4B2A8F6E8DDB5BA47EFB"><enum>(5)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="H234D978AB63147F3B2F4D5BCCCF08E31" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H3E9AA029B4764D89AD9B9D00D7F4DF04"><enum>(C)</enum><clause commented="no" display-inline="yes-display-inline" id="HA5B0702F60B240D89151CD0D15060252"><enum>(i)</enum><text display-inline="yes-display-inline">If a written request to place a product in the discontinued section of either of the lists referenced in subparagraph (A)(iii) is submitted to the Secretary on behalf of an applicant, and the request identifies the date the product is withdrawn from sale, then for purposes of assessing the prescription drug program fee under section 736(a)(2), the Secretary shall consider such product to have been included in the discontinued section on the later of—</text><subclause id="HC84C9081DCBE45AB86296E9EF78F2C2B" indent="up1"><enum>(I)</enum><text display-inline="yes-display-inline">the date such request was received; or</text></subclause><subclause id="H715A20152EA848F4B3D6C461EDCBB624" indent="up1"><enum>(II)</enum><text>if the product will be withdrawn from sale on a future date, such future date when the product is withdrawn from sale.</text></subclause></clause><clause id="H5D86B52BA3494FDD8AF96FD6DAC5EBD0" indent="up1"><enum>(ii)</enum><text>For purposes of this subparagraph, a product shall be considered withdrawn from sale once the applicant has ceased its own distribution of the product, whether or not the applicant has ordered recall of all previously distributed lots of the product, except that a routine, temporary interruption in supply shall not render a product withdrawn from sale.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H7F4172B1C96E4689A5321423BD420421"><enum>(c)</enum><header>Skin-Test diagnostic product</header><text display-inline="yes-display-inline">Section 735 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H9F088ABC7E2240C79016E8A5D833CA43" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H93B5CF08F9694C87983579B60F950A1B"><enum>(12)</enum><text display-inline="yes-display-inline">The term <term>skin-test diagnostic product</term>—</text><subparagraph id="HD64331F652464408AFA9BACF4EE84EF3"><enum>(A)</enum><text>means a product—</text><clause id="H9B6BA263F60341C0BD51F47EC600C49B"><enum>(i)</enum><text>for prick, scratch, intradermal, or subcutaneous administration;</text></clause><clause id="HF69087D553DF4B70A5B3C1AE3D82D8C9"><enum>(ii)</enum><text>expected to produce a limited, local reaction at the site of administration (if positive), rather than a systemic effect;</text></clause><clause id="HA58D16F4EB904917B2EA8DAD3B2FD44A"><enum>(iii)</enum><text>not intended to be a preventive or therapeutic intervention; and</text></clause><clause id="HE434E98C28BB4E71B5DD56E2FA846CDC"><enum>(iv)</enum><text>intended to detect an immediate- or delayed-type skin hypersensitivity reaction to aid in the diagnosis of—</text><subclause id="HE7D4FDCEF3EA4A0D9834C8BFA2DB094E"><enum>(I)</enum><text>an allergy to an antimicrobial agent;</text></subclause><subclause id="H3A5542640B884A4FA35D80360CD6CA0B"><enum>(II)</enum><text>an allergy that is not to an antimicrobial agent, if the diagnostic product was authorized for marketing prior to October 1, 2022; or</text></subclause><subclause id="H9710ECBAA7A340D0AC6CA0455F265AA7"><enum>(III)</enum><text>infection with fungal or mycobacterial pathogens; and</text></subclause></clause></subparagraph><subparagraph id="HC5FA754FE7A84C12B8C131D0B06CD84B"><enum>(B)</enum><text>includes positive and negative controls required to interpret the results of a product described in subparagraph (A).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H3F855C4DBB5545D3B7324C7FA1D9DBAC"><enum>103.</enum><header>Authority to assess and use drug fees</header><subsection id="H252A8B4AAFF842D7AB6FF98E9E67CEE0"><enum>(a)</enum><header>Types of fees</header><paragraph id="H9C393FF33F2847729686D9CDE9C105DE"><enum>(1)</enum><header>Human drug application fee</header><text display-inline="yes-display-inline">Section 736(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(a)</external-xref>) is amended—</text><subparagraph id="HFBDCCED37DCA4B379A1F72D231333F95"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding paragraph (1), by striking <quote>fiscal year 2018</quote> and inserting <quote>fiscal year 2023</quote>;</text></subparagraph><subparagraph id="HDC8791F0603949C88114021DB1B8B6FB"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1)(A), by striking <quote>(c)(5)</quote> each place it appears and inserting <quote>(c)(6)</quote>;</text></subparagraph><subparagraph id="H7501A1E7619F4F9A9C4EE6131D23256B"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (1)(C), by inserting <quote>prior to approval</quote> after <quote>or was withdrawn</quote>; and</text></subparagraph><subparagraph id="H0AB4A153F0D644D394DB90419F291289"><enum>(D)</enum><text>in paragraph (1), by adding at the end the following:</text><quoted-block style="OLC" id="H08A4F079D9834D788B741F72DCAEBE03" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H4934620A8C3445CDBF7B51475E8C0AD3"><enum>(H)</enum><header>Exception for skin-test diagnostic products</header><text display-inline="yes-display-inline">A human drug application for a skin-test diagnostic product shall not be subject to a fee under subparagraph (A).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H3DE5B0BC24FD4D70A9DE9EE7035D16A7"><enum>(2)</enum><header>Prescription drug program fee</header><text display-inline="yes-display-inline">Section 736(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(a)(2)</external-xref>) is amended—</text><subparagraph id="HE6DCF351A2954D8A9D9E12D49996AF2F"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H98253C608FBC4B6DADC40B6F4E49685E"><enum>(i)</enum><text>by striking <quote>Except as provided in subparagraphs (B) and (C)</quote> and inserting the following:</text><quoted-block style="OLC" id="H5EA52ECA6BD34502B81BC2FB08B1CB6B" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H1A135A7B74824BEDBFA9FF4FC3804CDC"><enum>(i)</enum><header>Fee</header><text display-inline="yes-display-inline">Except as provided in subparagraphs (B) and (C)</text></clause><after-quoted-block>;</after-quoted-block></quoted-block></clause><clause id="HC29E16F3D0524D87B91607606C3867BA"><enum>(ii)</enum><text>by striking <quote>subsection (c)(5)</quote> and inserting <quote>subsection (c)(6)</quote>; and </text></clause><clause id="H5D5926F0FBA54AF69C96CF0093960D83"><enum>(iii)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="HACA627CA73214B6F80BAABD1057A9DE9" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H2F71E312995F4FCEA8494203C17531EF"><enum>(ii)</enum><header>Special rule</header><text display-inline="yes-display-inline">If a drug product that is identified in a human drug application approved as of October 1 of a fiscal year is not a prescription drug product as of that date because the drug product is in the discontinued section of a list referenced in section 735(3)(A)(iii)<italic></italic>, and on any subsequent day during such fiscal year the drug product is a prescription drug product, then except as provided in subparagraphs (B) and (C), each person who is named as the applicant in a human drug application with respect to such product, and who, after September 1, 1992, had pending before the Secretary a human drug application or supplement with respect to such product, shall pay the annual prescription drug program fee established for a fiscal year under subsection (c)(6) for such prescription drug product. Such fee shall be due on the last business day of such fiscal year and shall be paid only once for each such product for a fiscal year in which the fee is payable.</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="H84F2165228394E988D93031FC3DDEACE"><enum>(B)</enum><text>by amending subparagraph (B) to read as follows:</text><quoted-block style="OLC" id="H52B5F8826BF7493696A62EA63A77F66B" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H846FEC4E936144C285285BD1A0D81193"><enum>(B)</enum><header>Exception for certain prescription drug products</header><text display-inline="yes-display-inline">A prescription drug program fee shall not be assessed for a prescription drug product under subparagraph (A) if such product is—</text><clause id="HCA0C0AF5AA3E42FF8B191F8846C0371B"><enum>(i)</enum><text display-inline="yes-display-inline">a large volume parenteral product (a sterile aqueous drug product packaged in a single-dose container with a volume greater than or equal to 100 mL, not including powders for reconstitution or pharmacy bulk packages) identified on the list compiled under section 505(j)(7);</text></clause><clause id="H46C9E611066948A4B1259E597016B96C"><enum>(ii)</enum><text display-inline="yes-display-inline">pharmaceutically equivalent (as defined in section 314.3 of title 21, Code of Federal Regulations (or any successor regulation)) to another product on the list of products compiled under section 505(j)(7) (not including the discontinued section of such list); or</text></clause><clause id="H90C17BF1B84849508421EEA5D158345D"><enum>(iii)</enum><text display-inline="yes-display-inline">a skin-test diagnostic product.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="H34DF5723CC174E1C94E6F495D94FC0A7"><enum>(b)</enum><header>Fee revenue amounts</header><paragraph id="H77ABFF0D0C49484BB0A2B55D829EB62B"><enum>(1)</enum><header>In general</header><text>Paragraph (1) of section 736(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(b)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H991831B3A68E426DB63E8EA06F4EAF00" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HF6BC51AA85A649CF9485024E6EFB15CA"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">For each of the fiscal years 2023 through 2027, fees under subsection (a) shall, except as provided in subsections (c), (d), (f), and (g), be established to generate a total revenue amount under such subsection that is equal to the sum of—</text><subparagraph id="H214C9C57042F47C697BEEB440519D241"><enum>(A)</enum><text>the annual base revenue for the fiscal year (as determined under paragraph (3));</text></subparagraph><subparagraph id="H219A680F77F64EB19F10023D003FABBA"><enum>(B)</enum><text>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));</text></subparagraph><subparagraph id="HB252C787A6AE471DB4BEED427629F207"><enum>(C)</enum><text>the dollar amount equal to the strategic hiring and retention adjustment for the fiscal year (as determined under subsection (c)(2));</text></subparagraph><subparagraph id="H3F7B099FD624408B9CA06942A13A7657"><enum>(D)</enum><text>the dollar amount equal to the capacity planning adjustment for the fiscal year (as determined under subsection (c)(3));</text></subparagraph><subparagraph id="HE48F184629A24D3AA8B1BBB859AE99E0"><enum>(E)</enum><text>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(4));</text></subparagraph><subparagraph id="H0249B3F50056446C8400A83725BC0B52"><enum>(F)</enum><text>the dollar amount equal to the additional direct cost adjustment for the fiscal year (as determined under subsection (c)(5)); and</text></subparagraph><subparagraph commented="no" id="H54058EA67E7B4377B049CEC5E49A564B"><enum>(G)</enum><text>additional dollar amounts for each fiscal year as follows:</text><clause commented="no" id="HFAA57EFB1CC44121A0FB9069549F2A82"><enum>(i)</enum><text display-inline="yes-display-inline">$65,773,693 for fiscal year 2023.</text></clause><clause commented="no" id="HF81CB64A341E4245BC6FB83F9962F0C2"><enum>(ii)</enum><text display-inline="yes-display-inline">$25,097,671 for fiscal year 2024.</text></clause><clause commented="no" id="H81BBF4366DE3446299BBDCD3AB3433FD"><enum>(iii)</enum><text display-inline="yes-display-inline">$14,154,169 for fiscal year 2025.</text></clause><clause commented="no" id="H1300ABD9EBE74ED9AD1CA8AE19E69699"><enum>(iv)</enum><text display-inline="yes-display-inline">$4,864,860 for fiscal year 2026.</text></clause><clause commented="no" id="H33AD91CA2D234038BDA85F1C94E1D701"><enum>(v)</enum><text display-inline="yes-display-inline">$1,314,620 for fiscal year 2027.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H7061389929B04E7C81B41D5E94F1A4A2"><enum>(2)</enum><header>Annual base revenue</header><text display-inline="yes-display-inline">Paragraph (3) of section 736(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(b)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H4E07AA8927384F6087F1D9C197574330" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H80262FCC270D4386A158EF7CBED3B8A5"><enum>(3)</enum><header>Annual base revenue</header><text display-inline="yes-display-inline">For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—</text><subparagraph id="H7CFF142854BC485B83AE822801567129"><enum>(A)</enum><text>for fiscal year 2023, $1,151,522,958; and</text></subparagraph><subparagraph id="H672D8561A9DE4CC5A8FFF7C1C198711F"><enum>(B)</enum><text display-inline="yes-display-inline">for fiscal years 2024 through 2027, the dollar amount of the total revenue amount established under paragraph (1) for the previous fiscal year, not including any adjustments made under subsection (c)(4) or (c)(5).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HFAE1AC9B62904D1396756EB0EF7327A2"><enum>(c)</enum><header>Adjustments; annual fee setting</header><paragraph id="H92C118D32F7B44668116894C977E8B8D"><enum>(1)</enum><header>Inflation adjustment</header><text>Section 736(c)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)(1)(B)(ii)</external-xref>) is amended by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington-Arlington-Alexandria, DC–VA–MD–WV</quote>.</text></paragraph><paragraph id="H0DA38C4617E344AABCE4D16CADA111FF"><enum>(2)</enum><header>Strategic hiring and retention adjustment</header><text display-inline="yes-display-inline">Section 736(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)</external-xref>) is amended—</text><subparagraph id="H286A0273736B45FD910D6FFCDB22E597"><enum>(A)</enum><text>by redesignating paragraphs (2) through (6) as paragraphs (3) through (7), respectively; and</text></subparagraph><subparagraph id="H67D4AB15EF7340EF9237ED089C45B226"><enum>(B)</enum><text>by inserting after paragraph (1) the following:</text><quoted-block style="OLC" id="H508A6794A246496A96ADBD6CD2F78FB4" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H79D6701F306E4833823E753003490036"><enum>(2)</enum><header>Strategic hiring and retention adjustment</header><text display-inline="yes-display-inline">For each fiscal year, after the annual base revenue established in subsection (b)(1)(A) is adjusted for inflation in accordance with paragraph (1), the Secretary shall further increase the fee revenue and fees by the following amounts:</text><subparagraph id="H73B942B697944073BCAF50A46C227C9C"><enum>(A)</enum><text>For fiscal year 2023, $9,000,000.</text></subparagraph><subparagraph id="H021E6FDFA45443E383ED073DA8AAC93A"><enum>(B)</enum><text>For each of fiscal years 2024 through 2027, $4,000,000.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H6797E50856D54AF9A2EE66E534004206"><enum>(3)</enum><header>Capacity planning adjustment</header><text display-inline="yes-display-inline">Paragraph (3), as redesignated, of section 736(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H7F89BE7072004EDFB9DA856910917F64" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H1F1CE33983C54890A327F659CC6E2F1A"><enum>(3)</enum><header>Capacity planning adjustment</header><subparagraph id="H827745AA2EAF4CCA834E1DC40550BD21"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For each fiscal year, after the annual base revenue established in subsection (b)(1)(A) is adjusted in accordance with paragraphs (1) and (2), such revenue shall be adjusted further for such fiscal year, in accordance with this paragraph, to reflect changes in the resource capacity needs of the Secretary for the process for the review of human drug applications.</text></subparagraph><subparagraph id="H288A0359282E4344968E63FA3F9B8AEC"><enum>(B)</enum><header>Methodology</header><text display-inline="yes-display-inline">For purposes of this paragraph, the Secretary shall employ the capacity planning methodology utilized by the Secretary in setting fees for fiscal year 2021, as described in the notice titled <quote>Prescription Drug User Fee Rates for Fiscal Year 2021</quote> published in the Federal Register on August 3, 2020 (85 Fed. Reg. 46651). The workload categories used in applying such methodology in forecasting shall include only the activities described in that notice and, as feasible, additional activities that are also directly related to the direct review of applications and supplements, including additional formal meeting types, the direct review of postmarketing commitments and requirements, the direct review of risk evaluation and mitigation strategies, and the direct review of annual reports for approved prescription drug products. Subject to the exceptions in the preceding sentence, the Secretary shall not include as workload categories in applying such methodology in forecasting any non-core review activities, including those activities that the Secretary referenced for potential future use in such notice but did not utilize in setting fees for fiscal year 2021.</text></subparagraph><subparagraph id="HF9DD04FDB7BE4E60B567ADBEC8460D5A"><enum>(C)</enum><header>Limitation</header><text display-inline="yes-display-inline">Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsections (b)(1)(A) (the annual base revenue for the fiscal year), (b)(1)(B) (the dollar amount of the inflation adjustment for the fiscal year), and (b)(1)(C) (the dollar amount of the strategic hiring and retention adjustment for the fiscal year).</text></subparagraph><subparagraph id="H9A524887AC3B4AEFB3B3A41C1C715336"><enum>(D)</enum><header>Publication in Federal Register</header><text display-inline="yes-display-inline">The Secretary shall publish in the Federal Register notice under paragraph (6) of the fee revenue and fees resulting from the adjustment and the methodologies under this paragraph.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HFD7A519B64D949E6A65F9ED03F6FF14A"><enum>(4)</enum><header>Operating reserve adjustment</header><text display-inline="yes-display-inline">Paragraph (4), as redesignated, of section 736(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)</external-xref>) is amended—</text><subparagraph id="H457F49E4051449168203F460F52EE09B"><enum>(A)</enum><text>by amending subparagraph (A) to read as follows:</text><quoted-block style="OLC" id="H05A84CC41E404A1EB1274892F58D2DD7" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="HB73C4689CD9048BDBD8F1D7FA06A8EFB"><enum>(A)</enum><header>Increase</header><text>For fiscal year 2023 and subsequent fiscal years, the Secretary shall, in addition to adjustments under paragraphs (1), (2), and (3), further increase the fee revenue and fees if such an adjustment is necessary to provide for operating reserves of carryover user fees for the process for the review of human drug applications for each fiscal year in at least the following amounts:</text><clause id="HEDD74787469643FF8E8A7E7CF163E158"><enum>(i)</enum><text display-inline="yes-display-inline">For fiscal year 2023, at least 8 weeks of operating reserves.</text></clause><clause id="H1219185E9DF940AA9EB8FBB935C77BC9"><enum>(ii)</enum><text>For fiscal year 2024, at least 9 weeks of operating reserves.</text></clause><clause id="HA7319A0EAB4A4C9098A692D3525C36DB"><enum>(iii)</enum><text>For fiscal year 2025 and subsequent fiscal years, at least 10 weeks of operating reserves.</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="HD9F6DAB5BB5A49A28D1EBE47D4679E63"><enum>(B)</enum><text>in subparagraph (C), by striking <quote>paragraph (5)</quote> and inserting <quote>paragraph (6)</quote>.</text></subparagraph></paragraph><paragraph id="H4108E7E56F6B4DD38C79D1FC4FE28F57"><enum>(5)</enum><header>Additional direct cost adjustment</header><text display-inline="yes-display-inline">Paragraph (5), as redesignated, of section 736(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="HFFB960AD4AA94A41A39021B4A241CA3C" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H266C4396CDDF414EA0302A6A0661D288"><enum>(5)</enum><header>Additional direct cost adjustment</header><subparagraph id="HEA6EBE595B934169A4F662719A8FEB74"><enum>(A)</enum><header>Increase</header><text>The Secretary shall, in addition to adjustments under paragraphs (1), (2), (3), and (4), further increase the fee revenue and fees—</text><clause id="H01608487F2D949AA9F93B863843804FF"><enum>(i)</enum><text>for fiscal year 2023, by $44,386,150; and</text></clause><clause id="H86F7DE448CB04DF7A7C2575657D26C5D"><enum>(ii)</enum><text>for each of fiscal years 2024 through 2027, by the amount set forth in clauses (i) through (iv) of subparagraph (B), as applicable, multiplied by the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–VA–MD–WV; Not Seasonally Adjusted; All Items; Annual Index) for the most recent year of available data, divided by such Index for 2021.</text></clause></subparagraph><subparagraph id="H4110E6D32A9A4229BA7CC3DF0D4913A8"><enum>(B)</enum><header>Applicable amounts</header><text>The amounts referred to in subparagraph (A)(ii) are the following:</text><clause id="H1F33693901AC4AEC9A521F5479123B9C"><enum>(i)</enum><text>For fiscal year 2024, $60,967,993.</text></clause><clause id="HBFD15A42F035484AB87098D5B84F6EEE"><enum>(ii)</enum><text>For fiscal year 2025, $35,799,314.</text></clause><clause id="HFF426BC1DECE42DEBE0581970EC97149"><enum>(iii)</enum><text>For fiscal year 2026, $35,799, 314.</text></clause><clause id="HD8B172A49A414CA9964E0CD5B87C98CB"><enum>(iv)</enum><text>For fiscal year 2027, $35,799,314.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HAD7F785BA09B468D9365C48849CE130C"><enum>(6)</enum><header>Annual fee setting</header><text display-inline="yes-display-inline">Paragraph (6), as redesignated, of section 736(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(c)</external-xref>) is amended by striking <quote>September 30, 2017</quote> and inserting <quote>September 30, 2022</quote>.</text></paragraph></subsection><subsection id="H8FE71CCF69BC4233A9C8213CF76F6E8C"><enum>(d)</enum><header>Crediting and availability of fees</header><text display-inline="yes-display-inline">Section 736(g)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(g)(3)</external-xref>) is amended by striking <quote>fiscal years 2018 through 2022</quote> and inserting <quote>fiscal years 2023 through 2027</quote>.</text></subsection><subsection id="H647C29FEA3BF4615B953B13C57CD5AB4"><enum>(e)</enum><header>Written requests for waivers, reductions, exemptions, and returns; disputes concerning fees</header><text display-inline="yes-display-inline">Section 736(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(i)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H85245D0D6C6044F887046B644CAA4818" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HA6C9EA9136D84075A43AC3A71E043B77"><enum>(i)</enum><header>Written requests for waivers, reductions, exemptions, and returns; disputes concerning fees</header><text display-inline="yes-display-inline">To qualify for consideration for a waiver or reduction under subsection (d), an exemption under subsection (k), or the return of any fee paid under this section, including if the fee is claimed to have been paid in error, a person shall—</text><paragraph id="HA90D34BC1089432E9CA064E19899E126"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 180 days after such fee is due, submit to the Secretary a written request justifying such waiver, reduction, exemption, or return; and</text></paragraph><paragraph id="H1D76EC84F5A846E28583828EABF8D619"><enum>(2)</enum><text>include in the request any legal authorities under which the request is made.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H09FDB56D20D04ABBA88F60A59254E41E"><enum>(f)</enum><header>Orphan drugs</header><text display-inline="yes-display-inline">Section 736(k) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(k)</external-xref>) is amended—</text><paragraph id="HF9401111F62A43F2852874C18DB9FF20"><enum>(1)</enum><text>in paragraph (1)(B), by striking <quote>during the previous year</quote> and inserting <quote>as determined under paragraph (2)</quote>; and</text></paragraph><paragraph id="HF53FFB41D1AB4ACE81F179760839B296"><enum>(2)</enum><text>by amending paragraph (2) to read as follows: </text><quoted-block style="OLC" id="HECE10A0CA5F04CE2989AC0052E61B293" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HCCF4821CC1C74A4199B3A1321364FDB8"><enum>(2)</enum><header>Evidence of qualification</header><text display-inline="yes-display-inline">An exemption under paragraph (1) applies with respect to a drug only if the applicant involved submits a certification that the applicant’s gross annual revenues did not exceed $50,000,000 for the last calendar year ending prior to the fiscal year for which the exemption is requested. Such certification shall be supported by—</text><subparagraph id="HF5445E7E1EBF4759895DB19C9E402FDE"><enum>(A)</enum><text>tax returns submitted to the United States Internal Revenue Service; or</text></subparagraph><subparagraph id="H6BB1B3FBD81847578D4BEE0587169330"><enum>(B)</enum><text>as necessary, other appropriate financial information.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="H500DD3C854784DD0BDB8AE863BC1972D" commented="no"><enum>104.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 736B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h-2">21 U.S.C. 379h–2</external-xref>) is amended—</text><paragraph id="HC2BCEBAF106A4D3AB70475F63EB2C8E7" commented="no"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(1), by striking <quote>Beginning with fiscal year 2018, not</quote> and inserting <quote>Not</quote>;</text></paragraph><paragraph id="HFC6C2FA802444A43BE84D79E5E50F6BD"><enum>(2)</enum><text>by striking <quote>Prescription Drug User Fee Amendments of 2017</quote> each place it appears and inserting <quote><short-title>Prescription Drug User Fee Amendments of 2022</short-title></quote>;</text></paragraph><paragraph id="H1C9D0BF039BD4E109035F6EC6DD45A81"><enum>(3)</enum><text display-inline="yes-display-inline">in subsection (a)(3)(A), by striking <quote>Not later than 30 calendar days after the end of the second quarter of fiscal year 2018, and not later than 30 calendar days after the end of each quarter of each fiscal year thereafter</quote> and inserting <quote>Not later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this part</quote>;</text></paragraph><paragraph id="H2E442223EBD54A7B904730FF153E97D4" commented="no"><enum>(4)</enum><text display-inline="yes-display-inline">in subsection (a)(3)(B), by adding at the end the following:</text><quoted-block style="OLC" id="H3E0D39C3A8734BBA99F9F74466286A43" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="HC0163881DFEA4B2D9EA93ACE0AAB76F2" commented="no"><enum>(v)</enum><text display-inline="yes-display-inline">For fiscal years 2023 and 2024, of the meeting requests from sponsors for which the Secretary has determined that a face-to-face meeting is appropriate, the number of face-to-face meetings requested by sponsors to be conducted in person (in such manner as the Secretary shall prescribe on the internet website of the Food and Drug Administration), and the number of such in-person meetings granted by the Secretary.</text></clause><after-quoted-block>;</after-quoted-block></quoted-block></paragraph><paragraph id="H913B60B0DD774D62B3D6C10FC837D69C"><enum>(5)</enum><text display-inline="yes-display-inline">in subsection (a)(4), by striking <quote>Beginning with fiscal year 2020, the</quote> and inserting <quote>The</quote>;</text></paragraph><paragraph id="H6AE8F3C06C56440F992B7E9C569283F4"><enum>(6)</enum><text display-inline="yes-display-inline">in subsection (b), by striking <quote>Beginning with fiscal year 2018, not</quote> and inserting <quote>Not</quote>;</text></paragraph><paragraph id="H5F125B59535D47BEAAE58A11D8200A38"><enum>(7)</enum><text display-inline="yes-display-inline">in subsection (c), by striking <quote>Beginning with fiscal year 2018, for</quote> and inserting <quote>For</quote>; and </text></paragraph><paragraph id="H755BDA2BB0324BD7A01F7BE63521448E" commented="no"><enum>(8)</enum><text>in subsection (f)—</text><subparagraph id="HF1F3523C3CA64EAFA523F2BC8D3E8180"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), in the matter preceding subparagraph (A), by striking <quote>fiscal year 2022</quote> and inserting <quote>fiscal year 2027</quote>; and </text></subparagraph><subparagraph id="H0FD70CBEA8DD4EB6BEE66FEAE0A93E2D"><enum>(B)</enum><text>in paragraph (5), by striking <quote>January 15, 2022</quote> and inserting <quote>January 15, 2027</quote>.</text></subparagraph></paragraph></section><section id="HE20CA73844DD44CABD30D75DAF32BEDC"><enum>105.</enum><header>Sunset dates</header><subsection id="H6D5141EC00454F578A99BC81DFA8C581"><enum>(a)</enum><header>Authorization</header><text>Sections 735 and 736 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g</external-xref>; 379h) shall cease to be effective October 1, 2027.</text></subsection><subsection id="H57A1E14D1DF14CD9AB5F0A9FDD7062B2"><enum>(b)</enum><header>Reporting Requirements</header><text>Section 736B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h-2">21 U.S.C. 379h–2</external-xref>) shall cease to be effective January 31, 2028.</text></subsection><subsection id="H60E1F06ABA754C0DB609580499CA7F4E"><enum>(c)</enum><header>Previous Sunset Provision</header><text display-inline="yes-display-inline">Effective October 1, 2022, subsections (a) and (b) of section 104 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="public-law" parsable-cite="pl/115/52">Public Law 115–52</external-xref>) are repealed.</text></subsection></section><section commented="no" id="HBE8F00717E4B4D9487AFF58B08D13C6E"><enum>106.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2022, or the date of the enactment of this Act, whichever is later, except that fees under part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g et seq.</external-xref>) shall be assessed for all human drug applications received on or after October 1, 2022, regardless of the date of the enactment of this Act.</text></section><section commented="no" display-inline="no-display-inline" id="HE4FB5FF4EB1C4585BFE0915A942B736E" section-type="subsequent-section"><enum>107.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g et seq.</external-xref>), as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to human drug applications and supplements (as defined in such part as of such day) that on or after October 1, 2017, but before October 1, 2022, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2023.</text></section></title><title id="H2D5599075AEE495BBB018D32321641FA"><enum>II</enum><header>Fees Relating to Devices</header><section id="H4452879561D24053BEB33334933AE1DC"><enum>201.</enum><header>Short title; finding</header><subsection id="H1E403DD5950E43928209634E28422C63"><enum>(a)</enum><header>Short title</header><text display-inline="yes-display-inline">This title may be cited as the <quote><short-title>Medical Device User Fee Amendments of 2022</short-title></quote>.</text></subsection><subsection id="HE6D082D524384FEFB63D634AEBA8EF24"><enum>(b)</enum><header>Finding</header><text display-inline="yes-display-inline">The Congress finds that the fees authorized under the amendments made by this title will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379i">21 U.S.C. 379i et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record. </text></subsection></section><section id="H6959EFF9915740C8AF55F818A9CC7793" section-type="subsequent-section"><enum>202.</enum><header>Definitions</header><text display-inline="no-display-inline">Section 737 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379i">21 U.S.C. 379i</external-xref>) is amended—</text><paragraph id="H9B246BA3AF334BE68722C19CB929DA92"><enum>(1)</enum><text>in paragraph (9)—</text><subparagraph id="H0C42BE2C6A4647FFBAC17F478F3DF0A5"><enum>(A)</enum><text>in the matter preceding subparagraph (A), by striking <quote>and premarket notification submissions</quote> and inserting <quote>premarket notification submissions, and de novo classification requests</quote>;</text></subparagraph><subparagraph id="H79B008F1074B42268233FB6AB9E350EC"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (D), by striking <quote>and submissions</quote> and inserting <quote>submissions, and requests</quote>;</text></subparagraph><subparagraph id="H4D3361F0430644358462051953581461"><enum>(C)</enum><text display-inline="yes-display-inline">in subparagraph (F), by striking <quote>and premarket notification submissions</quote> and inserting <quote>premarket notification submissions, and de novo classification requests</quote>;</text></subparagraph><subparagraph id="H929F0C7FE4BB4544A0D6ED5548F3E30E"><enum>(D)</enum><text display-inline="yes-display-inline">in each of subparagraphs (G) and (H), by striking <quote>or submissions</quote> and inserting <quote>submissions, or requests<italic></italic></quote>; and</text></subparagraph><subparagraph id="H1750B2EED6B94627AC017EB84D8DC32B"><enum>(E)</enum><text display-inline="yes-display-inline">in subparagraph (K), by striking <quote>or premarket notification submissions</quote> and inserting <quote>premarket notification submissions, or de novo classification requests</quote>; and</text></subparagraph></paragraph><paragraph id="H576AB409990841478535F45316084860"><enum>(2)</enum><text>in paragraph (11), by striking <quote>2016</quote> and inserting <quote>2021</quote>.</text></paragraph></section><section id="H4A60DA195ECF48209CA8E51465C31AA9"><enum>203.</enum><header>Authority to assess and use device fees</header><subsection id="H1F3E2668F8634645B0DBD8D6A5E16639"><enum>(a)</enum><header>Types of Fees</header><text display-inline="yes-display-inline">Section 738(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j(a)</external-xref>) is amended—</text><paragraph id="H8B9DE520E2424F1A9B1C116556F34E9D"><enum>(1)</enum><text>in paragraph (1), by striking <quote>fiscal year 2018</quote> and inserting <quote>fiscal year 2023</quote>; and</text></paragraph><paragraph id="H2049114F4CF44987B97BB940C40F719E"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="HCD72B5EAE38B4EFA91CF4553A163D86F"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H5D733C7206F94F8A8824DF02BE8C058D"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>October 1, 2017</quote> and inserting <quote>October 1, 2022</quote>;</text></clause><clause id="HA7D5D1C61CB34BA79C0E571E7C43E15D"><enum>(ii)</enum><text>in clause (iii), by striking <quote>75 percent</quote> and inserting <quote>80 percent</quote>; and</text></clause><clause id="H9919CE67FE104C93A301119A78B9BC3E"><enum>(iii)</enum><text>in clause (viii), by striking <quote>3.4 percent</quote> and inserting <quote>4.5 percent</quote>; </text></clause></subparagraph><subparagraph id="H28C78CD72B3544BAAF83473A47C8F7DC"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B)(iii), by striking <quote>or premarket notification submission</quote> and inserting <quote>premarket notification submission, or de novo classification request</quote>; and</text></subparagraph><subparagraph id="H92A89EC20C044C0A911C8017462F1FB9"><enum>(C)</enum><text>in subparagraph (C), by striking <quote>or periodic reporting concerning a class III device</quote> and inserting <quote>periodic reporting concerning a class III device, or de novo classification request</quote>.</text></subparagraph></paragraph></subsection><subsection id="H5FDE233EA4924AEE95925EA7E5C473E5"><enum>(b)</enum><header>Fee Amounts</header><text display-inline="yes-display-inline">Section 738(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j(b)</external-xref>) is amended—</text><paragraph id="HCFE2868BC18240C7A1380608188287DD"><enum>(1)</enum><text>in paragraph (1), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>;</text></paragraph><paragraph id="HD347505735644E54856EEE027A6151B4"><enum>(2)</enum><text>by amending paragraph (2) to read as follows:</text><quoted-block style="OLC" id="H6492DB603B5B4DC298B32BB66462D91C" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HED86BD0B124947A8A99EC33A9B9A64BC"><enum>(2)</enum><header>Base fee amounts specified</header><text display-inline="yes-display-inline">For purposes of paragraph (1), the base fee amounts specified in this paragraph are as follows: </text><table line-rules="hor-ver" rule-weights="4.4.4.4.0.0"><ttitle></ttitle><tgroup cols="6" thead-tbody-ldg-size="8.8.8" ttitle-size="0"><colspec coldef="txt" colname="col1" min-data-value="60"></colspec><colspec coldef="fig" colname="col2" min-data-value="8"></colspec><colspec coldef="fig" colname="col3" min-data-value="8"></colspec><colspec coldef="fig" colname="col4" min-data-value="8"></colspec><colspec coldef="fig" colname="col5" min-data-value="8"></colspec><colspec coldef="fig" colname="col6" min-data-value="8"></colspec><thead><row><entry align="center" colname="col1">Fee Type</entry><entry align="center" colname="col2">Fiscal Year 2023</entry><entry align="center" colname="col3">Fiscal Year 2024</entry><entry align="center" colname="col4">Fiscal Year 2025</entry><entry align="center" colname="col5">Fiscal Year 2026</entry><entry align="center" colname="col6">Fiscal Year 2027</entry></row></thead><tbody><row><entry colname="col1" stub-definition="txt-ldr" stub-hierarchy="1">Premarket Application</entry><entry colname="col2">$425,000</entry><entry colname="col3">$435,000</entry><entry colname="col4">$445,000</entry><entry colname="col5">$455,000</entry><entry colname="col6">$470,000</entry></row><row><entry colname="col1" stub-definition="txt-ldr" stub-hierarchy="1">Establishment Registration</entry><entry colname="col2">$6,250</entry><entry colname="col3">$6,875</entry><entry colname="col4">$7,100</entry><entry colname="col5">$7,575</entry><entry colname="col6">$8,465</entry></row></tbody></tgroup></table></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="H6B5EEEE76B80417D9482E0246D7ABF8A"><enum>(3)</enum><text>by amending paragraph (3) to read as follows:</text><quoted-block style="OLC" id="HD5DC48C734F9484FB27BDD25053F37B3" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HC1B844A58A28400399B1A2EFE3F2E308"><enum>(3)</enum><header>Total revenue amounts specified</header><text display-inline="yes-display-inline">For purposes of paragraph (1), the total revenue amounts specified in this paragraph are as follows:</text><subparagraph id="H2461E9D5121543FBB099E19F1CB81582"><enum>(A)</enum><text>$312,606,000 for fiscal year 2023.</text></subparagraph><subparagraph id="H401AD2E7092745F190A2D7DA06E0FA15"><enum>(B)</enum><text>$335,750,000 for fiscal year 2024.</text></subparagraph><subparagraph id="HDF5D41576E25409FB9E25DBC4848E353"><enum>(C)</enum><text>$350,746,400 for fiscal year 2025.</text></subparagraph><subparagraph id="H5A97638D11434E408FF3098446DA2C4D"><enum>(D)</enum><text>$366,486,300 for fiscal year 2026.</text></subparagraph><subparagraph id="H7D37953D640E4F359AE9CAA832517598"><enum>(E)</enum><text>$418,343,000 for fiscal year 2027.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H7D3B507FEC05455094986EE632AB877E"><enum>(c)</enum><header>Annual Fee Setting; Adjustments</header><text display-inline="yes-display-inline">Section 738(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j(c)</external-xref>) is amended—</text><paragraph id="H916CA2EF6608480CA6AC2675A01C98DB"><enum>(1)</enum><text>in paragraph (1), by striking <quote>2017</quote> and inserting <quote>2022</quote>;</text></paragraph><paragraph id="HAA7A74C2D2FD43F5A6FEB58BBF44B319"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (2)—</text><subparagraph id="HDF4DDCBF14524D00B7AEB29335CB26DC"><enum>(A)</enum><text>in subparagraph (A), by striking <quote>2018</quote> and inserting <quote>2023</quote>;</text></subparagraph><subparagraph id="HFEDDACC27EE34A1698EC6EF2595F694E"><enum>(B)</enum><text>in subparagraph (B)—</text><clause id="HC359655295294F4389B39ECF85EAE203"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>fiscal year 2018</quote> and inserting <quote>fiscal year 2023</quote>; and</text></clause><clause id="HE139A83842894FB184BA9C14911D5B16"><enum>(ii)</enum><text>in clause (ii), by striking <quote>fiscal year 2016</quote> and inserting <quote>fiscal year 2022</quote>;</text></clause></subparagraph><subparagraph id="HBFA06014CF4645FCA58173B7FF037B2D"><enum>(C)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington-Arlington-Alexandria, DC–VA–MD–WV</quote>; and</text></subparagraph><subparagraph id="HCF86A15825C741BB937F4817811A1680"><enum>(D)</enum><text>in subparagraph (D), in the matter preceding clause (i), by striking <quote>fiscal years 2018 through 2022</quote> and inserting <quote>fiscal years 2023 through 2027</quote>; </text></subparagraph></paragraph><paragraph id="HDF3233393514449CB3AC158D68FF4BE6"><enum>(3)</enum><text>in paragraph (3), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>; </text></paragraph><paragraph id="H34D819BF0BA94AB8BDE42D52E686C346"><enum>(4)</enum><text>by redesignating paragraphs (4) and (5) as paragraphs (7) and (8), respectively; and</text></paragraph><paragraph id="H1F6A052AFC024AA6A08B2B0C58ECAB29"><enum>(5)</enum><text>by inserting after paragraph (3) the following:</text><quoted-block style="OLC" id="H7245F1D3517D4D478E5DE14FFBA10C70" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HF95A5DE31DCD4926A5316EAF03B7C6B1"><enum>(4)</enum><header>Performance improvement adjustment</header><subparagraph id="H3C5C54745BFD45B793EB33FEE7175BDF"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For each of fiscal years 2025 through 2027, after the adjustments under paragraphs (2) and (3), the base establishment registration fee amounts for such fiscal year shall be increased to reflect changes in the resource needs of the Secretary due to improved review performance goals for the process for the review of device applications identified in the letters described in section 201(b) of the <short-title>Medical Device User Fee Amendments of 2022</short-title>, as the Secretary determines necessary to achieve an increase in total fee collections for such fiscal year equal to the following amounts:</text><clause id="H0386FF2F4061429FA8917A1537BEE662"><enum>(i)</enum><text display-inline="yes-display-inline">For fiscal year 2025, the product of—</text><subclause id="H112F1E24092D4A49A0FD0F9FBA7DED88"><enum>(I)</enum><text>the amount determined under subparagraph (B)(i)(I); and</text></subclause><subclause id="H1BFC69DA22414FBBA77D6BB27D4AD9F0"><enum>(II)</enum><text>the applicable inflation adjustment under paragraph (2)(B) for such fiscal year.</text></subclause></clause><clause id="H0B6FAD7347774395BC13A0676712DF92"><enum>(ii)</enum><text>For fiscal year 2026, the product of—</text><subclause id="H2A18F3F3952C4721B100B0D014D9C9A1"><enum>(I)</enum><text>the sum of the amounts determined under subparagraphs (B)(i)(II), (B)(ii)(I), and (B)(iii)(I); and</text></subclause><subclause id="HD1D1A819E1594D689FB8835B23B60D19"><enum>(II)</enum><text>the applicable inflation adjustment under paragraph (2)(B) for such fiscal year.</text></subclause></clause><clause id="HB0A6AC788612415889E17D8E7C63AE7B"><enum>(iii)</enum><text>For fiscal year 2027, the product of—</text><subclause id="H8BB36A0D210C4297A815CF20825D255B"><enum>(I)</enum><text>the sum of the amounts determined under subparagraphs (B)(i)(III), (B)(ii)(II), and (B)(iii)(II); and</text></subclause><subclause id="H781925D5A1FD484CBEE7E528AC1CC9DC"><enum>(II)</enum><text>the applicable inflation adjustment under paragraph (2)(B) for such fiscal year.</text></subclause></clause></subparagraph><subparagraph id="H11271AA7994749B9B62D98E0C6BBB6D4"><enum>(B)</enum><header>Amounts</header><clause id="H70AC614DE86B46AEBA517AC66418764E"><enum>(i)</enum><header>Pre-submission amount</header><text display-inline="yes-display-inline">For purposes of subparagraph (A), with respect to the pre-submission written feedback goal, the amounts determined under this subparagraph are as follows:</text><subclause id="H98F12F26E1A04FB1A2D3E35D05886772"><enum>(I)</enum><text>For fiscal year 2025, $15,396,600 if such goal for fiscal year 2023 is met.</text></subclause><subclause id="HE441A9810C38445AA8E22AAC47B89E2C"><enum>(II)</enum><text>For fiscal year 2026:</text><item id="HD67188F5697E4EF2AE29AAAA4977A649"><enum>(aa)</enum><text>$15,396,600 if such goal for fiscal year 2023 is met and such goal for fiscal year 2024 is not met.</text></item><item id="H9AC51DF6D78B410899FD35AA5BE15338"><enum>(bb)</enum><text>$36,792,200 if such goal for fiscal year 2024 is met.</text></item></subclause><subclause id="H7E1E9D8E5A904D4283219A81A2C975F4"><enum>(III)</enum><text>For fiscal year 2027:</text><item id="H968C526F7CCA4DC989E31D48CC562785"><enum>(aa)</enum><text>$15,396,600 if such goal for fiscal year 2023 is met and such goal for each of fiscal years 2024 and 2025 is not met.</text></item><item id="H596A6699EFC44B61B13D9387AC4ACB35"><enum>(bb)</enum><text>$36,792,200 if such goal for fiscal year 2024 is met and such goal for fiscal year 2025 is not met.</text></item><item id="H43D44FAB8FB8470DBA66D35AAA446177"><enum>(cc)</enum><text>$40,572,600 if such goal for fiscal year 2025 is met.</text></item></subclause></clause><clause id="HABCD0F8872494A80864C985365BFBF30"><enum>(ii)</enum><header>De novo classification amount</header><text display-inline="yes-display-inline">For purposes of subparagraph (A), with respect to the de novo decision goal, the amounts determined under this subparagraph are as follows:</text><subclause id="HC01745025F5D4B3C9F81422288592FDF"><enum>(I)</enum><text>For fiscal year 2026, $6,323,500 if such goal for fiscal year 2023 is met.</text></subclause><subclause id="H65C55F7DCBB2473ABBD77C4639253D65"><enum>(II)</enum><text>For fiscal year 2027:</text><item id="H3E52BC16F72E423AB48587D9019BA841"><enum>(aa)</enum><text>$6,323,500 if such goal for fiscal year 2023 is met and such goal for fiscal year 2024 is not met.</text></item><item id="HC5D8EB1B88794317B9CB4CBC2040DFBB"><enum>(bb)</enum><text>$11,765,400 if such goal for fiscal year 2024 is met.</text></item></subclause></clause><clause id="HFC52E032E58145E7BF03A73D387E7644"><enum>(iii)</enum><header>Premarket notification and premarket approval amount</header><text display-inline="yes-display-inline">For purposes of subparagraph (A), with respect to the 510(k) decision goal, 510(k) shared outcome total time to decision goal, PMA decision goal, and PMA shared outcome total time to decision goal, the amounts determined under this subparagraph are as follows:</text><subclause id="H9BF325692C2C4A628FD1EFCA3FA07ACE"><enum>(I)</enum><text>For fiscal year 2026, $1,020,000 if the four goals for fiscal year 2023 are met.</text></subclause><subclause id="H421295723F614838B22B39E7AEF0E3C8"><enum>(II)</enum><text>For fiscal year 2027:</text><item id="H38F1FBFBDF8D44D98477792D61F9CD3C"><enum>(aa)</enum><text>$1,020,000 if the four goals for fiscal year 2023 are met and one or more of the four goals for fiscal year 2024 are not met.</text></item><item id="H18E6EB04A5774C319072F20348088C2F"><enum>(bb)</enum><text display-inline="yes-display-inline">$3,906,000 if the four goals for fiscal year 2024 are met.</text></item></subclause></clause></subparagraph><subparagraph id="HFAF7E4BEFCFF4B439A5D7E8600A00437"><enum>(C)</enum><header>Performance calculation</header><text display-inline="yes-display-inline">For purposes of this paragraph, performance of the goals listed in subparagraph (D) shall be determined as specified in the letters described in section 201(b) of the <short-title>Medical Device User Fee Amendments of 2022</short-title> and based on data available as of the following dates:</text><clause id="HD4A4AB4C331F495FAE33BBE7E3635938"><enum>(i)</enum><text>The performance of the pre-submission written feedback goal shall be based on data available as of—</text><subclause id="H28AF04BB12494B75B44FDCF51B6AAAD6"><enum>(I)</enum><text>for fiscal year 2023, March 31, 2024;</text></subclause><subclause id="HDD6FAEA6EE804DE2BB73A6A7E34D5695"><enum>(II)</enum><text>for fiscal year 2024, March 31, 2025; and</text></subclause><subclause id="H6DDDE1150AB44E499C171EB2520F09CA"><enum>(III)</enum><text>for fiscal year 2025, March 31, 2026.</text></subclause></clause><clause id="H376700CC4D3443E38671DB224B87E94B"><enum>(ii)</enum><text>The performance of the de novo decision goal, 510(k) decision goal, 510(k) shared outcome total time to decision goal, PMA decision goal, and PMA shared outcome total time to decision goal shall be based on data available as of—</text><subclause id="HD4A7F61C956F401FB5D523C33C999D20"><enum>(I)</enum><text>for fiscal year 2023, March 31, 2025; and</text></subclause><subclause id="HEF5A9AEBD4674B03BEDC5E8C388076BF"><enum>(II)</enum><text>for fiscal year 2024, March 31, 2026.</text></subclause></clause></subparagraph><subparagraph id="HADED411774A948F7BBD9E4B716FB27D3"><enum>(D)</enum><header>Goals defined</header><text display-inline="yes-display-inline">For purposes of this paragraph, the terms <term>pre-submission written feedback goal</term>, <term>de novo decision goal</term>, <term>510(k) decision goal</term>, <term>510(k) shared outcome total time to decision goal</term>, <term>PMA decision goal</term>, and <term>PMA shared outcome total time to decision goal</term> refer to the goals identified by the same names in the letters described in section 201(b) of the <short-title>Medical Device User Fee Amendments of 2022</short-title>.</text></subparagraph></paragraph><paragraph id="HBB596634973C4A57B06B14D675493D5A"><enum>(5)</enum><header>Hiring adjustment</header><subparagraph id="H48048F3EB9FF47B084B5E739BA3F8452"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For each of fiscal years 2025 through 2027, after the adjustments under paragraphs (2), (3), and (4), if applicable, if the number of hires to support the process for the review of device applications falls below the thresholds specified in subparagraph (B) for the applicable fiscal years, the base establishment registration fee amounts shall be decreased as the Secretary determines necessary to achieve a reduction in total fee collections equal to the hiring adjustment amount under subparagraph (C).</text></subparagraph><subparagraph id="H8D78B2AA7E704DBFA2B5795ADCCCDC6B"><enum>(B)</enum><header>Thresholds</header><text display-inline="yes-display-inline">The thresholds specified in this subparagraph are as follows:</text><clause id="HFE0EF367A3694E91914312EC41DADDCB"><enum>(i)</enum><text>For fiscal year 2025, the threshold is 123 hires for fiscal year 2023.</text></clause><clause id="HBA41846C21994ECEAE89D788FCA04F4A"><enum>(ii)</enum><text>For fiscal year 2026, the threshold is 38 hires for fiscal year 2024.</text></clause><clause id="H84DF9D3E037A454D8315782F8E409FB0"><enum>(iii)</enum><text>For fiscal year 2027, the threshold is—</text><subclause id="H8AC65A66C226446EA5AA67E75DE620E6"><enum>(I)</enum><text>22 hires for fiscal year 2025 if the base establishment registration fees are not increased by the amount determined under paragraph (4)(A)(i); or</text></subclause><subclause id="H13F53D06EF6E49D59F0D99E31773F936"><enum>(II)</enum><text>75 hires for fiscal year 2025 if such fees are so increased.</text></subclause></clause></subparagraph><subparagraph id="H4969A08715184A1481B689C5B8CD72E5"><enum>(C)</enum><header>Hiring adjustment amount</header><text display-inline="yes-display-inline">The hiring adjustment amount for fiscal year 2025 and each subsequent fiscal year is the product of—</text><clause id="H27ECC0700568472696D0B991761A1411"><enum>(i)</enum><text>the number of hires by which the hiring goal specified in subparagraph (D) for the fiscal year before the prior fiscal year was not met;</text></clause><clause id="H8E3384884B0349A4BE6E3705CC6B73BC"><enum>(ii)</enum><text>$72,877; and</text></clause><clause id="H5730FF4DAFBD456C97A8B25235EBFFB7"><enum>(iii)</enum><text>the applicable inflation adjustment under paragraph (2)(B) for the fiscal year for which the hiring goal was not met.</text></clause></subparagraph><subparagraph id="H1C7B5123D39E4544B9A389D039AE161D"><enum>(D)</enum><header>Hiring goals</header><text display-inline="yes-display-inline">The hiring goals for each of fiscal years 2023 through 2025 are as follows:</text><clause id="H0EA894FE349543779F32646984D6E956"><enum>(i)</enum><text>For fiscal year 2023, 144 hires.</text></clause><clause id="H808970BE1A354704A28E36A02E170608"><enum>(ii)</enum><text>For fiscal year 2024, 42 hires.</text></clause><clause id="HC32A43FEC6F54059B6874CCC10342B1C"><enum>(iii)</enum><text>For fiscal year 2025:</text><subclause id="H8BB5107460B4475EB158B7E8289BE2DA"><enum>(I)</enum><text>24 hires if the base establishment registration fees are not increased by the amount determined under paragraph (4)(A)(i).</text></subclause><subclause id="H9DD64F31992148C0B4E20DB8EC099A79"><enum>(II)</enum><text>83 hires if the base establishment registration fees are increased by the amount determined under paragraph (4)(A)(i).</text></subclause></clause></subparagraph><subparagraph id="H0A6C190ACDB945D885AE5F1DB11F9F02"><enum>(E)</enum><header>Number of hires</header><text display-inline="yes-display-inline">For purposes of this paragraph, the number of hires shall be determined by the Secretary as set forth in the letters described in section 201(b) of the <short-title>Medical Device User Fee Amendments of 2022</short-title>.</text></subparagraph></paragraph><paragraph id="H81A893CD915445D583B22AA12EEBA319"><enum>(6)</enum><header>Operating reserve adjustment</header><subparagraph id="H60FC12F960704CC7BC6A1BDC091121F3"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For each of fiscal years 2023 through 2027, after the adjustments under paragraphs (2), (3), (4), and (5), if applicable, if the Secretary has operating reserves of carryover user fees for the process for the review of device applications in excess of the designated amount in subparagraph (B), the Secretary shall decrease the base establishment registration fee amounts to provide for not more than such designated amount of operating reserves.</text></subparagraph><subparagraph id="HA646FE31B0F147E4A4305E5CDF3C3161"><enum>(B)</enum><header>Designated amount</header><text display-inline="yes-display-inline">Subject to subparagraph (C), for each fiscal year, the designated amount in this subparagraph is equal to the sum of—</text><clause id="H7870832CA2A144BBA0BBB4024E63126A"><enum>(i)</enum><text>13 weeks of operating reserves of carryover user fees; and</text></clause><clause id="H75D9F8EF95CB4ECA8ABC5BC6E595B167"><enum>(ii)</enum><text display-inline="yes-display-inline">1 month of operating reserves maintained pursuant to paragraph (8).</text></clause></subparagraph><subparagraph id="H0EF83A0DCD3D4E14B0AF98E4C2FD162E"><enum>(C)</enum><header>Excluded amount</header><text display-inline="yes-display-inline">For the period of fiscal years 2023 through 2026, a total amount equal to $118,000,000 shall not be considered part of the designated amount under subparagraph (B) and shall not be subject to the decrease under subparagraph (A).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H1C00833A57934928877E9FF2F172EEC6"><enum>(d)</enum><header>Small businesses</header><text display-inline="yes-display-inline">Section 738 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j</external-xref>) is amended in each of subsections (d)(2)(B)(iii) and (e)(2)(B)(iii) by inserting <quote>, if extant,</quote> after <quote>national taxing authority</quote>.</text></subsection><subsection id="H05A226DEC9FC4B44A8EFA570A1D0DA4A"><enum>(e)</enum><header>Conditions</header><text display-inline="yes-display-inline">Section 738(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j(g)</external-xref>) is amended—</text><paragraph id="H4083956F70AC49AD9B69074CEBFCAFBF"><enum>(1)</enum><text>in paragraph (1)(A), by striking <quote>$320,825,000</quote> and inserting <quote>$398,566,000</quote>; and</text></paragraph><paragraph id="H22F5AC3E5A9B4DE49811DEB22E010E07"><enum>(2)</enum><text>in paragraph (2), by inserting <quote>de novo classification requests,</quote> after <quote>class III device,</quote>. </text></paragraph></subsection><subsection id="HE1D7866F911C4E3E864199BF7AADE708"><enum>(f)</enum><header>Crediting and Availability of Fees</header><text display-inline="yes-display-inline">Section 738(h)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j">21 U.S.C. 379j(h)(3)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="HAC7DA00152134DE799926B8A5137F19B" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HE149676B9FAC4E5A881CDE2404B8CD44"><enum>(3)</enum><header>Authorization of appropriations</header><subparagraph id="HF29917D516B34BF18AE3D8B7AAD704E6"><enum>(A)</enum><header>In general</header><text>For each of fiscal years 2023 through 2027, there is authorized to be appropriated for fees under this section an amount equal to the revenue amount determined under subparagraph (B), less the amount of reductions determined under subparagraph (C).</text></subparagraph><subparagraph id="H687CBF9F3FA64E3E8EAA8173C561294F"><enum>(B)</enum><header>Revenue amount</header><text>For purposes of this paragraph, the revenue amount for each fiscal year is the sum of—</text><clause id="H2BC228D8726E4DC2AF80305E5CD8F352"><enum>(i)</enum><text>the total revenue amount under subsection (b)(3) for the fiscal year, as adjusted under paragraphs (2) and (3) of subsection (c); and</text></clause><clause id="H3BD46A3D6CDF496FB4DCFF07BDF46D6C"><enum>(ii)</enum><text display-inline="yes-display-inline">the performance improvement adjustment amount for the fiscal year under subsection (c)(4), if applicable.</text></clause></subparagraph><subparagraph id="HC8043C81F19446F1B76D753A885F698B" commented="no"><enum>(C)</enum><header>Reductions</header><text display-inline="yes-display-inline">For purposes of this paragraph, the amount of reductions for each fiscal year is the sum of—</text><clause id="H67B8FFF3DDE24F5AB4ADFDD34F50AD89" commented="no"><enum>(i)</enum><text>the hiring adjustment amount for the fiscal year under subsection (c)(5), if applicable; and</text></clause><clause id="H949E83B6D92948328C6A88ABC3022566" commented="no"><enum>(ii)</enum><text>the operating reserve adjustment amount for the fiscal year under subsection (c)(6), if applicable.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H52AD4A75B44E47E7BAD689C2E43B4EEA"><enum>204.</enum><header>Reauthorization; reporting requirements</header><subsection id="H552B0B400FA145A8B53BDE589058EBBE"><enum>(a)</enum><header>Performance reports</header><text display-inline="yes-display-inline">Section 738A(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-1">21 U.S.C. 379j–1(a)</external-xref>) is amended—</text><paragraph id="HEA5679EDDD1E4737861B4FA0F27E24A4"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>fiscal year 2018</quote> each place it appears and inserting <quote>fiscal year 2023</quote>;</text></paragraph><paragraph id="H5D0D2245BF86497D9CB2428F5697D403"><enum>(2)</enum><text>by striking <quote>Medical Device User Fee Amendments of 2017</quote> each place it appears and inserting <quote>Medical Device User Fee Amendments of 2022</quote>;</text></paragraph><paragraph id="HB6FB9C28328049B186767737DC0FC763"><enum>(3)</enum><text>in paragraph (1)—</text><subparagraph id="HF68ED0F74C8A4B148A9200233ECCC667"><enum>(A)</enum><text>in subparagraph (A), by redesignating the second clause (iv) (relating to analysis) as clause (v); and</text></subparagraph><subparagraph id="H5326DD3361584607AF1B50B3C96049AF"><enum>(B)</enum><text>in subparagraph (A)(iv), by striking <quote>fiscal year 2020</quote> and inserting <quote>fiscal year 2023</quote>; and</text></subparagraph></paragraph><paragraph id="HCF9632E4D2BC4A6CA627AFEE0DAC3439"><enum>(4)</enum><text>in paragraph (4), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></paragraph></subsection><subsection id="HF6959E4ABAAA44F09FB3767571B6B38E"><enum>(b)</enum><header>Reauthorization</header><text display-inline="yes-display-inline">Section 738A(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-1">21 U.S.C. 379j–1(b)</external-xref>) is amended—</text><paragraph id="H5ED2D8079F754ECB8D38006E7218C70F"><enum>(1)</enum><text>in paragraph (1), by striking <quote>2022</quote> and inserting <quote>2027</quote>; and</text></paragraph><paragraph id="H5A3B2BDE35C842EB96A4CF3A4E565AC3"><enum>(2)</enum><text>in paragraph (5), by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></paragraph></subsection></section><section id="HBBBD199A5F4D4B42A610C70A941EF51D" display-inline="no-display-inline" commented="no"><enum>205.</enum><header>Conformity assessment pilot program</header><text display-inline="no-display-inline">Section 514(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360d">21 U.S.C. 360d(d)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="HE0EC145AAD59436AAA985E18250AA516" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H692AB4900C1D46A691EDE09BF1E5E0E2" commented="no"><enum>(d)</enum><header>Accreditation scheme for conformity assessment</header><paragraph id="H565D025AD75C415098CA93C60A139C7F" commented="no"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish a program under which—</text><subparagraph id="H1961594E868F4845811BD9300D12A080" commented="no"><enum>(A)</enum><text>testing laboratories meeting criteria specified in guidance by the Secretary may be accredited by accreditation bodies meeting criteria specified in guidance by the Secretary, to conduct testing to support the assessment of the conformity of a device to certain standards recognized under this section; and</text></subparagraph><subparagraph id="H27A3E756064C4C1BA0BED52078AD7FB0" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">subject to paragraph (2), results from tests conducted to support the assessment of conformity of devices as described in subparagraph (A) conducted by testing laboratories accredited pursuant to this subsection shall be accepted by the Secretary for purposes of demonstrating such conformity unless the Secretary finds that certain results of such tests should not be so accepted.</text></subparagraph></paragraph><paragraph id="H8D9CC058517F4D9E926CAD1FC47D3792" commented="no"><enum>(2)</enum><header>Secretarial review of accredited laboratory results</header><text>The Secretary may—</text><subparagraph id="H00DDC75FE11B4BC58B518486B7E1337B" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">review the results of tests conducted by testing laboratories accredited pursuant to this subsection, including by conducting periodic audits of such results or of the processes of accredited bodies or testing laboratories;</text></subparagraph><subparagraph id="HEC2D28ABA5B74C9D803607A3354ED95C" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">following such review, take additional measures under this Act<italic></italic>, as the Secretary determines appropriate, such as—</text><clause id="H0A1769C11EE24935826EA6EC3B9B967D" commented="no"><enum>(i)</enum><text>suspension or withdrawal of accreditation of a testing laboratory or recognition of an accreditation body under paragraph (1)(A); or</text></clause><clause id="HFA671C182B3A4BE4A07B239B8A482D5B" commented="no"><enum>(ii)</enum><text>requesting additional information with respect to a device; and</text></clause></subparagraph><subparagraph id="H94E70284D5524377A852ACF1B28AD4E5" commented="no"><enum>(C)</enum><text display-inline="yes-display-inline">if the Secretary becomes aware of information materially bearing on the safety or effectiveness of a device for which an assessment of conformity was supported by testing conducted by a testing laboratory accredited under this subsection, take such additional measures under this Act, as the Secretary determines appropriate, such as—</text><clause id="H80CA1344EE89440082CA006192B422BA" commented="no"><enum>(i)</enum><text>suspension or withdrawal of accreditation of a testing laboratory or recognition of an accreditation body under paragraph (1)(A); or</text></clause><clause id="HF1C8CDA5D99840D8A90AC151E56780AD" commented="no"><enum>(ii)</enum><text>requesting additional information with regard to such device.</text></clause></subparagraph></paragraph><paragraph id="HF951CA5180BD4AB1953D474D767FDC33" commented="no"><enum>(3)</enum><header>Implementation and reporting</header><subparagraph id="H3398A99535074CFE9861BD624CE3FC04" commented="no"><enum>(A)</enum><header>Pilot program transition</header><text display-inline="yes-display-inline">After September 30, 2023, the pilot program previously initiated under this subsection, as in effect prior to the date of enactment of the <short-title>Medical Device User Fee Amendments of 2022</short-title>, shall be considered to be completed, and the Secretary may continue operating a program consistent with this subsection.<italic></italic></text></subparagraph><subparagraph id="H8A4EF4B7A74A4852A4A9E79DE362A46D" commented="no"><enum>(B)</enum><header>Report</header><text display-inline="yes-display-inline"><italic></italic>The Secretary shall make available on the internet website of the Food and Drug Administration an annual report on the progress of the pilot program under this subsection.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H16847F1979084A75863108DD8A93A52B" commented="no"><enum>206.</enum><header>Reauthorization of third-party review program</header><text display-inline="no-display-inline">Section 523(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360m">21 U.S.C. 360m(c)</external-xref>) is amended by striking <quote>2022</quote> and inserting <quote>2027</quote>. </text></section><section id="HA6FA1A5ADD7B46FAB07388E6CE2F7520"><enum>207.</enum><header>Sunset dates</header><subsection id="H676DA8FE12974845B0518D74B38763B0"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Sections 737 and 738 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379i">21 U.S.C. 379i</external-xref>; 379j) shall cease to be effective October 1, 2027.</text></subsection><subsection id="HEA86F0192CFA4F08BFC4073743C875D7"><enum>(b)</enum><header>Reporting requirements</header><text display-inline="yes-display-inline">Section 738A (21 U.S.C. 379j– 1) of the Federal Food, Drug, and Cosmetic Act (regarding reauthorization and reporting requirements) shall cease to be effective January 31, 2028.</text></subsection><subsection id="H34610B6216DE4EC38C06003F346E98F9"><enum>(c)</enum><header>Previous sunset provisions</header><text display-inline="yes-display-inline">Effective October 1, 2022, subsections (a) and (b) of section 210 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="public-law" parsable-cite="pl/115/52">Public Law 115–52</external-xref>) are repealed.</text></subsection></section><section id="H621E5894A0E24E9F837A72E620A47C18"><enum>208.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2022, or the date of the enactment of this Act, whichever is later, except that fees under part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379i">21 U.S.C. 379i et seq.</external-xref>) shall be assessed for all submissions listed in section 738(a)(2)(A) of such Act received on or after October 1, 2022, regardless of the date of the enactment of this Act.</text></section><section id="H3225257D64944189B070A696370AFEB2"><enum>209.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379i">21 U.S.C. 379i et seq.</external-xref>), as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to the submissions listed in section 738(a)(2)(A) of such Act (as defined in such part as of such day) that on or after October 1, 2017, but before October 1, 2022, were received by the Food and Drug Administration with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2023.</text></section></title><title id="HB889EDDAC5A541ECAC8FDCAC8405422E" style="OLC"><enum>III</enum><header>Fees Relating to Generic Drugs</header><section id="HE8CC4BE31C334B13A5B7334F05512569"><enum>301.</enum><header>Short title; finding</header><subsection id="HFD4F980352C6426A82CC34E1F235F7AD"><enum>(a)</enum><header>Short title</header><text>This title may be cited as the <quote><short-title>Generic Drug User Fee Amendments of 2022</short-title></quote>.</text></subsection><subsection id="H4CA2130BB0F8451FAA42BAFA3CF020CC"><enum>(b)</enum><header>Finding</header><text>The Congress finds that the fees authorized by the amendments made by this title will be dedicated to human generic drug activities, as set forth in the goals identified for purposes of part 7 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.</text></subsection></section><section id="HA6B613AB0AE941D48929EA6921AEE704"><enum>302.</enum><header>Authority to assess and use human generic drug fees</header><subsection id="H173FA63EA61D463B8180C2E9984FCE95"><enum>(a)</enum><header>Types of fees</header><text>Section 744B(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(a)</external-xref>) is amended—</text><paragraph id="HD1458D785493487BADDB538B4287D077"><enum>(1)</enum><text>in the matter preceding paragraph (1), by striking <quote>fiscal year 2018</quote> and inserting <quote>fiscal year 2023</quote>;</text></paragraph><paragraph id="H444C9399916E4186A026B11C58675777"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (2)(C), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>;</text></paragraph><paragraph id="HDE465ABCDAA24765B45551DC87C17C95"><enum>(3)</enum><text display-inline="yes-display-inline">in paragraph (3)(B), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>;</text></paragraph><paragraph id="H15372CC9A0AB4023AA081D852BE19319"><enum>(4)</enum><text display-inline="yes-display-inline">in paragraph (4)(D), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>; and</text></paragraph><paragraph id="H60D7C63B683A408CAB576CF5363E501A"><enum>(5)</enum><text display-inline="yes-display-inline">in paragraph (5)(D), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></paragraph></subsection><subsection id="H4FCBBBAF7C014789A257D604B888D92E"><enum>(b)</enum><header>Fee revenue amounts</header><text>Section 744B(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(b)</external-xref>) is amended—</text><paragraph id="H31EA453DA4174086B8D81E93310B316A"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph id="H8DAF32DFD25E47378CF6103D17BBBD7C"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H85E693B1249442408190A29F126CCC56"><enum>(i)</enum><text>in the heading, by striking <quote><header-in-text level="subparagraph" style="OLC">2018</header-in-text></quote> and inserting <quote><header-in-text level="subparagraph" style="OLC">2023</header-in-text></quote>;</text></clause><clause id="H344F6F89F85B4B3CB820D579FAA0EEA4"><enum>(ii)</enum><text>by striking <quote>2018</quote> and inserting <quote>2023</quote>; and</text></clause><clause id="HC2F9713A3109469180C98B2678FB40DA"><enum>(iii)</enum><text display-inline="yes-display-inline">by striking <quote>$493,600,000</quote> and inserting <quote>$582,500,000</quote>; and</text></clause></subparagraph><subparagraph id="H57F6326CAF4948C88ECBCE91EAF79120"><enum>(B)</enum><text>by amending subparagraph (B) to read as follows:</text><quoted-block style="OLC" id="HAD568D8FCC974039A962BC91072477F5" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H156CFDB75F9F4FDB8E03C76289D2154F"><enum>(B)</enum><header>Fiscal years 2024 through 2027</header><clause id="H98C6600E90FE4D228381E67E96DA403D"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">For each of the fiscal years 2024 through 2027, fees under paragraphs (2) through (5) of subsection (a) shall be established to generate a total estimated revenue amount under such subsection that is equal to the base revenue amount for the fiscal year under clause (ii), as adjusted pursuant to subsection (c).</text></clause><clause id="H6C174F8EF2504CA68954C60A6EF3D646"><enum>(ii)</enum><header>Base revenue amount</header><text display-inline="yes-display-inline">The base revenue amount for a fiscal year referred to in clause (i) is equal to the total revenue amount established under this paragraph for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(3).</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H72D8C4235757401B9020037A9980473F"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="HC1D8DE4D6DB24047B2F270326DEB7391"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking <quote>one-third the amount</quote> and inserting <quote>twenty-four percent</quote>;</text></subparagraph><subparagraph id="HA575B075507C41F188967083C925E0DB"><enum>(B)</enum><text>in subparagraph (D), by striking <quote>Seven percent</quote> and inserting <quote>Six percent</quote>; and</text></subparagraph><subparagraph id="H91318993F1904C159A29A69CE2C50C5B"><enum>(C)</enum><text>in subparagraph (E)(i), by striking <quote>Thirty-five percent</quote> and inserting <quote>Thirty-six percent</quote>.</text></subparagraph></paragraph></subsection><subsection id="HD6FB094A25C1460EA3C5815B9A43A732"><enum>(c)</enum><header>Adjustments</header><text>Section 744B(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(c)</external-xref>) is amended—</text><paragraph id="H014815A648FD4C97A090AA298DA98191"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph id="HFE6BF8034775436B8956061BADBB83F5"><enum>(A)</enum><text>in the matter preceding subparagraph (A)—</text><clause id="HADFB35197BA04BD6919ECDB863D1A34A"><enum>(i)</enum><text>by striking <quote>2019</quote> and inserting <quote>2024</quote>; and</text></clause><clause id="H46A01DD32CFC461E962AE70F5F09FD44"><enum>(ii)</enum><text>by striking <quote>to equal the product of the total revenues established in such notice for the prior fiscal year multiplied</quote> and inserting <quote>to equal the base revenue amount for the fiscal year (as specified in subsection (b)(1)(B)) multiplied</quote>; and</text></clause></subparagraph><subparagraph id="H2380F08177DF4F91A207EB18DB06B461"><enum>(B)</enum><text>in subparagraph (C), by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington-Arlington-Alexandria, DC–VA–MD–WV</quote>; and</text></subparagraph></paragraph><paragraph id="H30F1DD79B57E41D4A2B51522DC99AEF2"><enum>(2)</enum><text>by striking paragraph (2) and inserting the following: </text><quoted-block style="OLC" id="H815CA064ED1A4EB6B040ECF5246167B6" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H005E407F9C4347ADBF0D47D14CCA4629"><enum>(2)</enum><header>Capacity planning adjustment</header><subparagraph id="HEEC6F5686C684B85944DACBBC84D5A58"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning with fiscal year 2024, the Secretary shall, in addition to the adjustment under paragraph (1), further increase the fee revenue and fees under this section for a fiscal year, in accordance with this paragraph, to reflect changes in the resource capacity needs of the Secretary for human generic drug activities.</text></subparagraph><subparagraph id="H45023DAB368C44A6AEC6D9DD263E0092"><enum>(B)</enum><header>Capacity planning methodology</header><text display-inline="yes-display-inline">The Secretary shall establish a capacity planning methodology for purposes of this paragraph, which shall—</text><clause id="H137D6E22CAAA4BC1BF1F8D2045D52437"><enum>(i)</enum><text>be derived from the methodology and recommendations made in the report titled <quote>Independent Evaluation of the GDUFA Resource Capacity Planning Adjustment Methodology: Evaluation and Recommendations</quote> announced in the Federal Register on August 3, 2020;</text></clause><clause id="HD839FC8E63204A4C8A2F559B0C4C1A93"><enum>(ii)</enum><text>incorporate approaches and attributes determined appropriate by the Secretary, including approaches and attributes made in such report, except that in incorporating such approaches and attributes the workload categories used in forecasting resources shall only be the workload categories specified in section VIII.B.2.e. of the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022<italic></italic>; and </text></clause><clause id="H50B96C0C4B534E3C8D02E7A493438CE0"><enum>(iii)</enum><text display-inline="yes-display-inline">be effective beginning with fiscal year 2024.</text></clause></subparagraph><subparagraph id="H7AA15A68C0F649C6A8421E464A7582F5" commented="no"><enum>(C)</enum><header>Limitations</header><clause id="H4BC0C0F0BF9543C2B02FB958A9430217" commented="no"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsection (b)(1)(B)(ii) (the base revenue amount for the fiscal year) and paragraph (1) (the dollar amount of the inflation adjustment for the fiscal year).</text></clause><clause id="HFA908F9BAEF54A748752B285DCDCF662" commented="no"><enum>(ii)</enum><header>Percentage limitation</header><text>An adjustment under this paragraph shall not exceed three percent of the sum described in clause (i) for the fiscal year, except that such limitation shall be four percent if—</text><subclause id="HF066DA6F02004F3CB1121CBD379873B9" commented="no"><enum>(I)</enum><text>for purposes of a fiscal year 2024 adjustment, the Secretary determines that during the period from April 1, 2021, through March 31, 2023—</text><item id="H594A4E78EAEB4E93A1625EA84F90E945" commented="no"><enum>(aa)</enum><text display-inline="yes-display-inline">the total number of abbreviated new drug applications submitted was greater than or equal to 2,000; or</text></item><item id="H550A4095F27E4CBBB7CA11BA446B4541" commented="no"><enum>(bb)</enum><text display-inline="yes-display-inline">thirty-five percent or more of abbreviated new drug applications submitted related to complex products (as that term is defined in section XI of the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022);</text></item></subclause><subclause id="HE1650C0CED0549EBAA294BCD23DB2812" commented="no"><enum>(II)</enum><text display-inline="yes-display-inline">for purposes of a fiscal year 2025 adjustment, the Secretary determines that during the period from April 1, 2022, through March 31, 2024<italic></italic>—</text><item id="H838E7273437A40848F38ADF0593921E3" commented="no"><enum>(aa)</enum><text>the total number of abbreviated new drug applications submitted was greater than or equal to 2,300; or</text></item><item id="HBED773C3C5884E13A99C6F928EF4A45E" commented="no"><enum>(bb)</enum><text>thirty-five percent or more of abbreviated new drug applications submitted related to complex products (as so defined);</text></item></subclause><subclause id="HAAD77B74252E47949205385145E38ECA" commented="no"><enum>(III)</enum><text>for purposes of a fiscal year 2026 adjustment, the Secretary determines that during the period from April 1, 2023, through March 31, 2025—</text><item id="H386B1A22867045B6AE9F3162E426F548" commented="no"><enum>(aa)</enum><text>the total number of abbreviated new drug applications submitted was greater than or equal to 2,300; or</text></item><item id="H38DDC1B57DA64F44803196A627E9984E" commented="no"><enum>(bb)</enum><text>thirty-five percent or more of abbreviated new drug applications submitted related to complex products (as so defined); and</text></item></subclause><subclause id="H89157654BE204F6193B0511883DBBB92" commented="no"><enum>(IV)</enum><text>for purposes of a fiscal year 2027 adjustment, the Secretary determines that during the period from April 1, 2024, through March 31, 2026—</text><item id="H85D14B5C58784AEFB27B07526DB4F3A1" commented="no"><enum>(aa)</enum><text>the total number of abbreviated new drug applications submitted was greater than or equal to 2,300; or</text></item><item id="H4160D5DF4C0A4C09B1B511CB3FF91E26" commented="no"><enum>(bb)</enum><text>thirty-five percent or more of abbreviated new drug applications submitted related to complex products (as so defined). </text></item></subclause></clause></subparagraph><subparagraph id="H53EB2300AC1F43A48E9A85608C7BE2B6" commented="no"><enum>(D)</enum><header>Publication in Federal Register</header><text>The Secretary shall publish in the Federal Register notice referred to in subsection (a) the fee revenue and fees resulting from the adjustment and the methodology under this paragraph.</text></subparagraph></paragraph><paragraph id="H1E3CBF0BD8E541C5B524FA051F73EDC8" commented="no"><enum>(3)</enum><header>Operating reserve adjustment</header><subparagraph id="H3633AAA8A6BD47D18AA461C6615DA668" commented="no"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For fiscal year 2024 and each subsequent fiscal year, the Secretary may, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees under this section for such fiscal year if such an adjustment is necessary to provide operating reserves of carryover user fees for human generic drug activities for not more than the number of weeks specified in subparagraph (B) with respect to that fiscal year.</text></subparagraph><subparagraph id="HDAB8C4621A214C78ABB0228BEE5DBD6B" commented="no"><enum>(B)</enum><header>Number of weeks</header><text>The number of weeks specified in this subparagraph is—</text><clause id="H2AAACEF36FD542F18B235456DE6F17D2" commented="no"><enum>(i)</enum><text>8 weeks for fiscal year 2024;</text></clause><clause id="HC3DC553BB81E4FDFA7DB5A2510372856" commented="no"><enum>(ii)</enum><text>9 weeks for fiscal year 2025; and</text></clause><clause id="HE22FDFC7704D47CBB6C2BE5B913EF83C" commented="no"><enum>(iii)</enum><text>10 weeks for each of fiscal year 2026 and 2027.</text></clause></subparagraph><subparagraph id="H8F9B53381DEB49C2B239BB6C1AC70697" commented="no"><enum>(C)</enum><header>Decrease</header><text>If the Secretary has carryover balances for human generic drug activities in excess of 12 weeks of the operating reserves referred to in subparagraph (A), the Secretary shall decrease the fee revenue and fees referred to in such subparagraph to provide for not more than 12 weeks of such operating reserves.</text></subparagraph><subparagraph id="HDD44F608BFB74DB4A2A720F98BF7A1FE" commented="no"><enum>(D)</enum><header>Rationale for adjustment</header><text>If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under subsection (a) publishing the fee revenue and fees for the fiscal year involved. </text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H7268188FC57744DF9BCD9BEFC21B88B8"><enum>(d)</enum><header>Annual fee setting</header><text>Section 744B(d)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(d)(1)</external-xref>) is amended—</text><paragraph id="H07233756D83C4285989915F8C9759D67"><enum>(1)</enum><text>in the paragraph heading, by striking <quote><header-in-text level="paragraph" style="OLC">2018 through 2022</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">2023 through 2027</header-in-text></quote>; and</text></paragraph><paragraph id="H6A17EE41509B45C0B455A1C60DB5ABDF"><enum>(2)</enum><text>by striking <quote>more than 60 days before the first day of each of fiscal years 2018 through 2022</quote> and inserting <quote>later than 60 days before the first day of each of fiscal years 2023 through 2027</quote>.</text></paragraph></subsection><subsection id="H36F65C6F6AD64DD5911D95B12B970B2B"><enum>(e)</enum><header>Crediting and availability of fees</header><text>Section 744B(i)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(i)(3)</external-xref>) is amended by striking <quote>fiscal years 2018 through 2022</quote> and inserting <quote>fiscal years 2023 through 2027</quote>.</text></subsection><subsection id="H135151FEA34F438D84EC2282CCD737B5"><enum>(f)</enum><header>Effect of failure to pay fees</header><text display-inline="yes-display-inline">The heading of paragraph (3) of section 744B(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-42">21 U.S.C. 379j–42(g)</external-xref>) is amended by striking <quote><header-in-text level="paragraph" style="OLC">and prior approval supplement fee</header-in-text></quote>. </text></subsection></section><section id="H8A8A5A89C1CB40929D7846D12AACD36A" commented="no"><enum>303.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 744C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-43">21 U.S.C. 379j–43</external-xref>) is amended—</text><paragraph id="HE2A48A4D2F7A4484BEBCA3701CAC14D7" commented="no"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(1), by striking <quote>Beginning with fiscal year 2018, not</quote> and inserting <quote>Not</quote>;</text></paragraph><paragraph id="H4086055617284807BEFC28FD55942CD8" commented="no"><enum>(2)</enum><text>by striking <quote>Generic Drug User Fee Amendments of 2017</quote> each place it appears and inserting <quote>Generic Drug User Fee Amendments of 2022</quote>;</text></paragraph><paragraph id="HAFC6E611557448999615DE628BB78B55" commented="no"><enum>(3)</enum><text>in subsection (a)(2), by striking <quote>Not later than 30 calendar days after the end of the second quarter of fiscal year 2018, and not later than 30 calendar days after the end of each quarter of each fiscal year thereafter</quote> and inserting <quote>Not later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this part</quote>;</text></paragraph><paragraph id="H840E3A4CA4AA433EAFFE12DCE74CBD67"><enum>(4)</enum><text>in subsection (a)(3), by striking <quote>Beginning with fiscal year 2020, the</quote> and inserting <quote>The</quote>; </text></paragraph><paragraph id="H8D00108292D9441D902F3F3C54078020"><enum>(5)</enum><text>in subsection (b), by striking <quote>Beginning with fiscal year 2018, not</quote> and inserting <quote>Not</quote>;</text></paragraph><paragraph id="H698136D9AE084BEA90A826559C5772F7"><enum>(6)</enum><text>in subsection (c), by striking <quote>Beginning with fiscal year 2018, for</quote> and inserting <quote>For</quote>; and </text></paragraph><paragraph id="HE5C1BB99ECB240F6A2FE59BC656F8207" commented="no"><enum>(7)</enum><text>in subsection (f)—</text><subparagraph id="HDAF63636020A4183918626465EDFE2A2" commented="no"><enum>(A)</enum><text>in paragraph (1), in the matter preceding subparagraph (A), by striking <quote>fiscal year 2022</quote> and inserting <quote>fiscal year 2027</quote>; and</text></subparagraph><subparagraph id="H31E4B2E360144A22A46048C52587B4F2" commented="no"><enum>(B)</enum><text>in paragraph (5), by striking <quote>January 15, 2022</quote> and inserting <quote>January 15, 2027</quote>.</text></subparagraph></paragraph></section><section id="H99CCD043C24047ADA3ACD50C04E1D83F"><enum>304.</enum><header>Sunset dates</header><subsection id="H486C747A58D943C7BAA238FE591111EF"><enum>(a)</enum><header>Authorization</header><text>Sections 744A and 744B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41</external-xref>; 379j–42) shall cease to be effective October 1, 2027.</text></subsection><subsection id="HC56A762CE908427993E45477A518DF34"><enum>(b)</enum><header>Reporting requirements</header><text>Section 744C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-43">21 U.S.C. 379j–43</external-xref>) shall cease to be effective January 31, 2028.</text></subsection><subsection id="HDB70790B8DF04373A03ABCB176620799"><enum>(c)</enum><header>Previous sunset provision</header><text display-inline="yes-display-inline">Effective October 1, 2022, subsections (a) and (b) of section 305 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="public-law" parsable-cite="pl/115/52">Public Law 115–52</external-xref>) are repealed.</text></subsection></section><section id="HD28F2B14A75B40CBB8DDCA4F04195455"><enum>305.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2022, or the date of the enactment of this Act, whichever is later, except that fees under part 7 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41 et seq.</external-xref>) shall be assessed for all abbreviated new drug applications received on or after October 1, 2022, regardless of the date of the enactment of this Act.</text></section><section id="H50EE0E5185BA4E0C9A54F68596A08C89"><enum>306.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 7 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41 et seq.</external-xref>), as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to abbreviated new drug applications (as defined in such part as of such day) that were received by the Food and Drug Administration within the meaning of section 505(j)(5)(A) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(A)</external-xref>), prior approval supplements that were submitted, and drug master files for Type II active pharmaceutical ingredients that were first referenced on or after October 1, 2017, but before October 1, 2022, with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2023.</text></section></title><title id="H8A083C08C3024165B6DA0E256C96CAA8"><enum>IV</enum><header>Fees Relating to Biosimilar Biological Products</header><section id="HC4E8959FC18B4DFC8536EED95F3D7A1B"><enum>401.</enum><header>Short title; finding</header><subsection id="H4A1BD4F635CD49FAAD224A9EF95F2B45"><enum>(a)</enum><header>Short Title</header><text>This title may be cited as the <quote><short-title>Biosimilar User Fee Amendments of 2022</short-title></quote>.</text></subsection><subsection id="HD890902749CE4E139B609D9B10089A19"><enum>(b)</enum><header>Finding</header><text display-inline="yes-display-inline">The Congress finds that the fees authorized by the amendments made by this title will be dedicated to expediting the process for the review of biosimilar biological product applications, including postmarket safety activities, as set forth in the goals identified for purposes of part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.</text></subsection></section><section id="H771DDFD488BC44B28F8EF0FFD8836B5A"><enum>402.</enum><header>Definitions</header><subsection id="HAE55B86A0E574D509FD9AF7295D5E9D6"><enum>(a)</enum><header>Adjustment factor</header><text display-inline="yes-display-inline">Section 744G(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51(1)</external-xref>) is amended to read as follows:</text><quoted-block display-inline="no-display-inline" id="HC0599E7D32C041DB8E1A7F0588D765A4" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph commented="no" id="H42B92BAC08684B7A8178D89C24D7521E"><enum>(1)</enum><text display-inline="yes-display-inline">The term <term>adjustment factor</term> applicable to a fiscal year is the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for September of the preceding fiscal year divided by such Index for September 2011.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H4FA0EF7A7FDD43CBBCC9F82F1A3A3FEF"><enum>(b)</enum><header>Biosimilar biological product application</header><text display-inline="yes-display-inline">Section 744G(4)(B)(iii) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51(4)(B)(iii)</external-xref>) is amended—</text><paragraph id="H6D9FE7CE6D594910B2D8492DBC7147F4"><enum>(1)</enum><text>by striking subclause (II) (relating to an allergenic extract product); and</text></paragraph><paragraph id="H9EC981C9785C49AB83FE538F192EEC63"><enum>(2)</enum><text>by redesignating subclauses (III) and (IV) as subclauses (II) and (III), respectively.</text></paragraph></subsection></section><section commented="no" id="H5545B12E326D4EB193FA3D727FEABAA6"><enum>403.</enum><header>Authority to assess and use biosimilar fees</header><subsection commented="no" id="HEFFBBEB38E0541C0B98A797A01525758"><enum>(a)</enum><header>Types of fees</header><paragraph id="H921678AD0DFF4D36BF3707BE2337BA7F"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The matter preceding paragraph (1) in section 744H(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)</external-xref>) is amended by striking <quote>fiscal year 2018</quote> and inserting <quote>fiscal year 2023</quote>.</text></paragraph><paragraph id="H80AE0467112641F8B031C171204951C1"><enum>(2)</enum><header>Initial biosimilar biological product development fee</header><text>Clauses (iv)(I) and (v)(II) of section 744H(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(1)(A)</external-xref>) are each amended by striking <quote>5 days</quote> and inserting <quote>7 days</quote>.</text></paragraph><paragraph id="HA4534CCC846A4481BFF3F1D642DC4EDF"><enum>(3)</enum><header>Annual biosimilar biological product development fee</header><text display-inline="yes-display-inline">Section 744H(a)(1)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(1)(B)</external-xref>) is amended—</text><subparagraph id="HF4D98289C0214D8BA0E9785108A90C6C"><enum>(A)</enum><text display-inline="yes-display-inline">in clause (i), by inserting before the period at the end the following: <quote>, except where such product (including, where applicable, ownership of the relevant investigational new drug application) is transferred to a licensee, assignee, or successor of such person, and written notice of such transfer is provided to the Secretary, in which case such licensee, assignee, or successor shall pay the annual biosimilar biological product development fee</quote>;</text></subparagraph><subparagraph id="HC9C14CEF16634097A3A9BA6B975F9DAF"><enum>(B)</enum><text>in clause (iii)—</text><clause id="H67AAD409B1454D38A2CEEFDA47AE0D0D"><enum>(i)</enum><text>in subclause (I), by striking <quote>or</quote> at the end;</text></clause><clause id="HB8AF746352714F4A80B9DED972678E56"><enum>(ii)</enum><text>in subclause (II), by striking the period at the end and inserting <quote>; or</quote>; and</text></clause><clause id="HAFF2672E632B443EB572A151D4A19C39"><enum>(iii)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="H2F9DAB1781924F438DF6ED3C053068D2" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subclause id="HDB6C17728018450A9EE8B9019B37EAFF"><enum>(III)</enum><text display-inline="yes-display-inline">been administratively removed from the biosimilar biological product development program for the product under subparagraph (E)(v).</text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="H8087126EB50A4E57B5196E4E105C5958"><enum>(C)</enum><text>in clause (iv), by striking <quote>is accepted for filing on or after October 1 of such fiscal year</quote> and inserting <quote>is subsequently accepted for filing</quote>.</text></subparagraph></paragraph><paragraph id="H9786123F8CAF40DE88DF055136E51D38"><enum>(4)</enum><header>Reactivation fee</header><text display-inline="yes-display-inline">Section 744H(a)(1)(D) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(1)(D)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H6C81F347AFFB453ABD01FBE5FB554746" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H876524FDBF474A6DB34AF91F2DEF8FC4"><enum>(D)</enum><header>Reactivation fee</header><clause id="H7C8EF9979EE548D78ADAFE108D0DCACE"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">A person that has discontinued participation in the biosimilar biological product development program for a product under subparagraph (C), or who has been administratively removed from the biosimilar biological product development program for a product under subparagraph (E)(v), shall, if the person seeks to resume participation in such program, pay all annual biosimilar biological product development fees previously assessed for such product and still owed and a fee (referred to in this section as <quote>reactivation fee</quote>) by the earlier of the following:</text><subclause id="H173BB9FA6C2B4205A5CA9574C69409AC"><enum>(I)</enum><text display-inline="yes-display-inline">Not later than 7 days after the Secretary grants a request by such person for a biosimilar biological product development meeting for the product (after the date on which such participation was discontinued or the date of administrative removal, as applicable). </text></subclause><subclause id="H92F89D3EFE164FACB6B4315DF6FD165E"><enum>(II)</enum><text display-inline="yes-display-inline">Upon the date of submission (after the date on which such participation was discontinued or the date of administrative removal, as applicable) by such person of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for that product.</text></subclause></clause><clause id="H58EB863B549B418B83EE75FFD8099B36"><enum>(ii)</enum><header>Application of annual fee</header><text display-inline="yes-display-inline">A person that pays a reactivation fee for a product shall pay for such product, beginning in the next fiscal year, the annual biosimilar biological product development fee under subparagraph (B), except where such product (including, where applicable, ownership of the relevant investigational new drug application) is transferred to a licensee, assignee, or successor of such person, and written notice of such transfer is provided to the Secretary, in which case such licensee, assignee, or successor shall pay the annual biosimilar biological product development fee. </text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H044785B20911431D9F52D2E48C285599"><enum>(5)</enum><header>Effect of failure to pay fees</header><text display-inline="yes-display-inline">Section 744H(a)(1)(E) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(1)(E)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H31E0199ABF00453AA6DB9460840B0BB5" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H6BD62D8F8542463A8CA613834C187840"><enum>(v)</enum><header>Administrative removal from the biosimilar biological product development program</header><text display-inline="yes-display-inline">If a person has failed to pay an annual biosimilar biological product development fee for a product as required under subparagraph (B) for a period of two consecutive fiscal years, the Secretary may administratively remove such person from the biosimilar biological product development program for the product. At least 30 days prior to administratively removing a person from the biosimilar biological product development program for a product under this clause, the Secretary shall provide written notice to such person of the intended administrative removal.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H7E19CCE7304C47CAA9395AB06DFE8328"><enum>(6)</enum><header>Biosimilar biological product application fee</header><text display-inline="yes-display-inline">Section 744H(a)(2)(D) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(2)(D)</external-xref>) is amended by inserting after <quote>or was withdrawn</quote> the following: <quote>prior to approval</quote>.</text></paragraph><paragraph id="HE536FB7B257B46F5ACC6B3201EC172F7"><enum>(7)</enum><header>Biosimilar biological product program fee</header><text display-inline="yes-display-inline">Section 744H(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)(3)</external-xref>) is amended—</text><subparagraph id="HA876DF3E040D49E4A3288781E723903A"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="HD9B9D28505304107A32DBBF1F0F7DAA7"><enum>(i)</enum><text>in clause (i), by striking <quote>and</quote> at the end;</text></clause><clause id="HF4D0A6A92A78448285644C4362B9FF3F"><enum>(ii)</enum><text display-inline="yes-display-inline">by redesignating clause (ii) as clause (iii); and</text></clause><clause id="HD1A95646B2EA40AA912727FDC3F0C6DC"><enum>(iii)</enum><text>by inserting after clause (i) the following:</text><quoted-block style="OLC" id="H249AEEFB0B7A4E8495EDA9C05EDE75C6" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H5239EF08B0C74EEB9B48F3864CF1EA09"><enum>(ii)</enum><text display-inline="yes-display-inline">may be dispensed only under prescription pursuant to section 503(b); and</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="H473A0B3D962D451A8E0191D35D579770"><enum>(B)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="HDF9E0FD77A6C41D3AA2C7DBF325E3C04" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H56980BA362E0442C83C6FD9752B16641"><enum>(E)</enum><header>Movement to discontinued list</header><clause id="HF88266EC5DA345D6951CEDAE50E3BED3"><enum>(i)</enum><header>Date of inclusion</header><text display-inline="yes-display-inline">If a written request to place a product on the list referenced in subparagraph (A) of discontinued biosimilar biological products is submitted to the Secretary on behalf of an applicant, and the request identifies the date the product is withdrawn from sale, then for purposes of assessing the biosimilar biological product program fee, the Secretary shall consider such product to have been included on such list on the later of—</text><subclause id="HCBA27E8B686B4C1087FAF248846C3A3A"><enum>(I)</enum><text>the date such request was received; or</text></subclause><subclause id="HDB0258C30DB3463291E5029FD75A2297"><enum>(II)</enum><text>if the product will be withdrawn from sale on a future date, such future date when the product is withdrawn from sale.</text></subclause></clause><clause id="H536B893CCA184123B763F9A38F70945D"><enum>(ii)</enum><header>Treatment as withdrawn from sale</header><text>For purposes of clause (i), a product shall be considered withdrawn from sale once the applicant has ceased its own distribution of the product, whether or not the applicant has ordered recall of all previously distributed lots of the product, except that a routine, temporary interruption in supply shall not render a product withdrawn from sale.</text></clause><clause id="H0798EC0E44D84A20819121F3E4BE471E"><enum>(iii)</enum><header>Special rule</header><text display-inline="yes-display-inline">If a biosimilar biological product that is identified in a biosimilar biological product application approved as of October 1 of a fiscal year appears, as of October 1 of such fiscal year, on the list referenced in subparagraph (A) of discontinued biosimilar biological products, and on any subsequent day during such fiscal year the biosimilar biological product does not appear on such list, then except as provided in subparagraph (D), each person who is named as the applicant in a biosimilar biological product application with respect to such product shall pay the annual biosimilar biological product program fee established for a fiscal year under subsection (c)(5) for such biosimilar biological product. Notwithstanding subparagraph (B), such fee shall be due on the last business day of such fiscal year and shall be paid only once for each such product for each fiscal year.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H865CCEBD61F1410280C549F5E5E99E12"><enum>(8)</enum><header>Biosimilar biological product fee</header><text display-inline="yes-display-inline">Section 744H(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(a)</external-xref>) is amended by striking paragraph (4).</text></paragraph></subsection><subsection id="HDBEBDAC992584EE5BA62A000574511B6"><enum>(c)</enum><header>Fee revenue amounts</header><text display-inline="yes-display-inline">Subsection (b) of section 744H of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52</external-xref>) is amended—</text><paragraph id="H98E8FB3A30ED422E91B38247D278E434"><enum>(1)</enum><text>by striking paragraph (1);</text></paragraph><paragraph id="H5471BA1E10824D74BD78E874FE0C3F68"><enum>(2)</enum><text>by redesignating paragraphs (2) through (4) as paragraphs (1) through (3), respectively;</text></paragraph><paragraph id="HE291AEA73C174E6A9DCF7437904CDA1A"><enum>(3)</enum><text>by amending paragraph (1) (as so redesignated) to read as follows: </text><quoted-block style="OLC" id="HC36B4C4CD55B4B2D9470E5A59E12AC4D" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HD99730E904A1477D9209FF5C0BD18208"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">For each of the fiscal years 2023 through 2027, fees under subsection (a) shall, except as provided in subsection (c), be established to generate a total revenue amount equal to the sum of—</text><subparagraph id="HC382C7434F5A4A07BDCD882935F7396F"><enum>(A)</enum><text>the annual base revenue for the fiscal year (as determined under paragraph (3)); </text></subparagraph><subparagraph id="HC1DB0375EAEB417C8783DDD600224CBC"><enum>(B)</enum><text>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));</text></subparagraph><subparagraph id="HD3F70194A50D40A197116FCFD61AFF7C"><enum>(C)</enum><text display-inline="yes-display-inline">the dollar amount equal to the strategic hiring and retention adjustment (as determined under subsection (c)(2));</text></subparagraph><subparagraph id="HDA8A9590C3F5497FA65860F24A11E305"><enum>(D)</enum><text>the dollar amount equal to the capacity planning adjustment for the fiscal year (as determined under subsection (c)(3)); </text></subparagraph><subparagraph id="H73EDFDD413C048169F6022185F2739F6"><enum>(E)</enum><text>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(4)); </text></subparagraph><subparagraph id="H93E153F1677940DE8650A4E6DA18880C"><enum>(F)</enum><text display-inline="yes-display-inline">for fiscal year 2023 an additional amount of $4,428,886; and</text></subparagraph><subparagraph id="H3E13F51FDDAA4A548E085B84D0E7AEB2"><enum>(G)</enum><text display-inline="yes-display-inline">for fiscal year 2024 an additional amount of $320,569<italic></italic>.</text></subparagraph></paragraph><after-quoted-block>; </after-quoted-block></quoted-block></paragraph><paragraph id="H550046CFBF8C4362961B742C08E0107F"><enum>(4)</enum><text display-inline="yes-display-inline">in paragraph (2) (as so redesignated)—</text><subparagraph id="HE86ADAB6FCEC4B3F91D4FEA1FC9474DD"><enum>(A)</enum><text>in the paragraph heading, by striking <quote><header-in-text level="paragraph" style="OLC">; limitations on fee amounts</header-in-text></quote>; </text></subparagraph><subparagraph id="H479AF79EBC6B41EEA818A07D2559AF28"><enum>(B)</enum><text>by striking subparagraph (B); and</text></subparagraph><subparagraph id="H1C054E81B02044B494CDA69DE2E369D7"><enum>(C)</enum><text>by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and</text></subparagraph></paragraph><paragraph id="HC279318A064F41F78CB656DE787A93FA"><enum>(5)</enum><text>by amending paragraph (3) (as so redesignated) to read as follows: </text><quoted-block style="OLC" id="HE1C67B9AC23745A4AE85811FBC790BE8" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HF7D9E9507F93496E951E1DCBB6515428"><enum>(3)</enum><header>Annual base revenue</header><text display-inline="yes-display-inline">For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—</text><subparagraph id="HAD6EB0147A5546CB8EED0A229DFA5BB1"><enum>(A)</enum><text display-inline="yes-display-inline">for fiscal year 2023, $43,376,922; and</text></subparagraph><subparagraph id="HCD38033A140640A8A76507D4C9312211"><enum>(B)</enum><text display-inline="yes-display-inline">for fiscal years 2024 through 2027, the dollar amount of the total revenue amount established under paragraph (1) for the previous fiscal year, excluding any adjustments to such revenue amount under subsection (c)(4).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H2DD7B71A906B4084B7EEC0DD02F7DB0F"><enum>(d)</enum><header>Adjustments; annual fee setting</header><text>Section 744H(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(c)</external-xref>) is amended—</text><paragraph id="H4F6D6526C7384170AF4545B1F0F99B06"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph id="H5A7FE1B20A7B4E46A90627C1307B3EDD"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="HB95273E7C2294D81B8E6417507E57C1E"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>subsection (b)(2)(B)</quote> and inserting <quote>subsection (b)(1)(B)</quote>; and</text></clause><clause id="HF448BCA28948468380BCD2842A420FFD"><enum>(ii)</enum><text>in clause (i), by striking <quote>subsection (b)</quote> and inserting <quote>subsection (b)(1)(A)</quote>; and</text></clause></subparagraph><subparagraph id="H2B22D8970E9C4867B84D1209732BC4D1"><enum>(B)</enum><text>in subparagraph (B)(ii), by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington-Arlington-Alexandria, DC–VA–MD–WV</quote>;</text></subparagraph></paragraph><paragraph id="HC956C6DEE34F489DBE8012CA92B2C475"><enum>(2)</enum><text>by striking paragraphs (2) through (4) and inserting the following: </text><quoted-block style="OLC" id="HB7B37ED242784DB9BB694310126F007C" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H1A11EFD898704B6FBC56EA77FD58D30F"><enum>(2)</enum><header>Strategic hiring and retention adjustment</header><text display-inline="yes-display-inline">For each fiscal year, after the annual base revenue under subsection (b)(1)(A) is adjusted for inflation in accordance with paragraph (1), the Secretary shall further increase the fee revenue and fees by $150,000.<italic></italic></text></paragraph><paragraph id="H0FF7144F4AF84845A87EF6DF0E60E811"><enum>(3)</enum><header>Capacity planning adjustment</header><subparagraph id="H6F0A9B2E8B3E4788A7FE572F2BD95CD8"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline"><italic></italic>For each fiscal year, the Secretary shall, in addition to the adjustments under paragraphs (1) and (2), further adjust the fee revenue and fees under this section for a fiscal year to reflect changes in the resource capacity needs of the Secretary for the process for the review of biosimilar biological product applications.</text></subparagraph><subparagraph id="H93C5F694973F4802930CB9A0161BFFDB"><enum>(B)</enum><header>Methodology</header><text display-inline="yes-display-inline">For purposes of this paragraph, the Secretary shall employ the capacity planning methodology utilized by the Secretary in setting fees for fiscal year 2021, as described in the notice titled <quote>Biosimilar User Fee Rates for Fiscal Year 2021</quote> published in the Federal Register on August 4, 2020 (85 Fed. Reg. 47220). The workload categories used in applying such methodology in forecasting shall include only the activities described in that notice and, as feasible, additional activities that are also directly related to the direct review of biosimilar biological product applications and supplements, including additional formal meeting types, the direct review of postmarketing commitments and requirements, the direct review of risk evaluation and mitigation strategies, and the direct review of annual reports for approved biosimilar biological products. Subject to the exceptions in the preceding sentence, the Secretary shall not include as workload categories in applying such methodology in forecasting any non-core review activities, including those activities that the Secretary referenced for potential future use in such notice but did not utilize in setting fees for fiscal year 2021.</text></subparagraph><subparagraph id="HA08DC86356DE44D8B4C4C776DB3CBBB4"><enum>(C)</enum><header>Limitations</header><text display-inline="yes-display-inline">Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsections (b)(1)(A) (the annual base revenue for the fiscal year), (b)(1)(B) (the dollar amount of the inflation adjustment for the fiscal year), and (b)(1)(C) (the dollar amount of the strategic hiring and retention adjustment).</text></subparagraph><subparagraph id="H188FAA737F354B769E32B0FBF21E987C"><enum>(D)</enum><header>Publication in Federal Register</header><text display-inline="yes-display-inline">The Secretary shall publish in the Federal Register notice under paragraph (5) the fee revenue and fees resulting from the adjustment and the methodologies under this paragraph.</text></subparagraph></paragraph><paragraph id="H1BBB49F9228E4567B3848769714F120F"><enum>(4)</enum><header>Operating reserve adjustment</header><subparagraph id="H187C0441A4ED41E48BC315ADA7451EC1"><enum>(A)</enum><header>Increase</header><text display-inline="yes-display-inline">For fiscal year 2023 and subsequent fiscal years, the Secretary shall, in addition to adjustments under paragraphs (1), (2), and (3), further increase the fee revenue and fees if such an adjustment is necessary to provide for at least 10 weeks of operating reserves of carryover user fees for the process for the review of biosimilar biological product applications.</text></subparagraph><subparagraph id="HB69FFE18246748DDA00E42ECBBA29616"><enum>(B)</enum><header>Decrease</header><clause id="H16284689C38D4BA7A3FD993BAAE5CD28"><enum>(i)</enum><header>Fiscal year 2023</header><text>For fiscal year 2023, if the Secretary has carryover balances for such process in excess of 33 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 33 weeks of such operating reserves.</text></clause><clause id="H27F883030F124D8FB902423C1ECDF8CC"><enum>(ii)</enum><header>Fiscal year 2024</header><text display-inline="yes-display-inline">For fiscal year 2024, if the Secretary has carryover balances for such process in excess of 27 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 27 weeks of such operating reserves.</text></clause><clause id="HF5F6EAF56B7646C8A2379F3B73A2685F"><enum>(iii)</enum><header>Fiscal year 2025 and subsequent fiscal years</header><text display-inline="yes-display-inline">For fiscal year 2025 and subsequent fiscal years, if the Secretary has carryover balances for such process in excess of 21 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 21 weeks of such operating reserves.</text></clause></subparagraph><subparagraph id="H1329E28A37D84CFE987EEA2D76F4C67C"><enum>(C)</enum><header>Federal Register notice</header><text display-inline="yes-display-inline">If an adjustment under subparagraph (A) or (B) is made, the rationale for the amount of the increase or decrease in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5)(B) establishing fee revenue and fees for the fiscal year involved.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="HCBE1C96E55524440A379EB7746FDBCEA"><enum>(3)</enum><text>in paragraph (5), in the matter preceding subparagraph (A), by striking <quote>2018</quote> and inserting <quote>2023</quote>. </text></paragraph></subsection><subsection commented="no" id="H5A26EB45FE774944AD3AD7A92C3DFAF9"><enum>(e)</enum><header>Crediting and availability of fees</header><text display-inline="yes-display-inline">Subsection (f)(3) of section 744H of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(f)(3)</external-xref>) is amended by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></subsection><subsection id="H8A64A1E2D7034446A64BB5D0DFFD2CD6"><enum>(f)</enum><header>Written requests for waivers and returns; disputes concerning fees</header><text display-inline="yes-display-inline">Section 744H(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-52">21 U.S.C. 379j–52(h)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="HBA628B6A1D6C44949A85B072467C57B1" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HF6597C1819EA4D228E88CFFE78758DBB"><enum>(h)</enum><header>Written requests for waivers and returns; disputes concerning fees</header><text display-inline="yes-display-inline">To qualify for consideration for a waiver under subsection (d), or for the return of any fee paid under this section, including if the fee is claimed to have been paid in error, a person shall submit to the Secretary a written request justifying such waiver or return and, except as otherwise specified in this section, such written request shall be submitted to the Secretary not later than 180 days after such fee is due. A request submitted under this paragraph shall include any legal authorities under which the request is made.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H963D13AC7E0B4CB49FD0EB59B775ACC9" commented="no"><enum>404.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 744I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-53">21 U.S.C. 379j–53</external-xref>) is amended—</text><paragraph id="H0DBD0E1F2B2E427B9D60CA36AB32437D" commented="no"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(1), by striking <quote>Beginning with fiscal year 2018, not</quote> and inserting <quote>Not</quote>;</text></paragraph><paragraph id="HCD5C8B0255BC48B9BE409C6527061411" commented="no"><enum>(2)</enum><text>by striking <quote>Biosimilar User Fee Amendments of 2017</quote> each place it appears and inserting <quote><short-title>Biosimilar User Fee Amendments of 2022</short-title></quote>;</text></paragraph><paragraph id="HEF9E71DACA39463EBF0AA3F9B3D24B62"><enum>(3)</enum><text>in subsection (a)(2), by striking <quote>Beginning with fiscal year 2018, the</quote> and inserting <quote>The</quote>; </text></paragraph><paragraph id="HBA482AD0F389455C898ADDDD6F8D74BE" commented="no"><enum>(4)</enum><text>in subsection (a)(3)(A), by striking <quote>Not later than 30 calendar days after the end of the second quarter of fiscal year 2018, and not later than 30 calendar days after the end of each quarter of each fiscal year thereafter</quote> and inserting <quote>Not later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this part</quote>;</text></paragraph><paragraph id="H896BDD4B928440CF863C7214161CE172"><enum>(5)</enum><text display-inline="yes-display-inline">in subsection (b), by striking <quote>Not later than 120 days after the end of fiscal year 2018 and each subsequent fiscal year for which fees are collected under this part</quote> and inserting <quote>Not later than 120 days after the end of each fiscal year for which fees are collected under this part</quote>;</text></paragraph><paragraph id="H94EDF9BE1EAD4F3E925057ECCCD327C4"><enum>(6)</enum><text>in subsection (c), by striking <quote>Beginning with fiscal year 2018, and for</quote> and inserting <quote>For</quote>; and</text></paragraph><paragraph id="H21254ED1FECC40069B35D1659CB34C5E" commented="no"><enum>(7)</enum><text>in subsection (f)—</text><subparagraph id="H91900DDF009D43E69849286738C97262" commented="no"><enum>(A)</enum><text>in paragraph (1), in the matter preceding subparagraph (A), by striking <quote>fiscal year 2022</quote> and inserting <quote>fiscal year 2027</quote>; and</text></subparagraph><subparagraph id="HF446C6DC5D3E446D9D9ECFF438004DAE" commented="no"><enum>(B)</enum><text>in paragraph (3), by striking <quote>January 15, 2022</quote> and inserting <quote>January 15, 2027</quote>.</text></subparagraph></paragraph></section><section id="H6EBE95544E254D03931F0E9B9649268B"><enum>405.</enum><header>Sunset dates</header><subsection id="H266447CE5B7E48B7B050F48909A12162"><enum>(a)</enum><header>Authorization</header><text>Sections 744G and 744H of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51</external-xref>, 379j–52) shall cease to be effective October 1, 2027.</text></subsection><subsection id="H9734707CF2344A20B0E1E1D52785AB69"><enum>(b)</enum><header>Reporting Requirements</header><text>Section 744I of the Federal Food, Drug, and Cosmetic Act shall cease to be effective January 31, 2028.</text></subsection><subsection id="H62A649B00D494E6EA376F808EAA4D4EC"><enum>(c)</enum><header>Previous Sunset Provision</header><text display-inline="yes-display-inline">Effective October 1, 2022, subsections (a) and (b) of section 405 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="public-law" parsable-cite="pl/115/52">Public Law 115–52</external-xref>) are repealed.</text></subsection></section><section id="H785D2A1E68CE40858D95C82061C24D0E"><enum>406.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2022, or the date of the enactment of this Act, whichever is later, except that fees under part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51 et seq.</external-xref>) shall be assessed for all biosimilar biological product applications received on or after October 1, 2022, regardless of the date of the enactment of this Act.</text></section><section commented="no" display-inline="no-display-inline" id="HDA3F7267B974441C833ED89CC3016538" section-type="subsequent-section"><enum>407.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51 et seq.</external-xref>), as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to biosimilar biological product applications and supplements (as defined in such part as of such day) that were accepted by the Food and Drug Administration for filing on or after October 1, 2017, but before October 1, 2022, with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2023.</text></section></title><title id="HA944948E00CF456283F345820122510D"><enum>V</enum><header>Improving Diversity in Clinical Studies</header><section id="H8A34873E0D9B4C79BD792FDDBEEAAD8B"><enum>501.</enum><header>Diversity action plans for clinical studies</header><subsection id="H681E38DDDE9A4667BA8C93FE33D2F6A6"><enum>(a)</enum><header>Drugs</header><text>Section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) is amended by adding at the end the following:</text><quoted-block id="HE9626335058B4C3E8A29F80CE2056F8F" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H0DB52DE2A6D64C11A02D552F3892F34F" indent="up1"><enum>(5)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H725A1B822A724C0A92D2DDD08573EA84"><enum>(A)</enum><text display-inline="yes-display-inline">In order for a new drug that is being studied in a phase 3 study, as defined in section 312.21(c) of title 21, Code of Federal Regulations (or successor regulations), or other pivotal study (other than bioavailability or bioequivalence studies), to be exempt pursuant to this subsection, the sponsor of a clinical investigation of such new drug shall submit to the Secretary a diversity action plan.</text></subparagraph><subparagraph id="HC5C66756991F429FA7FBBFFFAC9AA17B" indent="up1"><enum>(B)</enum><text>Such diversity action plan shall include—</text><clause id="HC98E64B5411A4C64AA3D31B93321F8A3"><enum>(i)</enum><text display-inline="yes-display-inline">the sponsor’s goals for enrollment in such clinical study;</text></clause><clause id="H7D32F31DB4A1493FBD40F2F5EE809106"><enum>(ii)</enum><text>the sponsor’s rationale for such goals; and</text></clause><clause id="H749B23412EF7498AA9DCC4697237BAA1"><enum>(iii)</enum><text>an explanation of how the sponsor intends to meet such goals.</text></clause></subparagraph><subparagraph id="HB4F2446BE11A40D2A1AC5A33E89A77B2" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">The sponsor shall submit such diversity action plan in the form and manner specified in the guidance required by section 524B as soon as practicable but no later than when the sponsor seeks feedback regarding such a phase 3 study or other pivotal study of the drug.</text></subparagraph><subparagraph id="H14387332DF704C88A1D4225F5192EE85" indent="up1"><enum>(D)</enum><text display-inline="yes-display-inline">The Secretary may waive the requirement in subparagraph (A) if the Secretary determines that a waiver is necessary based on what is known about the prevalence of the disease in terms of the patient population that may use the new drug.</text></subparagraph><subparagraph id="H37D5FF24BA064D14BA9B0AC89AB0592F" indent="up1"><enum>(E)</enum><text display-inline="yes-display-inline">No diversity action plan shall be required for a submission described in section 561.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H59C7C980D20B46AC94AF31FA2101B498" commented="no"><enum>(b)</enum><header>Devices</header><text>Section 520(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(g)</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H24EC752CA27D483F9B71E91FF0A730F7" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HC4367D7EC6F74A559636C0355C0101E8" indent="up1" commented="no"><enum>(9)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H7DD838A0F5854B5EACF02B5DBD0B7E29"><enum>(A)</enum><clause commented="no" display-inline="yes-display-inline" id="H067C94D2F7574E808A4742A49FAC3C37"><enum>(i)</enum><text>In order for a device in a clinical study for which submission of an application for an investigational device exemption is required to be exempt under this subsection, the sponsor of such study shall submit to the Secretary in such application a diversity action plan in the form and manner specified in the guidance required by section 524B.</text></clause><clause id="H5195EEE970154A3AB98897D2901E531D" indent="up2" commented="no"><enum>(ii)</enum><text>In order for a device in a clinical study for which submission of an application for an investigational device exemption is not required, except for a device being studied as described in section 812.2(c) of title 21, Code of Federal Regulations (or successor regulations), to be exempt under this subsection, the sponsor of such study shall develop and implement a diversity action plan. Such diversity action plan shall be submitted to the Secretary in any premarket notification under section 510(k), request for classification under section 513(f)(2), or application for premarket approval under section 515 for such device.</text></clause></subparagraph><subparagraph id="H9AE6514121BB49EBA917B6036E317732" indent="up1" commented="no"><enum>(B)</enum><text>A diversity action plan under clause (i) or (ii) of subparagraph (A) shall include—</text><clause id="H29E2A8DE60FB4358A136209DA0428CB8" commented="no"><enum>(i)</enum><text>the sponsor’s goals for enrollment in the clinical study;</text></clause><clause id="H67C23C803F0A4D7CA382C2CBA559B421" commented="no"><enum>(ii)</enum><text>the sponsor’s rationale for such goals; and</text></clause><clause id="H8C61C53661314F9EB1179CFBBA14A968" commented="no"><enum>(iii)</enum><text>an explanation of how the sponsor intends to meet such goals.</text></clause></subparagraph><subparagraph id="HA27BB0F9404B406988CB40A9A2A61048" indent="up1" commented="no"><enum>(C)</enum><text>The Secretary may waive the requirement in subparagraph (A) or (B) if the Secretary determines that a waiver is necessary based on what is known about the prevalence of the disease in terms of the patient population that may use the device.</text></subparagraph><subparagraph id="HD2E8E6AC67044A89B3ED6CAE0597C3C0" indent="up1" commented="no"><enum>(D)</enum><text>No diversity action plan shall be required for a submission described in section 561.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H38709DD9AEB6411EB39656E7709F4CA7"><enum>(c)</enum><header>Guidance</header><text>Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H2D0938A648BE441E96D6650A8A677696" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="HCD55F697FDED4FA6B245AC94E164D4AC"><enum>524B.</enum><header>Guidance on diversity action plans for clinical studies</header><subsection id="HA8058B1D9DE84B02A99CE43FF1D6260C"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall issue guidance relating to—</text><paragraph id="H7CD4EA101269418685E4D4B28F9C7BF3"><enum>(1)</enum><text>the format and content of the diversity action plans required by sections 505(i)(5) and 520(g)(9) pertaining to the sponsor’s goals for clinical study enrollment, disaggregated by age group, sex, race, geographic location, socioeconomic status, and ethnicity, including with respect to—</text><subparagraph id="HAC46D67553E2497191AFE49E471ACC94"><enum>(A)</enum><text>the rationale for the sponsor’s enrollment goals, which may include—</text><clause id="H2F0470EF64CA4840A69CB4FCFD336624"><enum>(i)</enum><text display-inline="yes-display-inline">the estimated prevalence or incidence in the United States of the disease or condition for which the drug or device is being developed or investigated, if such estimated prevalence or incidence is known or can be determined based on available data;</text></clause><clause id="H50DBA0D9EA2A4A2E84FEADFD2D341807"><enum>(ii)</enum><text>what is known about the disease or condition for which the drug or device is being developed or investigated;</text></clause><clause id="H888ACFDCA1C84D57B8776872B9B4F8D7"><enum>(iii)</enum><text>any relevant pharmacokinetic or pharmacogenomic data;</text></clause><clause id="H059FBDC22BAA48E7A4386112AAA8EBEC"><enum>(iv)</enum><text>what is known about the patient population for such disease or condition, including, to the extent data is available—</text><subclause id="HE9B4BA36355241098DA1405300611ABA"><enum>(I)</enum><text>demographic information, including age group, sex, race, geographic location, socioeconomic status, and ethnicity;</text></subclause><subclause id="H0F37CD078FAD4A6AA3F55A48C9A6552E"><enum>(II)</enum><text display-inline="yes-display-inline">non-demographic factors, including co-morbidities affecting the patient population; and</text></subclause><subclause id="H8FFBF46802EF4AE7B3C63321F1D2592C"><enum>(III)</enum><text>potential barriers to enrolling diverse participants, such as patient population size, geographic location, and socioeconomic status; and</text></subclause></clause><clause id="H66CF958716D148D49D7768B9702BCF9B"><enum>(v)</enum><text>any other data or information relevant to selecting appropriate enrollment goals, disaggregated by demographic subgroup, such as the inclusion of pregnant and lactating women; </text></clause></subparagraph><subparagraph id="H0CE94F4294F444BFA05E69C842D4FBFF"><enum>(B)</enum><text>an explanation for how the sponsor intends to meet such goals, including demographic-specific outreach and enrollment strategies, study-site selection, clinical study inclusion and exclusion practices, and any diversity training for study personnel; and</text></subparagraph><subparagraph id="HFBFE3F59AD534B10BAE9AF302A3D4348"><enum>(C)</enum><text>procedures for the public posting of key information from the diversity action plan that would be useful to patients and providers on the sponsor’s website, as appropriate; and</text></subparagraph></paragraph><paragraph id="H2331065C2D1748F9AF9F7BEBADC3F599"><enum>(2)</enum><text>how sponsors should include in regular reports to the Secretary—</text><subparagraph id="HE7B4995E8D5248A7A8ABDD4E46371AC2"><enum>(A)</enum><text>the sponsor’s progress in meeting the goals referred to in paragraph (1)(A); and</text></subparagraph><subparagraph id="H8E1FEABA69F64C1BAC0D2BEF63E021D1"><enum>(B)</enum><text>if the sponsor does not expect to meet such goals—</text><clause id="HCACD87AE67B34E938F08006CE1D67125"><enum>(i)</enum><text>any updates needed to be made to a diversity action plan referred to in paragraph (1) to help meet such goals; and</text></clause><clause id="H2873EE7E0AFF4CB682CFCBB4CBF6C80F"><enum>(ii)</enum><text>the sponsor’s reasons for why the sponsor does not expect to meet such goals.</text></clause></subparagraph></paragraph></subsection><subsection id="H1EA9FE6205304980A0B60577442920ED"><enum>(b)</enum><header>Issuance</header><text>The Secretary shall—</text><paragraph id="H1061EB3017184E31A5D9859113428FF0"><enum>(1)</enum><text>not later than 12 months after the date of enactment of this section, issue new draft guidance or update existing draft guidance described in subsection (a); and</text></paragraph><paragraph id="H52E131515E214CC0975C5FAA5BCDFE7E"><enum>(2)</enum><text>not later than 9 months after closing the comment period on such draft guidance, finalize such guidance.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H82C963A7EA8E4576BA3548CF11A009CE"><enum>(d)</enum><header>Applicability</header><text display-inline="yes-display-inline">Sections 505(i)(5) and 520(g)(9) of the Federal Food, Drug, and Cosmetic Act, as added by subsections (a) and (b) of this section, apply only with respect to clinical investigations with respect to which enrollment commences after the date that is 180 days after the publication of final guidance under section 524B(b)(2) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (c).</text></subsection></section><section id="H17D65F79003F42349880E185B8F94214"><enum>502.</enum><header>Evaluation of the need for FDA authority to mandate postapproval studies or postmarket surveillance due to insufficient demographic subgroup data</header><subsection id="H52ADAA5005AB45B79E23090035B443ED"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 2 years after the date of publication of final guidance pursuant to section 524B(b)(2) of the Federal Food, Drug, and Cosmetic Act, as added by section 501(c) of this Act, the Secretary of Health and Human Services shall commence an evaluation to assess whether additions or changes to statutes or regulations are warranted to ensure that sponsors conduct post-approval studies or postmarket surveillance where—</text><paragraph id="HED71721018694FB1B66C38E043FF1986"><enum>(1)</enum><text>premarket studies collected insufficient data for underrepresented subgroups according to the goals specified in the diversity action plans of such sponsors; and</text></paragraph><paragraph id="HA528515E35ED40EDADC1DF3A627D34B8"><enum>(2)</enum><text>the Secretary has requested additional studies be conducted.</text></paragraph></subsection><subsection id="H2C00263522A54170A80A45F738520C6D"><enum>(b)</enum><header>Determination and reporting</header><text>Not later than 180 days after the commencement of the evaluation under subsection (a), the Secretary of Health and Human Services shall submit a report to the Congress on the outcome of such evaluation, including any recommendations related to additional needed authorities.</text></subsection></section><section id="H309A4F99880D4C03A6285A7569ABB85B"><enum>503.</enum><header>Public workshops to enhance clinical study diversity</header><subsection id="HF9B42EDE06F44647A64B621CC968988F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with drug sponsors, medical device manufacturers, patients, and other stakeholders, shall convene one or more public workshops to solicit input from stakeholders on increasing the enrollment of historically underrepresented populations in clinical studies and encouraging clinical study participation that reflects the prevalence of the disease or condition among demographic subgroups, where appropriate, and other topics, including—</text><paragraph id="HCC8B8FB0B6444C939D2F5C62DFCD2937"><enum>(1)</enum><text display-inline="yes-display-inline">how and when to collect and present the prevalence or incidence data on a disease or condition by demographic subgroup, including possible sources for such data and methodologies for assessing such data;</text></paragraph><paragraph id="HB86BD31F365C40C7B76FA2EF76D35CC4"><enum>(2)</enum><text display-inline="yes-display-inline">considerations for the dissemination, after approval, of information to the public on clinical study enrollment demographic data;</text></paragraph><paragraph id="HDEB8C86902BE4E6EA70F44230D1CD19B"><enum>(3)</enum><text display-inline="yes-display-inline">the establishment of goals for enrollment in clinical trials, including the relevance of the estimated prevalence or incidence, as applicable, in the United States of the disease or condition for which the drug or device is being developed; and</text></paragraph><paragraph id="HA5BF0B5AF3A04A9B9CBC80C8B1571BAD"><enum>(4)</enum><text>approaches to support inclusion of underrepresented populations and to encourage clinical study participation that reflects the population expected to use the drug or device under study, including with respect to—</text><subparagraph id="H3564F0D004C048A28B134E602F2D1D8A"><enum>(A)</enum><text display-inline="yes-display-inline">the establishment of inclusion and exclusion criteria for certain subgroups, such as pregnant and lactating women and individuals with disabilities, including intellectual or developmental disabilities or mental illness;</text></subparagraph><subparagraph id="H7F11016275AC4FC6A2C310414D91D347"><enum>(B)</enum><text display-inline="yes-display-inline">considerations regarding informed consent with respect to individuals with intellectual or developmental disabilities or mental illness, including ethical and scientific considerations;</text></subparagraph><subparagraph id="HD4FD4A629A19459FB093148CDA69FB6E"><enum>(C)</enum><text display-inline="yes-display-inline">the appropriate use of decentralized trials or digital health tools;</text></subparagraph><subparagraph id="H5EE0C00E6BC4412590C2DDC18FC793CE"><enum>(D)</enum><text>clinical endpoints;</text></subparagraph><subparagraph id="HDAF17BF6D0F2412DA4CDA8E7ED25E536"><enum>(E)</enum><text>biomarker selection; and</text></subparagraph><subparagraph id="HF5E6B9EB4AE44691B1C27852640A4224"><enum>(F)</enum><text>studying analysis.</text></subparagraph></paragraph></subsection><subsection id="HD0160BDF777947F298507F46E6893197"><enum>(b)</enum><header>Public docket</header><text>The Secretary of Health and Human Services shall establish a public comment period to receive written comments related to the topics addressed during each public workshop convened under this section. The public comment period shall remain open for 60 days following the date on which each public workshop is convened.</text></subsection><subsection id="H4DE02A232E484FD99C44A0E77B2399B0"><enum>(c)</enum><header>Report</header><text>Not later than 180 days after the close of the public comment period for each public workshop convened under this section, the Secretary of Health and Human Services shall make available on the public website of the Food and Drug Administration a report on the topics discussed at such workshop. The report shall include a summary of, and response to, recommendations raised in such workshop.</text></subsection></section><section id="H73B6DB6BF902412596526CF00835BB1E"><enum>504.</enum><header>Annual summary report on progress to increase diversity in clinical studies</header><subsection id="H417322A1D85E411DA34306324899779A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning not later than 2 years after the date of enactment of this Act, and each year thereafter, the Secretary of Health and Human Services shall submit to the Congress, and publish on the public website of the Food and Drug Administration, a report that—</text><paragraph id="H5C30932E6685474EA05F30F9EDF3517F"><enum>(1)</enum><text display-inline="yes-display-inline">summarizes, in aggregate, the diversity action plans received pursuant to section 505(i)(5) or 520(g)(9) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) or (b) of section 501 of this Act; and</text></paragraph><paragraph id="HEE015B4C5BD049D496C274AAD9C06A90"><enum>(2)</enum><text>contains information on—</text><subparagraph id="HDD587D3E839942D79A9EC3757FB97C44"><enum>(A)</enum><text display-inline="yes-display-inline">for drugs, biological products, and devices approved, licensed, cleared, or classified under section 505, 515, 510(k), or 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>; 360e; 360(k); and 360(f)(2)), or section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>), whether the clinical studies conducted with respect to such applications met the demographic subgroup enrollment goals from the diversity action plan submitted for such applications;</text></subparagraph><subparagraph id="HD47C3D81347F4B038B8F67CF36884B7F"><enum>(B)</enum><text display-inline="yes-display-inline">the reasons provided for why enrollment goals from submitted diversity action plans were not met; and</text></subparagraph><subparagraph id="HB10077F621E84FD3B92BD9D589EBCEF8"><enum>(C)</enum><text>any postmarket studies of a drug or device in a demographic subgroup or subgroups required or recommended by the Secretary based on inadequate premarket clinical study diversity or based on other reasons where a premarket study lacked adequate diversity, including the status and completion date of any such study.</text></subparagraph></paragraph></subsection><subsection id="HEB8F4FF9B68545E3BF0D84DD240EFDAB"><enum>(b)</enum><header>Confidentiality</header><text>Nothing in this section shall be construed as authorizing the Secretary of Health and Human Services to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text></subsection></section><section id="HA92CEC138E7E4352B323EC50B90D8C51"><enum>505.</enum><header>Public meeting on clinical study flexibilities initiated in response to COVID–19 pandemic</header><subsection id="HFF8BA7B23F0F402692C0646355A40F82"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date on which the COVID–19 emergency period ends, the Secretary of Health and Human Services shall convene a public meeting to discuss the recommendations provided by the Food and Drug Administration during the COVID–19 emergency period to mitigate disruption of clinical studies, including recommendations detailed in the guidance entitled <quote>Conduct of Clinical Trials of Medical Products During the COVID–19 Public Health Emergency, Guidance for Industry, Investigators, and Institutional Review Boards</quote>, as updated on August 8, 2021, and by any subsequent updates to such guidance. The Secretary of Health and Human Services shall invite to such meeting representatives from the pharmaceutical and medical device industries who sponsored clinical studies during the COVID–19 emergency period and organizations representing patients.</text></subsection><subsection id="HBF99F58C7B774830A4D9A19D976D5DB5"><enum>(b)</enum><header>Topics</header><text>Not later than 90 days after the date on which the public meeting under subsection (a) is convened, the Secretary of Health and Human Services shall make available on the public website of the Food and Drug Administration a report on the topics discussed at such meeting. Such topics shall include discussion of—</text><paragraph id="HDDC2F106090748D293B1D490B363E51E"><enum>(1)</enum><text>the actions drug sponsors took to utilize such recommendations and the frequency at which such recommendations were employed;</text></paragraph><paragraph id="H9F582D87468B4FD38D86844817626E87"><enum>(2)</enum><text>the characteristics of the sponsors, studies, and patient populations impacted by such recommendations;</text></paragraph><paragraph id="HF40EEC2FB3B04DE9B6E196EFFAA1D30B"><enum>(3)</enum><text display-inline="yes-display-inline">a consideration of how recommendations intended to mitigate disruption of clinical studies during the COVID–19 emergency period, including any recommendations to consider decentralized clinical studies when appropriate, may have affected access to clinical studies for certain patient populations, especially unrepresented racial and ethnic minorities; and</text></paragraph><paragraph id="HBF0DE20DEABE4EF29B76202C617B5212"><enum>(4)</enum><text>recommendations for incorporating certain clinical study disruption mitigation recommendations into current or additional guidance to improve clinical study access and enrollment of diverse patient populations.</text></paragraph></subsection><subsection id="H42BBA7DF7FE14F0A8A6B70235043E240"><enum>(c)</enum><header>COVID–19 emergency period defined</header><text>In this section, the term <term>COVID–19 emergency period</term> has the meaning given the term <term>emergency period</term> in section 1135(g)(1)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320b-5">42 U.S.C. 1320b–5(g)(1)(B)</external-xref>).</text></subsection></section><section id="HEA1808DBFF024224AB21B524AD275CBC"><enum>506.</enum><header>Decentralized clinical studies</header><subsection id="HF8C958FE59494E0B8569E61E0B32E89B"><enum>(a)</enum><header>Guidance</header><text>The Secretary of Health and Human Services shall—</text><paragraph id="HBBAAA04062C2489280C8E34865B157A5"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 12 months after the date of enactment of this Act, issue draft guidance that addresses considerations for decentralized clinical studies, including considerations regarding the engagement, enrollment, and retention of a meaningfully diverse clinical population, with respect to race, ethnicity, age, sex, and geographic location, when appropriate; and</text></paragraph><paragraph id="HF5655C9EF0354681BD0F614CA67B8B52"><enum>(2)</enum><text display-inline="yes-display-inline">not later than 1 year after closing the comment period on such draft guidance, finalize such guidance.</text></paragraph></subsection><subsection id="H1B0BA9193B634C3A8560D409E31FAF79"><enum>(b)</enum><header>Content of guidance</header><text>The guidance under subsection (a) shall address the following:</text><paragraph id="HF9DF79AEF8104F46823DCD2E644CA102"><enum>(1)</enum><text>Recommendations for how digital health technology or other remote assessment options, such as telehealth, could support decentralized clinical studies, including guidance on considerations for selecting technological platforms and mediums, data collection and use, data integrity and security, and communication to study participants through digital technology.</text></paragraph><paragraph id="H20651E9AA9CF4E70889F4D04B87B7CAB"><enum>(2)</enum><text>Recommendations for subject recruitment and retention, including considerations for sponsors to minimize or reduce burdens for clinical study participants through the use of digital health technology, telehealth, local health care providers and laboratories, or other means.</text></paragraph><paragraph id="H37636B7963F74FA6B426683461C59C78"><enum>(3)</enum><text>Recommendations with respect to the evaluation of data collected within a decentralized clinical study setting.</text></paragraph></subsection><subsection id="H35130F27C22742C1BB92FEF032347552"><enum>(c)</enum><header>Definition</header><text>In this section, the term <term>decentralized clinical study</term> means a clinical study in which some or all of the study-related activities occur at a location separate from the investigator’s location.</text></subsection></section></title><title id="H984DF19901B946BA9FEA79ABF8C8B448"><enum>VI</enum><header>Generic Drug Competition</header><section id="H1FE480473C3D4CDCB0F219E9B7939D6C"><enum>601.</enum><header>Increasing transparency in generic drug applications</header><subsection id="H5AD64162FE4A499D97CECD97CBE49DA8"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(3)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H78434149B7374752A06362F5A4DE6606" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="HD281CABC72A341E1A6AE9160811DA335" indent="up2"><enum>(H)</enum><clause commented="no" display-inline="yes-display-inline" id="H0265A314E3774902BE771F14A516E18C"><enum>(i)</enum><text display-inline="yes-display-inline">Upon request (in controlled correspondence or otherwise) by a person that has submitted or intends to submit an abbreviated application for a new drug under this subsection for which the Secretary has specified in regulation, including under section 314.94(a)(9), title 21, Code of Federal Regulations (or a successor regulation), or recommended in applicable guidance, certain qualitative or quantitative criteria with respect to an inactive ingredient, or on the Secretary’s own initiative during the review of such abbreviated application, the Secretary shall inform the person whether such new drug is qualitatively and quantitatively the same as the listed drug. </text></clause><clause id="H12D5D56093C9487AB3A4946FA8D51A2B" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">Notwithstanding section 301(j), if the Secretary determines that such new drug is not qualitatively or quantitatively the same as the listed drug, the Secretary shall identify and disclose to the person—</text><subclause id="H92AA3A3D282C4FE8BB2389C2A9E96EFB"><enum>(I)</enum><text>the ingredient or ingredients that cause the new drug not to be qualitatively or quantitatively the same as the listed drug; and</text></subclause><subclause id="H8300B44BFEB8487BA690B1148FDAA7CC"><enum>(II)</enum><text>for any ingredient for which there is an identified quantitative deviation, the amount of such deviation.</text></subclause></clause><clause id="HCB1EE81A771D49B59BFE52F1538F5C5A" indent="up1"><enum>(iii)</enum><text display-inline="yes-display-inline">If the Secretary determines that such new drug is qualitatively and quantitatively the same as the listed drug, the Secretary shall not change or rescind such determination after the submission of an abbreviated application for such new drug under this subsection unless—</text><subclause id="H241BF67D994A45FAB683F453BEF9DD51"><enum>(I)</enum><text>the formulation of the listed drug has been changed and the Secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness; or</text></subclause><subclause id="H4DA6137AA9E74B30B96D5B9C73A7C347"><enum>(II)</enum><text>the Secretary makes a written determination that the prior determination must be changed because an error has been identified. </text></subclause></clause><clause id="H3BF8C231CAB84D1889BCCEE0993070C4" indent="up1"><enum>(iv)</enum><text display-inline="yes-display-inline">If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).</text></clause><clause id="HC08D7A00F5DA42308083BCE5D5E1049E" indent="up1"><enum>(v)</enum><text>The disclosures required by this subparagraph are disclosures authorized by law including for purposes of section 1905 of title 18, United States Code.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HCA4A43CD81134DEBB5F164FEE018924D"><enum>(b)</enum><header>Guidance</header><paragraph id="HBF6DE06AE969444986572D822098FB39"><enum>(1)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall issue draft guidance, or update guidance, describing how the Secretary will determine whether a new drug is qualitatively and quantitatively the same as the listed drug (as such terms are used in section 505(j)(3)(H) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a)), including with respect to assessing pH adjusters.</text></paragraph><paragraph id="HFFA2CE32C07844459EB06A3C41FDFE42"><enum>(2)</enum><header>Process</header><text display-inline="yes-display-inline">In issuing guidance as required by paragraph (1), the Secretary of Health and Human Services shall—</text><subparagraph id="HF04E0CCF34644B55B4859E594F269453"><enum>(A)</enum><text>publish draft guidance;</text></subparagraph><subparagraph id="H3B8FF43E021749829708518CCD1421F6"><enum>(B)</enum><text>provide a period of at least 60 days for comment on the draft guidance; and</text></subparagraph><subparagraph id="H95EE0817E55D4CF8A9323B6AB94BE597"><enum>(C)</enum><text display-inline="yes-display-inline">after considering any comments received, and not later than one year after the close of the comment period on the draft guidance, publish final guidance.</text></subparagraph></paragraph></subsection><subsection id="H9B7328DF265B44F0BCF257A1F6A92B59"><enum>(c)</enum><header>Applicability</header><text>Section 505(j)(3)(H) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies beginning on the date of enactment of this Act, irrespective of the date on which the guidance required by subsection (b) is finalized.</text></subsection></section><section id="HAFF266E7780E4F09A144ED64E73DA079"><enum>602.</enum><header>Enhancing access to affordable medicines</header><text display-inline="no-display-inline">Section 505(j)(10)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(10)(A)</external-xref>) is amended by striking clauses (i) through (iii) and inserting the following:</text><quoted-block style="OLC" id="H71BFB82F4D87449EBDD8EAC4F0571DFB" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H6BA7A9FE58CB4069863BD1F0E8874423" indent="up2"><enum>(i)</enum><text display-inline="yes-display-inline">a revision to the labeling of the listed drug has been approved by the Secretary within 90 days of when the application is otherwise eligible for approval under this subsection; </text></clause><clause id="H4BCCD6751B9B4176A0D1C20BB0FE2A29" indent="up2"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor of the application agrees to submit revised labeling for the drug that is the subject of the application not later than 60 days after approval under this subsection of the application; </text></clause><clause id="H24A22DC5CE2848018DADB1A06882D2CA" indent="up2"><enum>(iii)</enum><text display-inline="yes-display-inline">the labeling revision described under clause (i) does not include a change to the <quote>Warnings</quote> section of the labeling; and</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></section></title><title id="H30FF2E12D1A145C8BA81B0482C83D682"><enum>VII</enum><header>Research, Development, and Supply Chain Improvements</header><subtitle id="H3D9A08D3E0D74BEABD088DD283366129"><enum>A</enum><header>In General</header><section id="HDB7EA72398B64012BD2720134684F03C"><enum>701.</enum><header>Animal testing alternatives</header><text display-inline="no-display-inline">Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended—</text><paragraph id="H1CC69DA03A214A549B3065123CCF5020"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (b)(5)(B)(i)(II), by striking <quote>animal</quote> and inserting <quote>nonclinical tests</quote>;</text></paragraph><paragraph id="HB79209B908974A9FACC153FFC0034919"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (i)—</text><subparagraph id="H576A3ABEC9DF48CFA9E9CD69B7CE9479"><enum>(A)</enum><text>in paragraph (1)(A), by striking <quote>preclinical tests (including tests on animals)</quote> and inserting <quote>nonclinical tests</quote>; and</text></subparagraph><subparagraph id="HE5B73DAD2A7244B3A25BDFED28B7F5E6"><enum>(B)</enum><text>in paragraph (2)(B), by striking <quote>animal</quote> and inserting <quote>nonclinical tests</quote>; and</text></subparagraph></paragraph><paragraph id="H4F73FFE236D04B3AAFF03EBD9313A344"><enum>(3)</enum><text display-inline="yes-display-inline">after subsection (y), by inserting the following:</text><quoted-block style="OLC" id="HB35394D46EDD4DF289FAE3F2FC415F20" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HCF740195CFFD434D9F1160C64AACBFE2"><enum>(z)</enum><header>Nonclinical test defined</header><text display-inline="yes-display-inline">For purposes of this section, the term <term>nonclinical test</term> means a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test, that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug. Such test may include the following: </text><paragraph id="H1B4ED1EF837443EE91CFBBB15601C6B8"><enum>(1)</enum><text>Cell-based assays.</text></paragraph><paragraph id="H7BA323A8649641F6869511EE0FD96CAD"><enum>(2)</enum><text display-inline="yes-display-inline">Organ chips and microphysiological systems.</text></paragraph><paragraph id="H2CF8640DD2234BAEAD38A62B9BC20893"><enum>(3)</enum><text>Computer modeling.</text></paragraph><paragraph id="H85CAB76409304094986B9DACEEB4843D"><enum>(4)</enum><text>Other nonhuman or human biology-based test methods.</text></paragraph><paragraph id="H30001BE8266D40F6871D512FD4E32BCB"><enum>(5)</enum><text>Animal tests.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="H7CE1EFF637CA4572A5588E7D70FB6234"><enum>702.</enum><header>Emerging technology program</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/201">21 U.S.C. 201 et seq.</external-xref>) is amended by inserting after section 566 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-5">21 U.S.C. 360bbb–5</external-xref>) the following:</text><quoted-block style="OLC" id="HE73CF1500B1E42B594261ECE8B64CEAE" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="HF452EBCBA1994309928F814017228646"><enum>566A.</enum><header>Emerging technology program</header><subsection id="H9DA0B8FDFBEC4249BFB9713E92194055"><enum>(a)</enum><header>Program establishment</header><paragraph id="H1A17810091CE431B8716A777744C3779"><enum>(1)</enum><header>In general</header><text>The Secretary shall establish a program to support the adoption of, and improve the development of, innovative approaches to drug product design and manufacturing.</text></paragraph><paragraph id="H1AB761CB6DA04648B278E87591FD3B30"><enum>(2)</enum><header>Actions</header><text>In carrying out the program under paragraph (1), the Secretary may—</text><subparagraph id="HD03CA1E7547D4D439CA4AC224F24001A"><enum>(A)</enum><text display-inline="yes-display-inline">facilitate and increase communication between public and private entities, consortia, and individuals with respect to innovative drug product design and manufacturing;</text></subparagraph><subparagraph id="HCFDF34DC645F41F48E704D01DC7AB9A0"><enum>(B)</enum><text display-inline="yes-display-inline">solicit information regarding, and conduct or support research on, innovative approaches to drug product design and manufacturing;</text></subparagraph><subparagraph id="HE6775646735A4F41BD259CA9A0E087FE"><enum>(C)</enum><text>convene meetings with representatives of industry, academia, other Federal agencies, international agencies, and other interested persons, as appropriate;</text></subparagraph><subparagraph id="H962F43F38C054DB1B34C4349D5CB2954"><enum>(D)</enum><text display-inline="yes-display-inline">convene working groups to support drug product design and manufacturing research and development;</text></subparagraph><subparagraph id="HD44D57929E4242F7B5D3ED2AEB0ACF09"><enum>(E)</enum><text>support education and training for regulatory staff and scientists related to innovative approaches to drug product design and manufacturing;</text></subparagraph><subparagraph id="H7AB88A91CF924C0E8769CE1C3E08FFA3"><enum>(F)</enum><text display-inline="yes-display-inline">advance regulatory science related to the development and review of innovative approaches to drug product design and manufacturing; </text></subparagraph><subparagraph id="HC8AF25395AC8407D86750A278E66CB95"><enum>(G)</enum><text display-inline="yes-display-inline">convene or participate in working groups to support the harmonization of international regulatory requirements related to innovative approaches to drug product design and manufacturing; and</text></subparagraph><subparagraph id="HB388628A9BAC4FDF82930E506044AE8D"><enum>(H)</enum><text>award grants or contracts to carry out or support the program under paragraph (1).</text></subparagraph></paragraph><paragraph id="H0CD3295ABCF94D67AE1B752D6E20192A"><enum>(3)</enum><header>Grants and contracts</header><text>To seek a grant or contract under this section, an entity shall submit an application—</text><subparagraph id="H1F6A1EDCFC2D45D88E5DDFB838EF8F23"><enum>(A)</enum><text>in such form and manner as the Secretary may require; and</text></subparagraph><subparagraph id="HF1EEED636F3740E5821BBF3095A0A98E"><enum>(B)</enum><text>containing such information as the Secretary may require, including a description of—</text><clause id="H7F101EFFCBE9477FAC65DFC57F664768"><enum>(i)</enum><text>how the entity will conduct the activities to be supported through the grant or contract; and</text></clause><clause id="H22945AF2E79241B19618D3D24A2DE2C3"><enum>(ii)</enum><text display-inline="yes-display-inline">how such activities will further research and development related to, or adoption of, innovative approaches to drug product design and manufacturing.</text></clause></subparagraph></paragraph></subsection><subsection id="H195601B702E4448B8DEBB1F63DD96F09"><enum>(b)</enum><header>Guidance</header><text>The Secretary shall—</text><paragraph id="H9A1552282914410CAC9B6DED6550C08B"><enum>(1)</enum><text display-inline="yes-display-inline">issue or update guidance to help facilitate the adoption of, and advance the development of, innovative approaches to drug product design and manufacturing; and</text></paragraph><paragraph id="HDEE4DFB6EA1F4AC79B80B15BF2EACD6E"><enum>(2)</enum><text>include in such guidance descriptions of—</text><subparagraph id="H9798D7DF4CB44CD1BA0BB5583EBC129A"><enum>(A)</enum><text display-inline="yes-display-inline">any regulatory requirements related to the development or review of technologies related to innovative approaches to drug product design and manufacturing, including updates and improvements to such technologies after product approval; and</text></subparagraph><subparagraph id="H4E6A5A03EE4B499DB32BA58ED35AB08D"><enum>(B)</enum><text>data that can be used to demonstrate the identity, safety, purity, and potency of drugs manufactured using such technologies.</text></subparagraph></paragraph></subsection><subsection id="H928E23693715443AACC85E1B5DBA3CF9"><enum>(c)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 4 years after the date of enactment of this section, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing—</text><paragraph id="HC3FD54DC9BEF4D24BA73062B9404BA79"><enum>(1)</enum><text>an annual accounting of the allocation of funds made available to carry out this section; </text></paragraph><paragraph id="H1B1E5BFCA1D94747AB92ED72D27BB5D2"><enum>(2)</enum><text display-inline="yes-display-inline">a description of how Food and Drug Administration staff were utilized to carry out this section and, as applicable, any challenges or limitations related to staffing;</text></paragraph><paragraph id="HE353AD329681447B9FE10E8806EAE8E4"><enum>(3)</enum><text>the number of public meetings held or participated in by the Food and Drug Administration pursuant to this section, including meetings convened as part of a working group described in subparagraph (D) or (G) of subsection (a)(2), and the topics of each such meeting; and</text></paragraph><paragraph id="H385334D6A9904E28A44909F8F58377C9"><enum>(4)</enum><text>the number of drug products approved or licensed, after the date of enactment of this section, using an innovative approach to drug product design and manufacturing.</text></paragraph></subsection><subsection id="HFDE9E6137AC1474A86ED67718DF68256"><enum>(d)</enum><header>Authorization of appropriations</header><text>To carry out this section, there is authorized to be appropriated $20,000,000 for each fiscal year 2023 through 2027.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H10AEA6EC1DC54C498BDE78E1DE955A43"><enum>703.</enum><header>Improving the treatment of rare diseases and conditions</header><subsection id="H873FA851FA314ED598B54131B9D631ED"><enum>(a)</enum><header>Report on orphan drug program</header><paragraph id="HB7E6A1B13A684F1B8BEE5BCB379C7DEA"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than September 30, 2026, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report summarizing the activities of the Food and Drug Administration related to designating drugs under section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>) for a rare disease or condition and approving such drugs under section 505 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or licensing such drugs under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), including—</text><subparagraph id="H80DBFCCE501B42C39749503D0E6BA541"><enum>(A)</enum><text display-inline="yes-display-inline">the number of applications for such drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) received by the Food and Drug Administration, the number of such applications accepted and rejected for filing, and the number of such applications pending, approved, and disapproved by the Food and Drug Administration;</text></subparagraph><subparagraph id="H1C8CD416315F4C449E10212B35B0D394"><enum>(B)</enum><text>a description of trends in drug approvals for rare diseases and conditions across review divisions at the Food and Drug Administration;</text></subparagraph><subparagraph id="H42E17CFCD3C244AE9043AB7E6FAC5596"><enum>(C)</enum><text display-inline="yes-display-inline">the extent to which the Food and Drug Administration is consulting with external experts pursuant to section 569(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8">21 U.S.C. 360bbb–8(a)(2)</external-xref>) on topics pertaining to drugs for a rare disease or condition, including how and when any such consultation is occurring; and</text></subparagraph><subparagraph id="HDAA9EB572FAC429586BF6DAE6A68DCB3"><enum>(D)</enum><text>the Food and Drug Administration’s efforts to promote best practices in the development of novel treatments for rare diseases, including—</text><clause id="H5AA3C49FFC9241E8863307FE32778236"><enum>(i)</enum><text>reviewer training on rare disease-related policies, methods, and tools; and</text></clause><clause id="H77B7D6C702D84C41A139856C24C3D62D"><enum>(ii)</enum><text>new regulatory science and coordinated support for patient and stakeholder engagement.</text></clause></subparagraph></paragraph><paragraph id="H0D05A00F35F54EFD8E76E6D6FD6407E2"><enum>(2)</enum><header>Public availability</header><text>The Secretary shall make the report under paragraph (1) available to the public, including by posting the report on the website of the Food and Drug Administration.</text></paragraph><paragraph id="H95FF3303F74F4E029163F52A80459C30"><enum>(3)</enum><header>Information disclosure</header><text>Nothing in this subsection shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 1905 of title 18, United States Code, or subject to withholding under paragraph (4) of section 552(b) of title 5, United States Code (commonly referred to as the <quote>Freedom of Information Act</quote>).</text></paragraph></subsection><subsection id="H9EFC9C186DF84960BC7C6D4DD55E3C48"><enum>(b)</enum><header>Study on European Union safety and efficacy reviews of drugs for rare diseases and conditions</header><paragraph id="HFE2B0E50800E46E082425E777E9D033D"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall enter into a contract with an appropriate entity to conduct a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union, including—</text><subparagraph id="HED4108B318424F15B8D70AE077617D62"><enum>(A)</enum><text display-inline="yes-display-inline">flexibilities, authorities, or mechanisms available to regulators in the United States and the European Union specific to rare diseases or conditions;</text></subparagraph><subparagraph id="H723A9B1675CC47C49AADB97FC1EDBB02"><enum>(B)</enum><text display-inline="yes-display-inline">the consideration and use of supplemental data submitted during review processes in the United States and the European Union, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions;</text></subparagraph><subparagraph id="HB63951533A09491EBC55094C23DF2FA6"><enum>(C)</enum><text display-inline="yes-display-inline">an assessment of collaborative efforts between United States and European Union regulators related to—</text><clause id="H3F8382D3BD504FED81B62BB828FE96BE"><enum>(i)</enum><text>product development programs under review;</text></clause><clause id="H9EE6B2E3939241C783708D50308C8224"><enum>(ii)</enum><text>policies under development recently issued; and</text></clause><clause id="HFADFBA37001543BF95CF36A1C9B82CC4"><enum>(iii)</enum><text>scientific information related to product development or regulation; and</text></clause></subparagraph><subparagraph id="H4A2D40D77FF94CD19322D346E7F7EF92"><enum>(D)</enum><text display-inline="yes-display-inline">recommendations for how Congress can support collaborative efforts described in subparagraph (C).</text></subparagraph></paragraph><paragraph id="H6D3EDCB77CEC40F08BFF6F3DB57F24A7"><enum>(2)</enum><header>Consultation</header><text display-inline="yes-display-inline">The contract under paragraph (1) shall provide for consultation with relevant stakeholders, including—</text><subparagraph id="H528331B45DE44014B6E8E4BD705A603D"><enum>(A)</enum><text display-inline="yes-display-inline">representatives from the Food and Drug Administration and the European Medicines Agency;</text></subparagraph><subparagraph id="HAEF3D18B8C7E4AE99040299D2C78C2F7"><enum>(B)</enum><text>rare disease or condition patients; and</text></subparagraph><subparagraph id="H9EF297B5DE364392BDC7111D7B91CAE7"><enum>(C)</enum><text>patient groups that—</text><clause id="HD52534B121B54EBB9EB6B9181A23EA08"><enum>(i)</enum><text>represent rare disease or condition patients; and</text></clause><clause id="HD7FC416F50A543B5A064F703DCA55252"><enum>(ii)</enum><text>have international patient outreach.</text></clause></subparagraph></paragraph><paragraph id="HF8E8C25F66DB4C8184CB75E81F6E257F"><enum>(3)</enum><header>Report</header><text display-inline="yes-display-inline">The contract under paragraph (1) shall provide for, not later than 2 years after the date of entering into such contract—</text><subparagraph id="H28385E3549B549F5A5B75DCB42A3015D"><enum>(A)</enum><text>the completion of the study under paragraph (1); and</text></subparagraph><subparagraph id="HA0D14E3E7FA14490A7564F8290AEAA05"><enum>(B)</enum><text display-inline="yes-display-inline">the submission of a report on the results of such study to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate.</text></subparagraph></paragraph><paragraph id="H86551C60A71F4EC794B2C5D29F42BC8C"><enum>(4)</enum><header>Public availability</header><text display-inline="yes-display-inline">The contract under paragraph (1) shall provide for the appropriate entity referred to in paragraph (1) to make the report under paragraph (3) available to the public, including by posting the report on the website of the appropriate entity.</text></paragraph></subsection><subsection id="H3C56D0C452FB469D88EBCD943A0C0AD5"><enum>(c)</enum><header>Public meeting</header><paragraph id="H81F8DF7148364B7A956133F26186402D"><enum>(1)</enum><header>In general</header><text>Not later than December 31, 2023, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall convene one or more public meetings to solicit input from stakeholders regarding the approaches described in paragraph (2).</text></paragraph><paragraph id="H16ED2CBF911F465D985B9C1C5CA0BBA0"><enum>(2)</enum><header>Approaches</header><text display-inline="yes-display-inline">The public meeting or meetings under paragraph (1) shall address approaches to increasing and improving engagement with rare disease or condition patients, groups representing such patients, rare disease or condition expert<italic></italic>s, and experts on small population studies, in order to improve the understanding with respect to rare diseases or conditions of—</text><subparagraph id="H2C3B6DE2C0B34CABBC492ECE662FED21" display-inline="no-display-inline"><enum>(A)</enum><text>patient burden;</text></subparagraph><subparagraph id="H4F54E901A5024249964164C74B41878B"><enum>(B)</enum><text>treatment options; and</text></subparagraph><subparagraph id="HCFD4479886714CE09A2586FA6D5211F5"><enum>(C)</enum><text>side effects of treatments, including—</text><clause id="HB863F7B3B00F410D9F82B28D6A0D9F99"><enum>(i)</enum><text>comparing the side effects of treatments; and</text></clause><clause id="H2A612D93D0E7467887462D59752A66BA"><enum>(ii)</enum><text>understanding the risks of side effects relative to the health status of the patient and the progression of the disease or condition.</text></clause></subparagraph></paragraph><paragraph id="HA8E3C235684D4104951E1C32BC9BA823"><enum>(3)</enum><header>Public docket</header><text>The Secretary of Health and Human Services shall establish a public docket to receive written comments related to the approaches addressed during each public meeting under paragraph (1). Such public docket shall remain open for 60 days following the date of each such public meeting.</text></paragraph><paragraph id="H7F1748B382AD4AE38B9335E4E32002F5"><enum>(4)</enum><header>Reports</header><text>Not later than 180 days after each public meeting under paragraph (1), the Commissioner of Food and Drugs shall develop and publish on the website of the Food and Drug Administration a report on—</text><subparagraph id="H758261DB32B944608640E0602607435B"><enum>(A)</enum><text>the approaches discussed at the public meeting; and</text></subparagraph><subparagraph id="H463CB03B011E480DBF5354BB396A1EBF"><enum>(B)</enum><text>any related recommendations.</text></subparagraph></paragraph></subsection><subsection id="HC6AFFE9860F543FBBB0CFDA49F194D6E"><enum>(d)</enum><header>Consultation on the science of small population studies</header><text display-inline="yes-display-inline">Section 569(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8">21 U.S.C. 360bbb–8(a)(2)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H96D815FA20D1475B9239F305135EC499" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H80E6F7C53CEC45758E3A3683ADC238D1"><enum>(C)</enum><header>Small population studies</header><text display-inline="yes-display-inline">The external experts on the list maintained pursuant to subparagraph (A) may include experts on the science of small population studies.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H076755FDCA494575BD063322D23B5752"><enum>(e)</enum><header>Study on sufficiency and use of FDA mechanisms for incorporating the patient and clinician perspective in FDA processes related to applications concerning drugs for rare diseases or conditions</header><paragraph id="H4E0CFDB2E2664127A0EC52A1A604C0B6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall conduct a study on the use of Food and Drug Administration mechanisms and tools to ensure that patient and physician perspectives are considered and incorporated throughout the processes of the Food and Drug Administration—</text><subparagraph id="H419912504AF0490E8235FA373C5718C4"><enum>(A)</enum><text display-inline="yes-display-inline">for approving or licensing under section 505 of the Federal Food, Drug, or Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) a drug designated as a drug for a rare disease or condition under section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>); and</text></subparagraph><subparagraph id="HA6818FEE02DD43968A644E7B95E0E63A"><enum>(B)</enum><text display-inline="yes-display-inline">in making any determination related to such a drug’s approval, including assessment of the drug’s—</text><clause id="HB269D2CC9AF74ED79AD6BABF54DB6A4D"><enum>(i)</enum><text>safety or effectiveness; or</text></clause><clause id="H5AA2DBC8329742DFB6E859FE1AF6C62D"><enum>(ii)</enum><text>postapproval safety monitoring.</text></clause></subparagraph></paragraph><paragraph id="HDF5EC5621FF541D8B799730581CDCD01"><enum>(2)</enum><header>Topics</header><text>The study under paragraph (1) shall—</text><subparagraph id="HD3D40EEFB2E743FA9784A476046DCC86"><enum>(A)</enum><text display-inline="yes-display-inline">identify and compare the processes that the Food and Drug Administration has formally put in place and utilized to gather external expertise (including patients, patient groups, and physicians) related to applications for rare diseases or conditions;</text></subparagraph><subparagraph id="HBD1D8F43BF3F4058A999CFEE2B9EF102"><enum>(B)</enum><text display-inline="yes-display-inline">examine tools or mechanisms to improve efforts and initiatives of the Food and Drug Administration to collect and consider such external expertise with respect to applications for rare diseases or conditions throughout the application review and approval or licensure processes, including within internal benefit-risk assessments, advisory committee processes, and postapproval safety monitoring; and</text></subparagraph><subparagraph id="H4F96E04D404647F1BCE7DAF770ECA3DF"><enum>(C)</enum><text display-inline="yes-display-inline">examine processes or alternatives to address or resolve conflicts of interest that impede the Food and Drug Administration in gaining external expert input on rare diseases or conditions with a limited set of clinical and research experts. </text></subparagraph></paragraph><paragraph id="H272C2D060C9D4832855FA54A56D9D0D7"><enum>(3)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall— </text><subparagraph id="H391E8841B9A34F27BA2A4AECE83B4F1E"><enum>(A)</enum><text>complete the study under paragraph (1);</text></subparagraph><subparagraph id="H62F845C934BE4075B653E20DDB3A162F"><enum>(B)</enum><text>submit a report on the results of such study to the Congress; and</text></subparagraph><subparagraph id="HC74C0347513F4CBDA4EC54FA50E08874"><enum>(C)</enum><text display-inline="yes-display-inline">include in such report recommendations, if appropriate, for changes to the processes and authorities of the Food and Drug Administration to improve the collection and consideration of external expert opinions of patients, patient groups, and physicians with expertise in rare diseases or conditions.</text></subparagraph></paragraph></subsection><subsection id="H9464891FFB404818A2081A876D6D818C"><enum>(f)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <term>rare disease or condition</term> has the meaning given such term in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb(a)(2)</external-xref>).</text></subsection></section><section id="HF147978FC8E041BCBCBAACA867AB0AD8"><enum>704.</enum><header>Antifungal research and development</header><subsection id="H0EB7EF347F2F4A65BB1FA47C64009C1D"><enum>(a)</enum><header>Draft guidance</header><text>Not later than 3 years after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue draft guidance for industry for the purposes of assisting entities seeking approval under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or licensure under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) of antifungal therapies designed to treat coccidioidomycosis (commonly known as Valley Fever).</text></subsection><subsection id="H74DFE95A723D4485AA0748D4C56D6120"><enum>(b)</enum><header>Final guidance</header><text>Not later than 18 months after the close of the public comment period on the draft guidance issued pursuant to subsection (a), the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall finalize the draft guidance.</text></subsection><subsection id="H881758CA227D434ABE2AD39673A1758B"><enum>(c)</enum><header>Workshop</header><text>To assist entities developing preventive vaccines for fungal infections and coccidioidomycosis, the Secretary of Health and Human Services shall hold a public workshop.</text></subsection></section><section id="HCC6B5A4E475049C58E92E9CA47BAD0C8"><enum>705.</enum><header>Advancing qualified infectious disease product innovation</header><subsection id="H503B5AD48181415784E825375BD8BC73"><enum>(a)</enum><header>In general</header><text>Section 505E of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) is amended—</text><paragraph id="H10E6A8A0AD7F4CDB85D82B0F50FD62B4"><enum>(1)</enum><text>in subsection (c)—</text><subparagraph id="H916BFD62A8C54362B5F0DCADEBEC5461"><enum>(A)</enum><text>in paragraph (2), by striking <quote>or</quote> at the end;</text></subparagraph><subparagraph id="HF43B3CB8C015461895032F5E6181185F"><enum>(B)</enum><text>in paragraph (3), by striking the period at the end and inserting <quote>; or</quote>; and</text></subparagraph><subparagraph id="H2F6BE918A03E478A9B731B69AC7CA7FF"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block id="HE27803A67B7F46F9B66B9940C34F5403" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HA851644AB99D43CCB62823F178288D4B"><enum>(4)</enum><text>an application pursuant to section 351(a) of the Public Health Service Act.</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H376110481F7C432082DB1CE8EF131B84"><enum>(2)</enum><text>in subsection (d)(1), by inserting <quote>of this Act or section 351(a) of the Public Health Service Act</quote> after <quote>section 505(b)</quote>; and</text></paragraph><paragraph id="H04603F57B015476D907ED3DF93B6B827"><enum>(3)</enum><text>by amending subsection (g) to read as follows:</text><quoted-block id="HF1D404549DD149FC95FEC4D9AFEAA88C" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HBC6A3F3C1D9C464BAFDE4D0F551490D2"><enum>(g)</enum><header>Qualified infectious disease product</header><text>The term <term>qualified infectious disease product</term> means a drug, including an antibacterial or antifungal drug or a biological product, for human use that—</text><paragraph id="HF333BB4CAA014E0DAB75AE63A1E42929"><enum>(1)</enum><text>acts directly on bacteria or fungi or on substances produced by such bacteria or fungi; and</text></paragraph><paragraph id="H1DE320F1B1504665B3391AD7A9FBFCDC"><enum>(2)</enum><text>is intended to treat a serious or life-threatening infection, including such an infection caused by—</text><subparagraph id="H9C3A549313B042469CE6BA61367EA862"><enum>(A)</enum><text>an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or</text></subparagraph><subparagraph id="HAB7F82C2A90F4F2C99960AF0B7307C0D"><enum>(B)</enum><text>qualifying pathogens listed by the Secretary under subsection (f).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HAD5A3BF4ADCA4352B8666820947D2C51"><enum>(b)</enum><header>Priority review</header><text>Section 524A(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360n-1">21 U.S.C. 360n–1(a)</external-xref>) is amended by inserting <quote>of this Act or section 351(a) of the Public Health Service Act that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness<italic></italic></quote> before the period at the end.</text></subsection></section><section id="HE70950D1BA4E425FB7BBCF2B938CF571"><enum>706.</enum><header>Advanced manufacturing technologies designation pilot program</header><text display-inline="no-display-inline">Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by inserting after section 506J (<external-xref legal-doc="usc" parsable-cite="usc/21/356j">21 U.S.C. 356j</external-xref>) the following:</text><quoted-block id="HD4F0E188725F40BA8FE255AC37A76D7C" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="H5890EB1512364E9FBDDC578B5E36ED6A"><enum>506K.</enum><header>Advanced manufacturing technologies designation pilot program</header><subsection id="HDB4B537BD29B4DAEBE48E9514DC1D133"><enum>(a)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of this section, the Secretary shall initiate a pilot program under which persons may request designation of an advanced manufacturing technology as described in subsection (b).</text></subsection><subsection id="HB56034118C2B4671883F4A7CD3A0464D"><enum>(b)</enum><header>Designation process</header><text>The Secretary shall establish a process for the designation under this section of methods of manufacturing drugs, including biological products, and active pharmaceutical ingredients of such drugs, as advanced manufacturing technologies. A method of manufacturing, or a combination of manufacturing methods, is eligible for designation as an advanced manufacturing technology if such method or combination of methods incorporates a novel technology, or uses an established technique or technology in a novel way, that will substantially improve the manufacturing process for a drug and maintain equivalent or provide superior drug quality, including by—</text><paragraph id="H508DF1CEA3714742B1AFE85FF1C264E2"><enum>(1)</enum><text>reducing development time for a drug using the designated manufacturing method; or</text></paragraph><paragraph id="HA9B72869EA7F40D292CAF1F182232246"><enum>(2)</enum><text>increasing or maintaining the supply of—</text><subparagraph id="HE3E83F0CC3474114A45D6D382142CF08"><enum>(A)</enum><text>a drug that is described in section 506C(a) and is intended to treat a serious or life-threatening condition; or</text></subparagraph><subparagraph id="HBE0C8E4AE5F440FBBBB7899E9F8C9821"><enum>(B)</enum><text>a drug that is on the drug shortage list under section 506E.</text></subparagraph></paragraph></subsection><subsection id="H2E93CC85E65D480C9DE911D3C93DBF61"><enum>(c)</enum><header>Evaluation and designation of an advanced manufacturing technology</header><paragraph id="H219B75E5C20D411585323B2816D56B1E"><enum>(1)</enum><header>Submission</header><text>A person who requests designation of a method of manufacturing as an advanced manufacturing technology under this section shall submit to the Secretary data or information demonstrating that the method of manufacturing meets the criteria described in subsection (b) in a particular context of use. The Secretary may facilitate the development and review of such data or information by—</text><subparagraph id="H2A3C2FEF3F2A4B93A6C69BBDAD68B144"><enum>(A)</enum><text>providing timely advice to, and interactive communication with, such person regarding the development of the method of manufacturing; and</text></subparagraph><subparagraph id="HAAD8DAF88D58472A82985B2A712F8DAD"><enum>(B)</enum><text>involving senior managers and experienced staff of the Food and Drug Administration, as appropriate, in a collaborative, cross-disciplinary review of the method of manufacturing, as applicable.</text></subparagraph></paragraph><paragraph id="HD6E506AB8EFE4FFEB5F30C2A5400D9D4"><enum>(2)</enum><header>Evaluation and designation</header><text>Not later than 180 calendar days after the receipt of a request under paragraph (1), the Secretary shall determine whether to designate such method of manufacturing as an advanced manufacturing technology, in a particular context of use, based on the data and information submitted under paragraph (1) and the criteria described in subsection (b).</text></paragraph></subsection><subsection id="H1AF9CE7F16154D53B9848BE4926E703E"><enum>(d)</enum><header>Review of advanced manufacturing technologies</header><text>If the Secretary designates a method of manufacturing as an advanced manufacturing technology, the Secretary shall—</text><paragraph id="H7053F8BA6C464E05863A94EF05801F87"><enum>(1)</enum><text>expedite the development and review of an application submitted under section 505 of this Act or section 351 of the Public Health Service Act, including supplemental applications, for drugs that are manufactured using a designated advanced manufacturing technology and could help mitigate or prevent a shortage or substantially improve manufacturing processes for a drug and maintain equivalent or provide superior drug quality, as described in subsection (b); and</text></paragraph><paragraph id="H050061DE6F4B4155ADFAABA7007E2BF7"><enum>(2)</enum><text>allow the holder of an advanced technology designation, or a person authorized by the advanced manufacturing technology designation holder, to reference or rely upon, in an application submitted under section 505 of this Act or section 351 of the Public Health Service Act, including a supplemental application, data and information about the designated advanced manufacturing technology for use in manufacturing drugs in the same context of use for which the designation was granted.</text></paragraph></subsection><subsection id="HEABD7E4141F04570B5D9895114C868FA"><enum>(e)</enum><header>Implementation and evaluation of advanced manufacturing technologies pilot</header><paragraph id="HF415DB77EB1941A1A1E4D9B3DD29EA50"><enum>(1)</enum><header>Public meeting</header><text>The Secretary shall publish in the Federal Register a notice of a public meeting, to be held not later than 180 days after the date of enactment of this section, to discuss and obtain input and recommendations from relevant stakeholders regarding—</text><subparagraph id="HC02C2DBF39734C009B8913EED1014746"><enum>(A)</enum><text>the goals and scope of the pilot program, and a suitable framework, procedures, and requirements for such program; and</text></subparagraph><subparagraph id="HAA767DCFD64A45F494750E02D80E18D3"><enum>(B)</enum><text>ways in which the Food and Drug Administration will support the use of advanced manufacturing technologies and other innovative manufacturing approaches for drugs.</text></subparagraph></paragraph><paragraph id="HF18FF915ACE846638FCDE1801268C4E3"><enum>(2)</enum><header>Pilot program guidance</header><subparagraph id="H60B935C906204B46A81071F90D71DD1E"><enum>(A)</enum><header>In general</header><text>The Secretary shall—</text><clause id="HC470F114D8AD4CCD8798A828F855A636"><enum>(i)</enum><text>not later than 180 days after the public meeting under paragraph (1), issue draft guidance regarding the goals and implementation of the pilot program under this section; and</text></clause><clause id="H7DF81E72D62D493FA8086F9D4A020DED"><enum>(ii)</enum><text>not later than 2 years after the date of enactment of this section, issue final guidance regarding the implementation of such program.</text></clause></subparagraph><subparagraph id="HFAE92C2E1B7640F09DA83EAA8289BD3E"><enum>(B)</enum><header>Content</header><text>The guidance described in subparagraph (A) shall address—</text><clause id="H3F5281D3851D41EA869C920751042831"><enum>(i)</enum><text>the process by which a person may request a designation under subsection (b);</text></clause><clause id="HE5AD1BDD8D8D4EFC80F507311DEDC0EA"><enum>(ii)</enum><text>the data and information that a person requesting such a designation is required to submit under subsection (c), and how the Secretary intends to evaluate such submissions;</text></clause><clause id="HED039CF472A9475582259453C4C632D6"><enum>(iii)</enum><text>the process to expedite the development and review of applications under subsection (d); and</text></clause><clause id="H2490E573AE3241C3B89380552887BD9F"><enum>(iv)</enum><text>the criteria described in subsection (b) for eligibility for such a designation.</text></clause></subparagraph></paragraph><paragraph id="H7FCBADE24AC640C880A2E5FFF6954C20"><enum>(3)</enum><header>Report</header><text>Not later than 3 years after the date of enactment of this section and annually thereafter, the Secretary shall publish on the website of the Food and Drug Administration and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing a description and evaluation of the pilot program being conducted under this section, including the types of innovative manufacturing approaches supported under the program. Such report shall include the following:</text><subparagraph id="HCE81331C91C9491AA44875997EFC8741"><enum>(A)</enum><text>The number of persons that have requested designations and that have been granted designations.</text></subparagraph><subparagraph id="H15699C3F50C44B32A270CF0761E73AAA"><enum>(B)</enum><text>The number of methods of manufacturing that have been the subject of designation requests and that have been granted designations.</text></subparagraph><subparagraph id="H86003F8F9CEB4317ABE0E6BF1D115305"><enum>(C)</enum><text>The average number of calendar days for completion of evaluations under subsection (c)(2).</text></subparagraph><subparagraph id="HA8D4A68D850345BC804E65637E84EF89"><enum>(D)</enum><text>An analysis of the factors in data submissions that are relevant to determinations to designate and not to designate after evaluation under subsection (c)(2).</text></subparagraph><subparagraph id="HB1E279DEABC84816A7520E12B9B2822D"><enum>(E)</enum><text>The number of applications received under section 505 of this Act or section 351 of the Public Health Service Act, including supplemental applications, that have included an advanced manufacturing technology designated under this section, and the number of such applications approved.</text></subparagraph></paragraph></subsection><subsection id="HE59AAE6D76CB471CB1360D08858A1E81"><enum>(f)</enum><header>Sunset</header><text>The Secretary—</text><paragraph id="H1D0A996B3A2949AAB4E29BD71A8D6B4B"><enum>(1)</enum><text>may not consider any requests for designation submitted under subsection (c) after October 1, 2029; and</text></paragraph><paragraph id="H4E92DA3571A245B587366F0FA26D6C41"><enum>(2)</enum><text>may continue all activities under this section with respect to advanced manufacturing technologies that were designated pursuant to subsection (d) prior to such date, if the Secretary determines such activities are in the interest of the public health.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H64C0E97BCFFF4396BAE66613143D5E12"><enum>707.</enum><header>Public workshop on cell therapies</header><text display-inline="no-display-inline">Not later than 3 years after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall convene a public workshop with relevant stakeholders to discuss best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue-, and cellular-based medical products (and the latest scientific information about such products) that are regulated as drugs under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>) and biological products under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), namely, stem-cell and other cellular therapies.</text></section><section id="HABD915002E794862AD8A5895F550518B"><enum>708.</enum><header>Reauthorization of best pharmaceuticals for children</header><text display-inline="no-display-inline">Section 409I(d)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284m">42 U.S.C. 284m(d)(1)</external-xref>) is amended by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></section><section id="HA140D3A4D44041C3B0B71690343C3A55"><enum>709.</enum><header>Reauthorization for humanitarian device exemption and demonstration grants for improving pediatric availability</header><subsection id="HEA4CC17CE04E4A65A63AEDD4132FC47D"><enum>(a)</enum><header>Humanitarian device exemption</header><text display-inline="yes-display-inline">Section 520(m)(6)(A)(iv) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(m)(6)(A)(iv)</external-xref>) is amended by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></subsection><subsection id="HD6B4030D9CB74907A5B2787F9530E700"><enum>(b)</enum><header>Pediatric Medical Device Safety and Improvement Act</header><text>Section 305(e) of the Pediatric Medical Device Safety and Improvement Act of 2007 (<external-xref legal-doc="public-law" parsable-cite="pl/110/85">Public Law 110–85</external-xref>) is amended by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></subsection></section><section id="H5E6BB07EBE86451FA18F2488A8956579"><enum>710.</enum><header>Reauthorization of provision related to exclusivity of certain drugs containing single enantiomers</header><text display-inline="no-display-inline">Section 505(u)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(u)(4)</external-xref>) is amended by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></section><section id="H035F88099C7742AA8C337CCE1BFCED46"><enum>711.</enum><header>Reauthorization of the critical path public-private partnership program</header><text display-inline="no-display-inline">Section 566(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-5">21 U.S.C. 360bbb–5(f)</external-xref>) is amended by striking <quote>$6,000,000 for each of fiscal years 2018 through 2022</quote> and inserting <quote>$10,000,000 for each of fiscal years 2023 through 2027</quote>.</text></section><section id="HA7AF67BB67984F45B9469273B4941043"><enum>712.</enum><header>Reauthorization of orphan drug grants</header><text display-inline="no-display-inline">Section 5 of the Orphan Drug Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ee">21 U.S.C. 360ee</external-xref>) is amended—</text><paragraph id="H45D0F98881EC4A05AA8541F3CCBA3DDC"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="H25C3CCBD324C44BABA56BBD92FBDED97"><enum>(A)</enum><text>by striking <quote>and (3)</quote> and inserting <quote>(3)</quote>; and</text></subparagraph><subparagraph id="HF1A172521B304FAAB978C3B6BBACAC35"><enum>(B)</enum><text>by inserting before the period at the end the following: <quote>, and (4) developing regulatory science pertaining to the chemistry, manufacturing, and controls of individualized medical products to treat individuals with rare diseases or conditions</quote>; and</text></subparagraph></paragraph><paragraph id="H89222552BB0C43BC80B05CABB752F8CF"><enum>(2)</enum><text>in subsection (c), by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>.</text></paragraph></section><section id="HF74DA43AE1A746EBB5AA62E5208ABB1D"><enum>713.</enum><header>Research into pediatric uses of drugs; additional authorities of Food and Drug Administration regarding molecularly targeted cancer drugs</header><subsection id="HA0091E4AF338423FA18973617DB1571B"><enum>(a)</enum><header>In general</header><paragraph id="H703F510CAA9E4E98910C684A9DF8F135"><enum>(1)</enum><header>Additional active ingredient for application drug; limitation regarding novel-combination application drug</header><text>Section 505B(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(3)</external-xref>) is amended—</text><subparagraph id="HC5BDCB175043431F86166E2B8FBA3E8E"><enum>(A)</enum><text>by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and</text></subparagraph><subparagraph id="H659D91BFF3D84FB0A99311C7B220C806"><enum>(B)</enum><text>by striking subparagraph (A) and inserting the following:</text><quoted-block style="OLC" id="H32076BDC77A448099CEB40E03725710A" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H9CFDE1A420B44886A95053D284767EA8"><enum>(A)</enum><header>In general</header><text>For purposes of paragraph (1)(B), the investigation described in this paragraph is (as determined by the Secretary) a molecularly targeted pediatric cancer investigation of—</text><clause id="H2281A1EFD4BA4BC1B780633DE27327A3"><enum>(i)</enum><text>the drug or biological product for which the application referred to in such paragraph is submitted; or</text></clause><clause id="H47E32538356A42979CEA3B7DB8C854ED"><enum>(ii)</enum><text>such drug or biological product in combination with—</text><subclause id="H8C8E300A7FAA4097965885670F56F802"><enum>(I)</enum><text display-inline="yes-display-inline">an active ingredient of a drug or biological product—</text><item id="H33B3D3F1DDF84DCB820D17067BA62997"><enum>(aa)</enum><text>for which an approved application under section 505(j) under this Act or under section 351(k) of the Public Health Service Act is in effect; and</text></item><item id="HAF8BE14FBCB745218CBB0A3EB53530FD"><enum>(bb)</enum><text>that is determined by the Secretary to be the standard of care for treating a pediatric cancer; or</text></item></subclause><subclause id="HB951DCEC173E4BD6910C3418BF2ADEBF"><enum>(II)</enum><text display-inline="yes-display-inline">an active ingredient of a drug or biological product—</text><item id="H5A213523ED4440D09102EF883353F593"><enum>(aa)</enum><text>for which an approved application under section 505(b) of this Act or section 351(a) of the Public Health Service Act to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and</text></item><item id="H59EA4755D3334A99AA2C5E7B20676A14"><enum>(bb)</enum><text>that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer. </text></item></subclause></clause></subparagraph><subparagraph id="HF492F036B1974758905EF8885D83FA79"><enum>(B)</enum><header>Additional requirements</header><clause id="H448BCCEF000C4B22BD78B8020C28ECB9"><enum>(i)</enum><header>Design of investigation</header><text display-inline="yes-display-inline">A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.</text></clause><clause id="H67F834C96DB248CCAAC172DD2320540C"><enum>(ii)</enum><header>Limitation</header><text>An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—</text><subclause id="H27C22177B5D54160B04B2B7604B2E6CF"><enum>(I)</enum><text>a single new active ingredient; or </text></subclause><subclause id="HF752FA17E24346F1874F7487DF7977C1"><enum>(II)</enum><text>more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient has been previously approved to treat an adult cancer. </text></subclause></clause><clause id="H4360FEBEBC35438DB9087E844760CC88"><enum>(iii)</enum><header>Results of already-completed preclinical studies of application drug</header><text>The Secretary may require that reports on an investigation required pursuant to paragraph (1)(B) include the results of all preclinical studies on which the decision to conduct such investigation was based.</text></clause><clause id="H90D594336E3747E9A6DDC1B0BBF0A730"><enum>(iv)</enum><header>Rule of construction regarding inactive ingredients</header><text>With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H5BA726DCF0E74B42B9E19F6F5BAE802C"><enum>(2)</enum><header>Determination of applicable requirements</header><text display-inline="yes-display-inline">Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)(1)</external-xref>) is amended by adding at the end the following: <quote>The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) shall apply with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).</quote>. </text></paragraph><paragraph id="H0A671696BAF342F09B7944B58C16F0FD"><enum>(3)</enum><header>Clarifying applicability</header><text display-inline="yes-display-inline"><italic></italic>Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(1)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HF0D0675F543C4AFF9E2169D4234C2812" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H947962C95C3D45ED8D2FB074372E5253"><enum>(C)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be subject to the requirements of subparagraph (B).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H30CA799B08244FA98AC14AA746E4F2B0"><enum>(4)</enum><header>Conforming amendments</header><text>Section 505B(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)</external-xref>) is amended—</text><subparagraph id="H09D3D1C164AD46B0A751265BE12473BA"><enum>(A)</enum><text>in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking <quote>investigations described in this paragraph</quote> and inserting <quote>investigations referred to in subparagraph (A)</quote>; and</text></subparagraph><subparagraph id="HF8E429C6836C403F8A19F7CBA6299409"><enum>(B)</enum><text>in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking <quote>the assessments under paragraph (2)(B)</quote> and inserting <quote>the assessments required under paragraph (1)(A)</quote>.</text></subparagraph></paragraph></subsection><subsection id="H498FD7A964D74C018065B81D59F80220"><enum>(b)</enum><header>Guidance</header><text display-inline="yes-display-inline">The Secretary shall—</text><paragraph id="HBB4C1D0395914AADA438471EA35F7A73"><enum>(1)</enum><text>not later than 6 months after the date of enactment of this Act, issue draft guidance on the implementation of the requirements in subsection (a); and</text></paragraph><paragraph id="HA8DE4A43B9FB41088800636D58CE21E6"><enum>(2)</enum><text>not later than 12 months after closing the comment period on such draft guidance, finalize such guidance.</text></paragraph></subsection><subsection id="HED5E345C94EE404B83F34FCEDACD62EF" commented="no"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">The amendments made by this section apply with respect to any application under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) and any application under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), that is submitted on or after the date that is 3 years after the date of enactment of this Act.</text></subsection><subsection id="H7E0185B190AD4EB29FE8C036123F3C1D"><enum>(d)</enum><header>Reports to Congress</header><paragraph id="H5D3BA3EDD0E646CD9832F5D8B34FC1FC"><enum>(1)</enum><header>Secretary of Health and Human Services</header><text display-inline="yes-display-inline">Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the Secretary’s efforts, in coordination with industry, to ensure implementation of the amendments made by subsection (a).</text></paragraph><paragraph id="H3B4A2D362BAE4FDC8C3EBE3CA32DE4EE"><enum>(2)</enum><header>GAO study and report</header><subparagraph id="HAD84A1AC9BD6488A8062B568BC19E895"><enum>(A)</enum><header>Study</header><text>Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study of the effectiveness of requiring assessments and investigations described in section 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.355c), as amended by subsection (a), in the development of drugs and biological products for pediatric cancer indications.</text></subparagraph><subparagraph id="HBF8E038C29084D39A9A0D18AD6DB58DF"><enum>(B)</enum><header>Findings</header><text>Not later than 4 years after the date of enactment of this Act, the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the findings of the study conducted under subparagraph (A).</text></subparagraph></paragraph></subsection></section></subtitle><subtitle id="HF2F48029B55D4E008F34E2B5C6D06E0C"><enum>B</enum><header>Inspections</header><section id="H569DD81C83FF405FAE69BFFC51018F74"><enum>721.</enum><header>Factory inspection</header><subsection id="H6C66B8676041425D9922583728794127"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 704(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(a)(1)</external-xref>) is amended by striking <quote>restricted devices</quote> each place it appears and inserting <quote>devices</quote>. </text></subsection><subsection id="H292036696506455895276C77D978ECF1"><enum>(b)</enum><header>Records or other information</header><paragraph id="H68511D43D7E14A8794A7760CF7CE9FAB"><enum>(1)</enum><header>Establishments</header><text>Section 704(a)(4)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(a)(4)(A)</external-xref>) is amended—</text><subparagraph id="H24A3DD514B49490D804A8EA78DBC41A7"><enum>(A)</enum><text>by striking <quote>an establishment that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug</quote> and inserting <quote>an establishment that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or device, or that is subject to inspection under paragraph (5)(C),</quote>; and</text></subparagraph><subparagraph id="H64AEE603258742A1A8D31DCE4503D5DE"><enum>(B)</enum><text>by inserting after <quote>a sufficient description of the records requested</quote> the following: <quote>and a rationale for requesting such records or other information in advance of, or in lieu of, an inspection</quote>.</text></subparagraph></paragraph><paragraph id="H29E46E30A5824F44A1693F22082CFD30"><enum>(2)</enum><header>Guidance</header><subparagraph id="HC8739282715F43FFAEA6A271A045C6DE"><enum>(A)</enum><header>In general</header><text>The Secretary of Health and Human Services shall issue or update guidance describing—</text><clause id="HBEA01BB2E775466082FC37D480F1B9D3"><enum>(i)</enum><text>circumstances in which the Secretary intends to issue requests for records or other information in advance of, or in lieu of, an inspection under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, as amended by paragraph (1);</text></clause><clause id="H0055DAFEB60D4BF0854871C225A92A36"><enum>(ii)</enum><text>processes for responding to such requests electronically or in physical form; and</text></clause><clause id="H43092129419D49ADB0ABCA711FE6A4DF"><enum>(iii)</enum><text>factors the Secretary intends to consider in evaluating whether such records and other information are provided within a reasonable timeframe, within reasonable limits, and in a reasonable manner, accounting for resource and other limitations that may exist, including for small businesses.</text></clause></subparagraph><subparagraph id="HFF154BAE4561434D9A944414810FA4FB"><enum>(B)</enum><header>Timing</header><text>The Secretary of Health and Human Services shall—</text><clause id="H70A784686BC5461D817AB2717F0ED53A"><enum>(i)</enum><text>not later than 1 year after the date of enactment of this Act, issue draft guidance under subparagraph (A); and</text></clause><clause id="H57E3BE983A914FAFA64D579AF3A205FC"><enum>(ii)</enum><text>not later than 1 year after the close of the comment period for such draft guidance, issue final guidance under subparagraph (A).</text></clause></subparagraph></paragraph></subsection><subsection id="H26A0AFFD9C5C4559B4AB09FD7654332F"><enum>(c)</enum><header>Bioresearch monitoring inspections</header><paragraph id="HA1A26480F8D64AEBA0BF1EDCFCBE3049"><enum>(1)</enum><header>In general</header><text>Section 704(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(a)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H012135493CF94CCAAF8A066C44FAFB0E" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H1628D8E7B0E340FF8C63FF9F7CC81BFC"><enum>(5)</enum><header>Bioresearch monitoring inspections</header><subparagraph id="HDDA1FCCF25B646A2A4405245D57B42CB"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may, to ensure the accuracy and reliability of studies and records or other information described in subparagraph (B) and to assess compliance with applicable requirements under this Act or the Public Health Service Act, enter sites and facilities specified in subparagraph (C) in order to inspect such records or other information.</text></subparagraph><subparagraph id="H26DF70BCA1B1453AB2EE0B2A687D35D7"><enum>(B)</enum><header>Information subject to inspection</header><text display-inline="yes-display-inline">An inspection under this paragraph shall extend to all records and other information related to the studies and submissions described in subparagraph (E), including records and information related to the conduct, results, and analyses of, and the protection of human and animal trial participants participating in, such studies.</text></subparagraph><subparagraph id="H81E367DBC52644E9A87ED1B12126CF45"><enum>(C)</enum><header>Sites and facilities subject to inspection</header><clause id="H38EDFD4861554D75BD920F57E90E57CB"><enum>(i)</enum><header>Sites and facilities described</header><text>The sites and facilities subject to inspection by the Secretary under this paragraph are those owned or operated by a person described in clause (ii) and which are (or were) utilized by such person in connection with—</text><subclause id="H00B12EDB89CE454ABE3799926302EEE8"><enum>(I)</enum><text>developing an application or other submission to the Secretary under this Act or the Public Health Service Act related to marketing authorization for a product described in paragraph (1);</text></subclause><subclause id="H0D68D52560C64575B48F834A3C88571F"><enum>(II)</enum><text>preparing, conducting, or analyzing the results of a study described in subparagraph (E); or</text></subclause><subclause id="H049DEF75019F40268B121B803CE15B65"><enum>(III)</enum><text>holding any records or other information described in subparagraph (B).</text></subclause></clause><clause id="H71F53B5656D24ADB8FDDDE873588432E"><enum>(ii)</enum><header>Persons described</header><text>A person described in this clause is—</text><subclause id="H6EA16FBC31754FA1AFA924693A5BF550"><enum>(I)</enum><text>the sponsor of an application or submission specified in subparagraph (E);</text></subclause><subclause id="H51ADA35F6A934FE9B5524E9573A45B06"><enum>(II)</enum><text>a person engaged in any activity described in clause (i) on behalf of such a sponsor, through a contract, grant, or other business arrangement with such sponsor;</text></subclause><subclause id="H55BFD01BE6EC40B69FECEADD500EB4DB"><enum>(III)</enum><text>an institutional review board, or other individual or entity, engaged by contract, grant, or other business arrangement with a nonsponsor in preparing, collecting, or analyzing records or other information described in subparagraph (B); or</text></subclause><subclause id="HC4FF2667023F48B3BF2D07BC030A9931"><enum>(IV)</enum><text display-inline="yes-display-inline">any person not otherwise described in this clause that conducts, or has conducted, a study described in subparagraph (E) yielding records or other information described in subparagraph (B).</text></subclause></clause></subparagraph><subparagraph id="HC7AC0BDECD4A4F9EA37CF63991CBE5C4"><enum>(D)</enum><header>Conditions of inspection</header><clause id="HE4D4AC13321D4B22A38203DCD6628C15"><enum>(i)</enum><header>Access to information subject to inspection</header><text>Subject to clause (ii), an entity that owns or operates any site or facility subject to inspection under this paragraph shall provide the Secretary with access to records and other information described in subparagraph (B) that is held by or under the control of such entity, including—</text><subclause id="H6F7337F170DF4DCD8580FF7D0D1DCAEC"><enum>(I)</enum><text>permitting the Secretary to record or copy such information for purposes of this paragraph;</text></subclause><subclause id="H5A2482E612954C2EB96E26115048A485"><enum>(II)</enum><text>providing the Secretary with access to any electronic information system utilized by such entity to hold, process, analyze, or transfer any records or other information described in subparagraph (B); and</text></subclause><subclause id="H3A6F55CD612141EFA640D364601B73D6"><enum>(III)</enum><text display-inline="yes-display-inline">permitting the Secretary to inspect the facilities, equipment, written procedures, processes, and conditions through which records or other information described in subparagraph (B) is or was generated, held, processed, analyzed, or transferred.</text></subclause></clause><clause id="H2ECE4C3001E5491683BBC95931B7AF04"><enum>(ii)</enum><header>No effect on applicability of provisions for protection of proprietary information or trade secrets</header><text>Nothing in clause (i) shall negate, supersede, or otherwise affect the applicability of provisions, under this or any other Act, preventing or limiting the disclosure of confidential commercial information or other information considered proprietary or trade secret.</text></clause><clause id="H23D054EB2166478C9E35F51E29F3AA69"><enum>(iii)</enum><header>Reasonableness of inspections</header><text>An inspection under this paragraph shall be conducted at reasonable times and within reasonable limits and in a reasonable manner.</text></clause></subparagraph><subparagraph id="H21AEAA6149C34B20AFD565CADE91E411"><enum>(E)</enum><header>Studies and submissions described</header><text display-inline="yes-display-inline">The studies and submissions described in this subparagraph are each of the following:</text><clause id="HDA676845EE7343CD931EEE61DD19FD22"><enum>(i)</enum><text display-inline="yes-display-inline">Clinical and nonclinical studies submitted to the Secretary in support of, or otherwise related to, applications and other submissions to the Secretary under this Act or the Public Health Service Act for marketing authorization of a product described in paragraph (1).</text></clause><clause id="H6674BF0725604603878A3A7A9717235A"><enum>(ii)</enum><text display-inline="yes-display-inline">Postmarket safety activities conducted under this Act or the Public Health Service Act.</text></clause><clause id="H1AB182E6337F4CC991CDF2305FA1C977"><enum>(iii)</enum><text>Any other clinical investigation of—</text><subclause id="H9C5FDCB84BA14B0E8C2CF3CA61FF5F57"><enum>(I)</enum><text display-inline="yes-display-inline">a drug subject to section 505 or 512 of this Act or section 351 of the Public Health Service Act; or</text></subclause><subclause id="H5360BF8A6FE04A8293B6B2DCB296FC9B"><enum>(II)</enum><text display-inline="yes-display-inline">a device subject to section 520(g).</text></subclause></clause><clause id="HA455CE81DCC543E787235CF66671F295"><enum>(iv)</enum><text display-inline="yes-display-inline">Any other submissions made under this Act or the Public Health Service Act with respect to which the Secretary determines an inspection under this paragraph is warranted in the interest of public health.</text></clause></subparagraph><subparagraph id="HB871AB4456D84D9589FB8371B51B5526"><enum>(F)</enum><header>Clarification</header><text>This paragraph clarifies the authority of the Secretary to conduct inspections of the type described in this paragraph and shall not be construed as a basis for inferring that, prior to the date of enactment of this paragraph, the Secretary lacked the authority to conduct such inspections, including under this Act or the Public Health Service Act.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H4EB9F1856A8748B29EDB1538CAA9728A"><enum>(2)</enum><header>Review of processes and practices; guidance for industry</header><subparagraph id="HD2AD83481D60439DAA5EB1E615F701CA"><enum>(A)</enum><header>In general</header><text>The Secretary of Health and Human Services shall—</text><clause id="H29AB39CCAD034A699AB8E15BD9550017"><enum>(i)</enum><text>review processes and practices in effect as of the date of enactment of this Act applicable to inspections of foreign and domestic sites and facilities described in subparagraph (C)(i) of section 704(a)(5) of the Federal Food, Drug, and Cosmetic Act, as added by paragraph (1); and</text></clause><clause id="H095D714D316546C6BB583987D81E4F50"><enum>(ii)</enum><text>evaluate whether any updates are needed to facilitate the consistency of such processes and practices. </text></clause></subparagraph><subparagraph id="HB5AC59D8AB89413F835DFF882EC16A5A"><enum>(B)</enum><header>Guidance</header><clause id="H0D22FBA8CD05466C8F15746700C1F496"><enum>(i)</enum><header>In general</header><text>The Secretary of Health and Human Services shall issue guidance describing the processes and practices applicable to inspections of sites and facilities described in subparagraph (C)(i) of section 704(a)(5) of the Federal Food, Drug, and Cosmetic Act, as added by paragraph (1), including with respect to the types of records and information required to be provided, best practices for communication between the Food and Drug Administration and industry in advance of or during an inspection or request for records or other information, and other inspections-related conduct, to the extent not specified in existing publicly available Food and Drug Administration guides and manuals for such inspections.</text></clause><clause id="H6F9CB9BC60BA4D6C8C53D7A9F752EDB5"><enum>(ii)</enum><header>Timing</header><text>The Secretary of Health and Human Services shall—</text><subclause id="HF0E1019D2CF5475884A32363B96FCE68"><enum>(I)</enum><text>not later than 18 months after the date of enactment of this Act, issue draft guidance under clause (i); and</text></subclause><subclause id="H29BB3C767B604837ADBBF9054949BC35"><enum>(II)</enum><text>not later than 1 year after the close of the public comment period for such draft guidance, issue final guidance under clause (i).</text></subclause></clause></subparagraph></paragraph></subsection></section><section id="H36C8801954F842C39647B52B81F47CEC"><enum>722.</enum><header>Uses of certain evidence</header><text display-inline="no-display-inline">Section 703 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/373">21 U.S.C. 373</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HE55EEFC7A0024F199AC84F05CD29DD40" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HE479494C141448178784C0E5946CF7C9"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">The limitations on the Secretary’s use of evidence obtained under this section, or any evidence which is directly or indirectly derived from such evidence, in a criminal prosecution of the person from whom such evidence was obtained shall not apply to evidence, including records or other information, obtained under authorities other than this section, unless such limitations are specifically incorporated by reference in such other authorities.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H2368E585D5B34A78A23968974B2446B9" section-type="subsequent-section"><enum>723.</enum><header>Improving FDA inspections</header><subsection id="H38145754B52E45619BC38C962E37A79C"><enum>(a)</enum><header>Risk factors for establishments</header><text display-inline="yes-display-inline">Section 510(h)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(h)(4)</external-xref>) is amended—</text><paragraph id="H042F3520FA884BB1A0ACEABA04807B78"><enum>(1)</enum><text>by redesignating subparagraph (F) as subparagraph (G); and</text></paragraph><paragraph id="H9D7363A06BB443F9A7133BC5A09E2A7C"><enum>(2)</enum><text>by inserting after subparagraph (E) the following: </text><quoted-block style="OLC" id="H1866DE5ADC6A43D2885842B93C395C0E" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="HF7D86135C3DF4634A5047B2B9AC1BE09"><enum>(F)</enum><text display-inline="yes-display-inline">The compliance history of establishments in the country or region in which the establishment is located that are subject to regulation under this Act, including the history of violations related to products exported from such country or region that are subject to such regulation.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HFCF45E91419E40BFA1C41B6062C41999"><enum>(b)</enum><header>Use of records</header><text display-inline="yes-display-inline">Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(a)(4)</external-xref>) is amended—</text><paragraph id="H3A436CA7821D41CA8148BF0F16666B5D"><enum>(1)</enum><text>by redesignating subparagraph (C) as subparagraph (D); and</text></paragraph><paragraph id="H6B8596040F294DD9AA94C8097F3000B9"><enum>(2)</enum><text>by inserting after subparagraph (B) the following:</text><quoted-block style="OLC" id="H7EEAE829D9AD43CCB6710E1B4D34AEF3" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H6A9611D7B75448D69A05664C2405D5C0" indent="up2"><enum>(C)</enum><text display-inline="yes-display-inline">The Secretary may rely on any records or other information that the Secretary may inspect under this section to satisfy requirements that may pertain to a preapproval or risk-based surveillance inspection, or to resolve deficiencies identified during such inspections, if applicable and appropriate. </text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HE59AD18B9B594A7FAA9FFA9171D262B8"><enum>(c)</enum><header>Recognition of foreign government inspections</header><text display-inline="yes-display-inline">Section 809 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384e">21 U.S.C. 384e</external-xref>) is amended—</text><paragraph id="H314C8DB03F594B799C9BFF7FD422F594"><enum>(1)</enum><text>in subsection (a)(1), by inserting <quote>preapproval or</quote> before <quote>risk-based inspections</quote>; and </text></paragraph><paragraph id="HE511AE53B1B845F596CC0FA1D910DE08"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="H7AD10F720D944D89B01E73F663823856" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HC00D8390BA01477682277F99F4D9A63B"><enum>(c)</enum><header>Periodic review</header><paragraph id="HDFEF89333444405CB9B85A306B0973ED"><enum>(1)</enum><header>In general</header><text>Beginning not later than 1 year after the date of the enactment of the <short-title>Food and Drug Amendments of 2022</short-title>, the Secretary shall periodically assess whether additional arrangements and agreements with a foreign government or an agency of a foreign government, as allowed under this section, are appropriate.</text></paragraph><paragraph id="H6C3F52FBD1A742759DF1E4D275F7E80A"><enum>(2)</enum><header>Reports to Congress</header><text display-inline="yes-display-inline">Beginning not later than 4 years after the date of the enactment of the <short-title>Food and Drug Amendments of 2022</short-title>, and every 4 years thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the findings and conclusions of each review conducted under paragraph (1).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="H8E609FE61BA444B1A9A788FB58C52DD3"><enum>724.</enum><header>GAO report on inspections of foreign establishments manufacturing drugs</header><subsection id="HBEDF673F831C48DD838C40B9F3661F3B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of the enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on inspections conducted by—</text><paragraph id="H5753765E494C4F788257A10BAF6E284C"><enum>(1)</enum><text>the Secretary of Health and Human Services (in this section referred to as the <quote>Secretary</quote>) of foreign establishments pursuant to subsections (h) and (i) of section 510 and section 704 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360</external-xref>; 374); or</text></paragraph><paragraph id="HFCBDA51F39D14079839CF3CE514862B5"><enum>(2)</enum><text>a foreign government or an agency of a foreign government pursuant to section 809 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384e">21 U.S.C. 384e</external-xref>).</text></paragraph></subsection><subsection id="HEC0DE0EF4A224D76AF8FB815862FED46"><enum>(b)</enum><header>Contents</header><text>The report conducted under subsection (a) shall include—</text><paragraph id="HA0FB33F052D549A8979A4A257485F4B8"><enum>(1)</enum><text>what alternative tools, including remote inspections or remote evaluations, other countries are utilizing to facilitate inspections of foreign establishments;</text></paragraph><paragraph id="H6199E421A18E4C8EA9A15B05173FCBA5"><enum>(2)</enum><text display-inline="yes-display-inline">how frequently trusted foreign regulators conduct inspections of foreign facilities that could be useful to the Food and Drug Administration to review in lieu of its own inspections;</text></paragraph><paragraph id="HEE1AC6D703374AAE8A17C422E5736B0C"><enum>(3)</enum><text display-inline="yes-display-inline">how frequently and under what circumstances, including for what types of inspections, the Secretary utilizes existing agreements or arrangements under section 809 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384e">21 U.S.C. 384e</external-xref>) and whether the use of such agreements could be appropriately expanded;</text></paragraph><paragraph id="H8C2ECA5CF40E410FBC35CBEC2178296F"><enum>(4)</enum><text>whether the Secretary has accepted reports of inspections of facilities in China and India conducted by entities with which they have entered into such an agreement or arrangement;</text></paragraph><paragraph id="H76F410E52A6D42B68C97D61FB17135EB"><enum>(5)</enum><text>what additional foreign governments or agencies of foreign governments the Secretary has considered entering into a mutual recognition agreement with and, if applicable, reasons why the Secretary declined to enter into a mutual recognition agreement with such foreign governments or agencies;</text></paragraph><paragraph id="H18DE622E17BC41E097802D4ECAD2E4D8"><enum>(6)</enum><text>what tools, if any, the Secretary used to facilitate inspections of domestic facilities that could also be effectively utilized to appropriately inspect foreign facilities;</text></paragraph><paragraph id="H080DFA69BA2A4D50992F1B9FC0716569"><enum>(7)</enum><text display-inline="yes-display-inline">what steps the Secretary has taken to identify and evaluate tools and strategies the Secretary may use to continue oversight with respect to inspections when in-person inspections are disrupted;</text></paragraph><paragraph id="H4811A0C193A042E4A1EB5883C43CFCE5"><enum>(8)</enum><text display-inline="yes-display-inline">how the Secretary is considering incorporating alternative tools into the inspection activities conducted pursuant to the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>); and</text></paragraph><paragraph id="H0C82A87D359B4723A613383AF46527EF"><enum>(9)</enum><text display-inline="yes-display-inline">what steps the Secretary has taken to identify and evaluate how the Secretary may use alternative tools to address workforce shortages to carry out such inspection activities.</text></paragraph></subsection></section><section id="H9EE8CE03CB004998B3DDD85301CA1048" section-type="subsequent-section"><enum>725.</enum><header>Unannounced foreign facility inspections pilot program</header><subsection id="H371B61117B1444418B1ABE52DF6BA993"><enum>(a)</enum><header>In general</header><text>The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall conduct a pilot program under which the Secretary increases the conduct of unannounced surveillance inspections of foreign human drug establishments and evaluates the differences between such inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection. Such pilot program shall evaluate—</text><paragraph id="H9A8B3022CB154805A54275804A593E1C"><enum>(1)</enum><text display-inline="yes-display-inline">differences in the number and type of violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351(a)(2)(B)</external-xref>) identified as a result of unannounced and announced inspections of foreign human drug establishments and any other significant differences between each type of inspection;</text></paragraph><paragraph id="H773BCBCA6D124169933166B6E3707FC0"><enum>(2)</enum><text>costs and benefits associated with conducting announced and unannounced inspections of foreign human drug establishments; </text></paragraph><paragraph id="H19BA1CA7E1DF452BA307149580B037ED"><enum>(3)</enum><text>barriers to conducting unannounced inspections of foreign human drug establishments and any challenges to achieving parity between domestic and foreign human drug establishment inspections; and</text></paragraph><paragraph id="H075A83E9B4C54A5AB201DFE0FF5064C3"><enum>(4)</enum><text>approaches for mitigating any negative effects of conducting announced inspections of foreign human drug establishments.</text></paragraph></subsection><subsection id="HF3E3967701E04602AAE6130EB1C7AB15"><enum>(b)</enum><header>Pilot program scope</header><text display-inline="yes-display-inline">The inspections evaluated under the pilot program under this section shall be routine surveillance inspections and shall not include inspections conducted as part of the Secretary’s evaluation of a request for approval to market a drug submitted under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>) or the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/201">42 U.S.C. 201 et seq.</external-xref>).</text></subsection><subsection id="HF11B56F2D1424305B5B993CDCEBF7510"><enum>(c)</enum><header>Pilot program initiation</header><text>The Secretary shall initiate the pilot program under this section not later than 180 days after the date of enactment of this Act.</text></subsection><subsection id="H01FB7EC4876D45CCA14D3B333F1AD8BF"><enum>(d)</enum><header>Report</header><text>The Secretary shall, not later than 180 days following the completion of the pilot program under this section, make available on the website of the Food and Drug Administration a final report on the pilot program under this section, including—</text><paragraph id="HE2C3CA9F8FD749D1B11152ACACA919FD"><enum>(1)</enum><text>findings and any associated recommendations with respect to the evaluation under subsection (a), including any recommendations to address identified barriers to conducting unannounced inspections of foreign human drug establishments;</text></paragraph><paragraph id="HF89C106EEAB24413AC2C19CC69D8C5D0"><enum>(2)</enum><text>findings and any associated recommendations regarding how the Secretary may achieve parity between domestic and foreign human drug inspections; and </text></paragraph><paragraph id="HA8FFCE77840E4CB99F8FF9D959CF6B9D"><enum>(3)</enum><text>the number of unannounced inspections during the pilot program that would not be unannounced under existing practices. </text></paragraph></subsection></section><section id="H4A2EE50C31EE467F846A732FA54D4DBF"><enum>726.</enum><header>Reauthorization of inspection program</header><text display-inline="no-display-inline">Section 704(g)(11) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(g)(11)</external-xref>) is amended by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></section><section id="H87C14AD17C38431B8541D9AB482A8660"><enum>727.</enum><header>Enhancing intra-agency coordination and public health assessment with regard to compliance activities</header><subsection id="HF028E6C36C5249D78BD9A01193209CE2"><enum>(a)</enum><header>Coordination</header><text>Section 506D of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356d">21 U.S.C. 356d</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H924CED6CE34847F09A6F874C68A87912" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HB2C8E7BE5D0F4C93A2AD316DC7EB2F36"><enum>(g)</enum><header>Coordination</header><text>The Secretary shall ensure timely and effective internal coordination and alignment among the field investigators of the Food and Drug Administration and the staff of the Center for Drug Evaluation and Research’s Office of Compliance and Drug Shortage Program regarding—</text><paragraph id="HD0BED33702C04858B6BD573667490DE4"><enum>(1)</enum><text>the reviews of reports shared pursuant to section 704(b)(2); and</text></paragraph><paragraph id="HBC305B547297405BAB5DA8ACC8E50ECF"><enum>(2)</enum><text>any feedback or corrective or preventive actions in response to such reports.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H334E2ABE1F9042C08515F9A924552F42"><enum>(b)</enum><header>Reporting</header><paragraph id="HB70B75C3BC6040BE87D5F787F1943F3C"><enum>(1)</enum><header>In general</header><text>Section 506C–1(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c-1">21 U.S.C. 356c–1(a)(2)</external-xref>) is amended to read as follows:</text><quoted-block id="H1FA1DC6187AE4019B9609362E0F399CA" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HD34B651A96814633AE53E25F3D9AF20D"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="HD2AC52D4176B4133A1317F8C6196B82B"><enum>(A)</enum><text>describes the communication between the field investigators of the Food and Drug Administration and the staff of the Center for Drug Evaluation and Research’s Office of Compliance and Drug Shortage Program, including the Food and Drug Administration’s procedures for enabling and ensuring such communication;</text></subparagraph><subparagraph id="HEB1BCE51BF2942249A14324FB22B1923" indent="up1"><enum>(B)</enum><text>provides the number of reports described in section 704(b)(2) that were required to be sent to the appropriate offices of the Food and Drug Administration and the number of such reports that were sent; and</text></subparagraph><subparagraph id="H24353A05550F4F4183CF94583E08FB76" indent="up1"><enum>(C)</enum><text>describes the coordination and alignment activities undertaken pursuant to section 506D(g);</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H5CD6C2653C6249529665CFD0E5578E56"><enum>(2)</enum><header>Applicability</header><text>The amendment made by paragraph (1) shall apply with respect to reports submitted on or after March 31, 2023. </text></paragraph></subsection></section><section id="H5468090BDB114C90AC31EA5D7B516E7B"><enum>728.</enum><header>Reporting of mutual recognition agreements for inspections and review activities</header><subsection id="H2CA10605993D405FB6AEE0848FFDE915"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than December 31, 2022, and annually thereafter, the Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall publish a report on the public website of the Food and Drug Administration on the utilization of agreements entered into pursuant to section 809 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384e">21 U.S.C. 384e</external-xref>) or otherwise entered into by the Secretary in the previous fiscal year to recognize inspections between drug regulatory authorities across countries and international regions with analogous review criteria to the Food and Drug Administration, such as the Pharmaceutical Inspection Co-Operation Scheme, the Mutual Recognition Agreement with the European Union, and the Australia-Canada-Singapore-Switzerland-United Kingdom Consortium<italic></italic>.</text></subsection><subsection id="HDD869DC11F3540299F834F5C0F65F52E"><enum>(b)</enum><header>Content</header><text>The report under subsection (a) shall include each of the following:</text><paragraph id="HA38A42702ED64BE99F0002DBAF42FBEC"><enum>(1)</enum><text>The total number of establishments that are registered under section 510(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(i)</external-xref>), and the number of such establishments in each region of interest.</text></paragraph><paragraph id="HE8EF4E54FF174A4EBD061DCE5028CFCE"><enum>(2)</enum><text><italic></italic> The total number of inspections conducted at establishments described in paragraph (1), disaggregated by inspections conducted—</text><subparagraph id="H630931D98A3C433AB0192C9585A4967B"><enum>(A)</enum><text display-inline="yes-display-inline">pursuant to an agreement or other recognition described in subsection (a); and</text></subparagraph><subparagraph id="H768E62004488448B9CC1680E391DF450"><enum>(B)</enum><text display-inline="yes-display-inline">by employees or contractors of the Food and Drug Administration.</text></subparagraph></paragraph><paragraph id="HA321A0EAB1E742CF95C9103A919C5909"><enum>(3)</enum><text>Of the inspections described in paragraph (2), the total number of inspections in each region of interest.</text></paragraph><paragraph id="HE2433F8A424E4A169C4A37D740B6E6D2"><enum>(4)</enum><text>Of the inspections in each region of interest reported pursuant to paragraph (3), the number of inspections in each FDA inspection category<italic></italic>.</text></paragraph><paragraph id="H392DB9E9FFE84E77951221D89615B4C1"><enum>(5)</enum><text><italic></italic>Of the number of inspections reported under each of paragraphs (3) and (4)—</text><subparagraph id="HB08CF222918D4DA99BCA88E1E4EBED05"><enum>(A)</enum><text>the number of inspections which have been conducted pursuant to an agreement or other recognition described in subsection (a); and</text></subparagraph><subparagraph id="H671D12EF0A5C408F9D4B867BD77E7E54"><enum>(B)</enum><text>the number of inspections which have been conducted by employees or contractors of the Food and Drug Administration.</text></subparagraph></paragraph></subsection><subsection id="H5A3AAEEB580E4BEB83A2D3B3B49A5475"><enum>(c)</enum><header>Definitions</header><text>In this section:</text><paragraph id="H2E0710F1EB864B4394E66BAF0A5DAC76"><enum>(1)</enum><header>FDA inspection category</header><text>The term <term>FDA inspection category</term> means the following inspection categories:</text><subparagraph id="HFF0E4D9AD43F49A6973D711B68E91A72"><enum>(A)</enum><text>Inspections to support approvals of changes to the manufacturing process of drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></subparagraph><subparagraph id="HCE65F2B93EE64144A68E9352A1AD2D4B"><enum>(B)</enum><text>Surveillance inspections.</text></subparagraph><subparagraph id="HD59D6CC4B7EB4C46BAB7296FE42F6088"><enum>(C)</enum><text>For-cause inspections.</text></subparagraph></paragraph><paragraph id="H5F7FE0C102304801B308B7E980E9E0F2"><enum>(2)</enum><header>Region of interest</header><text>The term <term>region of interest</term> means China, India, the European Union, and any other geographic region as the Secretary determines appropriate.</text></paragraph></subsection></section><section id="H0C4C499339A944098476348C0CF1AEC7"><enum>729.</enum><header>Enhancing transparency of drug facility inspection timelines</header><text display-inline="no-display-inline">Section 902 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref> note) is amended to read as follows:</text><quoted-block id="H0C15D1FB80F74D7ABE0E7331841963AB" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="H31DEAB5EB10B4848B6D5FF8B69B49BB2"><enum>902.</enum><header>Annual report on inspections</header><text display-inline="no-display-inline">Not later than 120 days after the end of each fiscal year, the Secretary of Health and Human Services shall post on the public website of the Food and Drug Administration information related to inspections of facilities necessary for approval of a drug under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), approval of a device under section 515 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e</external-xref>), or clearance of a device under section 510(k) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>) that were conducted during the previous fiscal year. Such information shall include the following:</text><paragraph id="H53C3EE49A99047608E8B3BB2E9644481"><enum>(1)</enum><text>The median time following a request from staff of the Food and Drug Administration reviewing an application or report to the beginning of the inspection, including—</text><subparagraph id="H34960B44C1A0459693EF4631222658E6"><enum>(A)</enum><text>the median time for drugs described in section 505(j)(11)(A)(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(11)(A)(i)</external-xref>);</text></subparagraph><subparagraph id="H37A4AB126B30452898D653125B99A4F4"><enum>(B)</enum><text>the median time for drugs described in section 506C(a) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c(a)</external-xref>) only; and</text></subparagraph><subparagraph id="HE5A810CE024F4A209BE40D1117824E52"><enum>(C)</enum><text>the median time for drugs on the drug shortage list in effect under section 506E of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356e">21 U.S.C. 356e</external-xref>).</text></subparagraph></paragraph><paragraph id="HE6AB73DA753848DA82CA18DDD6A84349"><enum>(2)</enum><text>The median time from the issuance of a report pursuant to section 704(b) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(b)</external-xref>) to the sending of a warning letter, issuance of an import alert, or holding of a regulatory meeting for inspections for which the Secretary concluded that regulatory or enforcement action was indicated, including the median time for each category of drugs listed in subparagraphs (A) through (C) of paragraph (1).</text></paragraph><paragraph id="H4B3A0F773A074A76B98524A2B7FE0373"><enum>(3)</enum><text>The median time from the sending of a warning letter, issuance of an import alert, or holding of a regulatory meeting to resolution of the actions indicated to address the conditions or practices observed during an inspection.</text></paragraph><paragraph id="H32EC13422FD94101A8A7D859E183C596"><enum>(4)</enum><text display-inline="yes-display-inline">The number of facilities that failed to implement adequate corrective or preventive actions following a report pursuant to such section 704(b), resulting in a withhold recommendation, including the number of such times for each category of drugs listed in subparagraphs (A) through (C) of paragraph (1).</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></section></subtitle></title><title id="HE4A7D6CCC1254A76A0762ACE00FD0125"><enum>VIII</enum><header>Transparency, Program Integrity, and Regulatory Improvements</header><section id="H61BEF6B1F9534AACA831F868DE408CD8"><enum>801.</enum><header>Prompt reports of marketing status by holders of approved applications for biological products</header><subsection id="H72E3BDCFC90942A9A5BA9AB4FBF6E4FE"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) is amended—</text><paragraph id="H50D536556C1A487D95F13FB75528E3D3"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="HB0867BEB40074D76B9F35FF99E85518B"><enum>(A)</enum><text>in the matter preceding paragraph (1), by striking <quote>The holder of an application approved under subsection (c) or (j) of section 505</quote> and inserting <quote>The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act</quote>;</text></subparagraph><subparagraph id="HE0931659115447E2BEF77BB6746BAE31"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>established name</quote> and inserting <quote>established name (for biological products, by proper name)</quote>; and</text></subparagraph><subparagraph id="HBC3606731B8945DC8328E70BC4CFFFDA"><enum>(C)</enum><text>in paragraph (3), by striking <quote>or abbreviated application number</quote> and inserting <quote>, abbreviated application number, or biologics license application number</quote>; and </text></subparagraph></paragraph><paragraph id="H500868B301AC489DBD3EA35EA5B772F9"><enum>(2)</enum><text>in subsection (b)—</text><subparagraph id="H0532FF4491C84A14A1506B45B3911688"><enum>(A)</enum><text>in the matter preceding paragraph (1), by striking <quote>The holder of an application approved under subsection (c) or (j)</quote> and inserting <quote>The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act</quote>;</text></subparagraph><subparagraph id="H5C479ACB18304F8BBC6EE6157035E7E7"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>established name</quote> and inserting <quote>established name (for biological products, by proper name)</quote>; and</text></subparagraph><subparagraph id="H81B4DF197B95411EA2C91CD942A40120"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>or abbreviated application number</quote> and inserting <quote>, abbreviated application number, or biologics license application number</quote>.</text></subparagraph></paragraph></subsection><subsection id="HEA0314695E554AC89AFC42831D208384"><enum>(b)</enum><header>Additional one-Time report</header><text display-inline="yes-display-inline">Subsection (c) of section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H146C6A39368B4B91BC04C2323B6FB903" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H8327C700908E4CDF962ED647F2911628"><enum>(c)</enum><header>Additional one-Time report</header><text display-inline="yes-display-inline">Within 180 days of the date of enactment of the <short-title>Food and Drug Amendments of 2022</short-title>, all holders of applications approved under subsection (a) or (k) of section 351 of the Public Health Service Act shall review the information in the list published under section 351(k)(9)(A) and shall submit a written notice to the Secretary—</text><paragraph id="H01BA2EFF829B47739847084D3ABCCB96"><enum>(1)</enum><text display-inline="yes-display-inline">stating that all of the application holder’s biological products in the list published under section 351(k)(9)(A) that are not listed as discontinued are available for sale; or</text></paragraph><paragraph id="H95626A1D2DED403D89CF72EEAE1A9DED"><enum>(2)</enum><text display-inline="yes-display-inline">including the information required pursuant to subsection (a) or (b), as applicable, for each of the application holder’s biological products that are in the list published under section 351(k)(9)(A) and not listed as discontinued, but have been discontinued from sale or never have been available for sale.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HBF5F5BC6C7724448AA59D25EC9190A50"><enum>(c)</enum><header>Purple Book</header><text display-inline="yes-display-inline">Section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) is amended—</text><paragraph id="H3971AE41D1A2422BBB4526FEDA654A5F"><enum>(1)</enum><text display-inline="yes-display-inline">by striking subsection (d) and inserting the following:</text><quoted-block style="OLC" id="H5324D74D600049FCBE14CFE4C9F354C9" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H31849B07E3CF443DA477833251021F33"><enum>(d)</enum><header>Failure To meet requirements</header><text display-inline="yes-display-inline">If a holder of an approved application fails to submit the information required under subsection (a), (b), or (c), the Secretary may—</text><paragraph id="H5FC9413B55094845A8017F83BAEFAC92"><enum>(1)</enum><text>move the application holder’s drugs from the active section of the list published under section 505(j)(7)(A) to the discontinued section of the list, except that the Secretary shall remove from the list in accordance with section 505(j)(7)(C) drugs the Secretary determines have been withdrawn from sale for reasons of safety or effectiveness; and</text></paragraph><paragraph id="H0926E248430141BBB6B2A2252D8A3314"><enum>(2)</enum><text display-inline="yes-display-inline">identify the application holder’s biological products as discontinued in the list published under section 351(k)(9)(A) of the Public Health Service Act, except that the Secretary shall remove from the list in accordance with section 351(k)(9)(B) of such Act biological products for which the license has been revoked or suspended for reasons of safety, purity, or potency.</text></paragraph></subsection><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="HA18F10B62917496A861F985E4CCE6035"><enum>(2)</enum><text>in subsection (e)—</text><subparagraph id="H6FAC1BCF0932436C921026FC47AB55C6"><enum>(A)</enum><text display-inline="yes-display-inline">by inserting after the first sentence the following: <quote>The Secretary shall update the list published under section 351(k)(9)(A) of the Public Health Service Act based on information provided under subsections (a), (b), and (c) by identifying as discontinued biological products that are not available for sale, except that biological products for which the license has been revoked or suspended for safety, purity, or potency reasons shall be removed from the list in accordance with section 351(k)(9)(B) of the Public Health Service Act.</quote>;</text></subparagraph><subparagraph id="HAF8239A0645C419185B6B5FCC6EABC71"><enum>(B)</enum><text>by striking <quote>monthly updates to the list</quote> and inserting <quote>monthly updates to the lists referred to in the preceding sentences</quote>; and</text></subparagraph><subparagraph id="H28D68BC5E5054117AF5CD0852AA629DA"><enum>(C)</enum><text>by striking <quote>and shall update the list based on</quote> and inserting <quote>and shall update such lists based on</quote>.</text></subparagraph></paragraph></subsection><subsection id="H5B352C4C74034F74A4D47BC4E9B9F379"><enum>(d)</enum><header>Technical corrections</header><text display-inline="yes-display-inline">Section 506I(e) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i(e)</external-xref>) is amended—</text><paragraph id="H6C9095F131064E3EA036C6B6153408BC"><enum>(1)</enum><text>by striking <quote>subsection 505(j)(7)(A)</quote> and inserting <quote>section 505(j)(7)(A)</quote>; and</text></paragraph><paragraph id="H714EC8E059B44FE9BCBCE72BD7A3B647"><enum>(2)</enum><text>by striking <quote>subsection 505(j)(7)(C)</quote> and inserting <quote>section 505(j)(7)(C)</quote>. </text></paragraph></subsection></section><section id="H79C6319CF4C04B6BBCDCAF35C52A85B5"><enum>802.</enum><header>Encouraging blood donation</header><subsection id="H94618313980A47DFA014649DC31B483D"><enum>(a)</enum><header>Streamlining patient and blood donor input</header><text display-inline="yes-display-inline">Section 3003 of the 21st Century Cures Act (21 U.S.C. 360bbb–8c note) is amended to read as follows:</text><quoted-block style="OLC" id="H43BC20BDC11D46B4A2EAE65261907E5D" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="H394FB119BE1B4C069330D16400986B64"><enum>3003.</enum><header>Streamlining patient and blood donor input</header><text display-inline="no-display-inline"><external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/35">Chapter 35</external-xref> of title 44, United States Code, shall not apply to the collection of information to which a response is voluntary, to solicit—</text><paragraph id="H898ADE9F936846A6BFB0BEF24633D92E"><enum>(1)</enum><text>the views and perspectives of patients under section 569C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8c">21 U.S.C. 360bbb–8c</external-xref>) (as amended by section 3001) or section 3002; or</text></paragraph><paragraph id="HEA7C766B674144C1AF0F79CDBD10B570"><enum>(2)</enum><text display-inline="yes-display-inline">information from blood donors or potential blood donors to support the development of recommendations by the Secretary of Health and Human Services acting through the Commissioner of Food and Drugs concerning blood donation.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H067D00E1416A49F2876A359B74950A73"><enum>(b)</enum><header>Clerical amendment</header><text display-inline="yes-display-inline">The table of contents in section 1(b) of the 21st Century Cures Act is amended by striking the item relating to section 3003 and inserting the following: </text><quoted-block style="OLC" id="HD4FA7DCCFE324080B4DA854FA9D14019" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><toc regeneration="no-regeneration" changed="added" reported-display-style="italic" committee-id="HIF00"><toc-entry level="section">Sec. 3003. Streamlining patient and blood donor input.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H8391A71A16E74FE88DCCAFF3BE78AC05"><enum>803.</enum><header>Regulation of certain products as drugs</header><text display-inline="no-display-inline">Section 503 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353</external-xref>) is amended by adding at the end the following:</text><quoted-block style="traditional" id="H959914E04C784407AB55230E7C30E7F7" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HC88C1017C6ED4F12AA5DDDEA62CC86B8"><enum>(h)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H008918AFFBB245A7B609096FF55BE683"><enum>(1)</enum><text display-inline="yes-display-inline">Any contrast agent, radioactive drug, or OTC monograph drug shall be deemed to be a drug under section 201(g) and not a device under section 201(h).</text></paragraph><paragraph id="H28A6BA0D6B1547AABCA6BBF42DFB820F" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">For purposes of this subsection:</text><subparagraph id="H3FD905E179204918B057C43A0554236E"><enum>(A)</enum><text>The term <term>contrast agent</term> means an article that is intended for use in conjunction with a medical imaging device, and—</text><clause id="H8F586E8E0C56408BBACBBE4918EDC274"><enum>(i)</enum><text>is a diagnostic radiopharmaceutical, as defined in sections 315.2 and 601.31 of title 21, Code of Federal Regulations (or any successor regulations); or</text></clause><clause id="H9F5B7298F17A42C5893D11520DB79F6D"><enum>(ii)</enum><text>is a diagnostic agent that improves the visualization of structure or function within the body by increasing the relative difference in signal intensity within the target tissue, structure, or fluid.</text></clause></subparagraph><subparagraph id="H947964F346854F8BBFA8ECD3DD8C2FB1"><enum>(B)</enum><text>The term ‘radioactive drug’ has the meaning given such term in section 310.3(n) of title 21, Code of Federal Regulations (or any successor regulations), except that such term does not include—</text><clause id="H9B8D1304955A478383AB797B27070BBF"><enum>(i)</enum><text>an implant or article similar to an implant; </text></clause><clause id="H114C8811E1044DBDA344A3BF83B7D076"><enum>(ii)</enum><text>an article that applies radiation from outside of the body; or </text></clause><clause id="HE58B258024154C79B2163A8AFB474184"><enum>(iii)</enum><text>the radiation source of an article described in clause (i) or (ii).</text></clause></subparagraph><subparagraph id="H829C9AF688B6496EBE3447CCFAFFE8AE"><enum>(C)</enum><text>The term ‘OTC monograph drug’ has the meaning given such term in section 744L.</text></subparagraph></paragraph><paragraph id="HA2EEFBBADCF84666926B7B47975770CC" indent="up1"><enum>(3)</enum><text display-inline="yes-display-inline">Nothing in this subsection shall be construed as allowing for the classification of a product as a drug (as defined in section 201(g)) if such product—</text><subparagraph id="H7E8FF149E63A4ACA9F358A8B0C566F94"><enum>(A)</enum><text>is not described in paragraph (1); and</text></subparagraph><subparagraph id="HE5841C34ED7B4C10A05F2112C854719C"><enum>(B)</enum><text>meets the definition of a device under section 201(h),</text></subparagraph><continuation-text continuation-text-level="paragraph">unless another provision of this Act otherwise indicates a different classification.</continuation-text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H46FADEFD8DD649D08ABEE803AFA1E6BB"><enum>804.</enum><header>Postapproval studies and program integrity for accelerated approval drugs</header><subsection id="H698ED870B4244C20AFC095CD2195E910"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(c)</external-xref>) is amended—</text><paragraph id="HCA8312FB5DB74A6ABE7946CBEFFC7E49"><enum>(1)</enum><text>by striking paragraph (2) and inserting the following:</text><quoted-block style="OLC" id="H59B58827DA7549A695DA31D0EF92EE0E" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H873748884B6A40A7A21455A9395BA18E" commented="no"><enum>(2)</enum><header>Limitation</header><subparagraph id="H0DC87B84BAA447CEBA8ABA34B7778B6F" commented="no"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Approval of a product under this subsection may be subject to 1 or both of the following requirements:</text><clause id="H5D0BD5E352E04FD6BB4F31089C976166" commented="no"><enum>(i)</enum><text display-inline="yes-display-inline">That the sponsor conduct an appropriate postapproval study or studies (which may be augmented or supported by real world evidence) to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit.</text></clause><clause id="HAB5308E12D2447DB9926551212769613" commented="no"><enum>(ii)</enum><text display-inline="yes-display-inline">That the sponsor submit copies of all promotional materials related to the product during the preapproval review period and, following approval and for such period thereafter as the Secretary determines to be appropriate, at least 30 days prior to dissemination of the materials.</text></clause></subparagraph><subparagraph id="H3E95B70FD0F94E0181F83B02CF10649E" commented="no"><enum>(B)</enum><header>Studies not required</header><text display-inline="yes-display-inline">If the Secretary does not require that the sponsor of a product approved under accelerated approval conduct a postapproval study under this paragraph, the Secretary shall publish on the website of the Food and Drug Administration the rationale for why such study is not appropriate or necessary.</text></subparagraph><subparagraph id="HADF3674BF499450BB424937CC91471F2" commented="no"><enum>(C)</enum><header>Postapproval study conditions</header><text display-inline="yes-display-inline">Not later than the time of approval of a product under accelerated approval, the Secretary shall specify the conditions for a postapproval study or studies required to be conducted under this paragraph with respect to such product, which may include enrollment targets, the study protocol, and milestones, including the target date of study completion<italic></italic>.</text></subparagraph><subparagraph id="HAA3DB215D70C4105A403E8891E36E29D" commented="no"><enum>(D)</enum><header>Studies begun before approval</header><text display-inline="yes-display-inline">The Secretary may require such study or studies to be underway prior to approval.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="H9F758853F2354758A90F06483F6D07E2"><enum>(2)</enum><text>by striking paragraph (3) and inserting the following: </text><quoted-block style="OLC" id="HEFC5AD2625664832AE12150CC2583215" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H56808FCA81524062807999C362F7DF3E"><enum>(3)</enum><header>Expedited withdrawal of approval</header><subparagraph id="HF3EB0AC4AFED4C568E8EFBAE2C04820D"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may withdraw approval of a product approved under accelerated approval using expedited procedures described in subparagraph (B), if—</text><clause id="H9EBF83996E17407C9EA1D669A9A21E9F"><enum>(i)</enum><text display-inline="yes-display-inline">the sponsor fails to conduct any required postapproval study of the product with due diligence, including with respect to conditions specified by the Secretary under paragraph (2)(C);</text></clause><clause id="H2F214D6F611A40A5824A4CF10D38DCD2"><enum>(ii)</enum><text display-inline="yes-display-inline">a study required to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit of the product fails to verify and describe such effect or benefit;</text></clause><clause id="HDEF12C8182EB4B9EAB8DB5A5202571EB"><enum>(iii)</enum><text display-inline="yes-display-inline">other evidence demonstrates that the product is not shown to be safe or effective under the conditions of use; or</text></clause><clause id="H837D9E8211294E7899D44161D705F9DB"><enum>(iv)</enum><text display-inline="yes-display-inline">the sponsor disseminates false or misleading promotional materials with respect to the product.</text></clause></subparagraph><subparagraph id="H80AA4CE95F1545D891E5D285FBA3FBF3"><enum>(B)</enum><header>Expedited procedures described</header><text display-inline="yes-display-inline">Expedited procedures described in this subparagraph shall consist of, prior to the withdrawal of accelerated approval—</text><clause id="H0C0439FAD674497CA5194AE6E8F89997"><enum>(i)</enum><text>providing the sponsor with—</text><subclause id="H21DB6ACFC9E04729A472801DB8168C74"><enum>(I)</enum><text>due notice;</text></subclause><subclause id="H0A8C72530F3842A7A04295B30ECD5D4A"><enum>(II)</enum><text>an explanation for the proposed withdrawal;</text></subclause><subclause id="HD9FC1C6B8B6446F7A7676172B7B66F0B"><enum>(III)</enum><text>an opportunity for a meeting with the Commissioner of Food and Drugs or the Commissioner’s designee; and</text></subclause><subclause id="HDA3EF9EA3F0E4A3BB2E38FEF8749F882"><enum>(IV)</enum><text>an opportunity for written appeal to—</text><item id="H36145EA6BB0248529324D5E81FBCDA34"><enum>(aa)</enum><text>the Commissioner of Food and Drugs; or</text></item><item id="H1E9540163F8049808F02737981619526"><enum>(bb)</enum><text>a designee of the Commissioner who has not participated in the proposed withdrawal of approval (other than a meeting pursuant to subclause (III)) and is not a subordinate of an individual (other than the Commissioner) who participated in such proposed withdrawal; </text></item></subclause></clause><clause id="H2B781A24EFD146EAAAA5D511911FC448"><enum>(ii)</enum><text>providing an opportunity for public comment on the notice proposing to withdraw approval;</text></clause><clause id="H056D604F930E4461AB737C8E2F0B51E9"><enum>(iii)</enum><text>the publication of a summary of the public comments received, and the Secretary’s response to such comments, on the website of the Food and Drug Administration; and</text></clause><clause id="H0C6C2A68517D44E2A7659DDD3E000729"><enum>(iv)</enum><text>convening and consulting an advisory committee on issues related to the proposed withdrawal, if requested by the sponsor and if no such advisory committee has previously advised the Secretary on such issues with respect to the withdrawal of the product prior to the sponsor’s request.</text></clause></subparagraph></paragraph><paragraph id="HFF00D662566D4DD5BF15725363C3EB0C"><enum>(4)</enum><header>Labeling</header><subparagraph id="H09D16D271CF8433A923F812B669DF4CF"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subparagraph (B), the labeling for a product approved under accelerated approval shall include—</text><clause id="H91890C7AD0254917B038AB245477E0C2"><enum>(i)</enum><text>a statement indicating that the product was approved under accelerated approval; </text></clause><clause id="H0814568D90F24BF9BCC3EB536573EB1C"><enum>(ii)</enum><text>a statement indicating that continued approval of the product is subject to postmarketing studies to verify clinical benefit;</text></clause><clause id="H0407EF18B5C24C3CA05E5EEEEA4918E0"><enum>(iii)</enum><text display-inline="yes-display-inline">identification of the surrogate or intermediate endpoint or endpoints that supported approval and any known limitations of such surrogate or intermediate endpoint or endpoints in determining clinical benefit; and</text></clause><clause id="H2E281B653A62438DB786011A81E13259"><enum>(iv)</enum><text>a succinct description of the product and any uncertainty about anticipated clinical benefit and a discussion of available evidence with respect to such clinical benefit.</text></clause></subparagraph><subparagraph id="H4CD0703AD42542FA9280107E58002987"><enum>(B)</enum><header>Applicability</header><text display-inline="yes-display-inline">The labeling requirements of subparagraph (A) shall apply only to products approved under accelerated approval for which the predicted effect on irreversible morbidity or mortality or other clinical benefit has not been verified.</text></subparagraph><subparagraph id="HDDEAD38A33F14A849FF86D99F25A520C"><enum>(C)</enum><header>Rule of construction</header><text>With respect to any application pending before the Secretary on the date of enactment of the Food and Drug Amendments of 2022, the Secretary shall allow any applicable changes to the product labeling required to comply with subparagraph (A) to be made by supplement after the approval of such application.</text></subparagraph></paragraph><paragraph id="H3EF7BA8BD6BA4B94A5A0C98F0C37A22A"><enum>(5)</enum><header>Reporting</header><text>Not later than September 30, 2025, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing circumstances in which the Secretary considered real world evidence submitted to support postapproval studies required under this subsection that were completed after the date of enactment of the <short-title>Food and Drug Amendments of 2022</short-title>.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H6CB39249CAFB4825BDB5851E3C5F6EFC"><enum>(b)</enum><header>Reports of postmarketing studies</header><text>Section 506B(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356b">21 U.S.C. 356b(a)</external-xref>) is amended—</text><paragraph id="HC76FB7401BF54574B35BA9733384FDFF"><enum>(1)</enum><text>by redesignating paragraph (2) as paragraph (3); and</text></paragraph><paragraph id="HEBBFB791466A4FEDB4CA07018A0785C0"><enum>(2)</enum><text>by inserting after paragraph (1) the following: </text><quoted-block style="OLC" id="H51D39FA531C94DB6AB7EB95E67C6D5BC" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="HA3CE3F7326F04FE981EBE51C035A4EDF"><enum>(2)</enum><header>Accelerated approval</header><text display-inline="yes-display-inline">Notwithstanding paragraph (1), a sponsor of a drug approved under accelerated approval shall submit to the Secretary a report of the progress of any study required under section 506(c), including progress toward enrollment targets, milestones, and other information as required by the Secretary, not later than 180 days after the approval of such drug and not less frequently than every 180 days thereafter, until the study is completed or terminated. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HF9E179818BB0488A8B51A12FB883D9CA"><enum>(c)</enum><header>Guidance</header><paragraph id="H2FC94BF9312043E0B065B5C1B615E79E"><enum>(1)</enum><header>In general</header><text>The Secretary of Health and Human Services shall issue guidance describing—</text><subparagraph id="H5A13029BCDD14015A13F76C8CB99B66B"><enum>(A)</enum><text>how sponsor questions related to the identification of novel surrogate or intermediate clinical endpoints may be addressed in early-stage development meetings with the Food and Drug Administration;</text></subparagraph><subparagraph id="H20C06CC206EE45E498E5EBB97AFC7195"><enum>(B)</enum><text display-inline="yes-display-inline">the use of novel clinical trial designs that may be used to conduct appropriate postapproval studies as may be required under section 506(c)(2)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(c)(2)(A)</external-xref>), as amended by subsection (a); and</text></subparagraph><subparagraph id="HE688A0B2BE0D4F1EBC5849E6147B1250"><enum>(C)</enum><text display-inline="yes-display-inline">the expedited procedures described in section 506(c)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(c)(3)(B)</external-xref>).</text></subparagraph></paragraph><paragraph id="H2995B0037741491C963F2F3DF7EEA037"><enum>(2)</enum><header>Final guidance</header><text>The Secretary shall issue—</text><subparagraph id="H934674D211EB4E5DB059C9F88BD66546"><enum>(A)</enum><text display-inline="yes-display-inline">draft guidance under paragraph (1) not later than 18 months after the date of enactment of this Act; and</text></subparagraph><subparagraph id="HAB026E80CCBA4F5BA96A4C571B1643DC"><enum>(B)</enum><text>final guidance not later than 1 year after the close of the public comment period on such draft guidance.</text></subparagraph></paragraph></subsection><subsection id="H8DE7D75011F24ECCBCACDED268B0D0E2"><enum>(d)</enum><header>Rare disease endpoint advancement pilot</header><paragraph id="H699AA0C4D07347E2AD17139457DBEAC6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall establish a pilot program under which the Secretary will establish procedures to provide increased interaction with sponsors of rare disease drug development programs for purposes of advancing the development of efficacy endpoints, including surrogate and intermediate endpoints, for drugs intended to treat rare diseases, including through—</text><subparagraph id="H75E665D53F9C4B4A88235DDCB7CE4F27"><enum>(A)</enum><text display-inline="yes-display-inline">determining eligibility of participants for such a program; and</text></subparagraph><subparagraph id="HA32775701F4342D6A2E154E9BECEB5F7"><enum>(B)</enum><text display-inline="yes-display-inline">developing and implementing a process for applying to, and participating in, such a program.</text></subparagraph></paragraph><paragraph id="H6E4382A965C24E9F92460DFAF21893FA"><enum>(2)</enum><header>Public workshops</header><text>The Secretary shall conduct up to 3 public workshops, which shall be completed not later than September 30, 2026, to discuss topics relevant to the development of endpoints for rare diseases, which may include discussions about—</text><subparagraph id="HD60BF5D4ECED43A1BC461AC2081D8174"><enum>(A)</enum><text>novel endpoints developed through the pilot program established under this subsection; and</text></subparagraph><subparagraph id="HA84DB2A802C248E68A91B661046D8B8F"><enum>(B)</enum><text display-inline="yes-display-inline">as appropriate, the use of real world evidence and real world data to support the validation of efficacy endpoints, including surrogate and intermediate endpoints, for rare diseases.</text></subparagraph></paragraph><paragraph id="H6A7D9F29D5D544858474387089BAA123"><enum>(3)</enum><header>Report</header><text>Not later than September 30, 2027, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the outcomes of the pilot program established under this subsection.</text></paragraph><paragraph id="H7CA0F70F8BB04E62A9F30E6244B4012D"><enum>(4)</enum><header>Guidance</header><text display-inline="yes-display-inline">Not later than September 30, 2027, the Secretary shall issue guidance describing best practices and strategies for development of efficacy endpoints, including surrogate and intermediate endpoints, for rare diseases.</text></paragraph><paragraph id="H4BDD695742614084B68D11B464331A51"><enum>(5)</enum><header>Sunset</header><text display-inline="yes-display-inline">The Secretary may not accept any new application or request to participate in the program established by this subsection on or after October 1, 2027.</text></paragraph></subsection></section><section id="H5D9A9876CADE479ABC84D59B061BAD7D"><enum>805.</enum><header>Facilitating the use of real world evidence</header><subsection id="HABF02A54F1DF434F90BC6189BF66BBE9"><enum>(a)</enum><header>Guidance</header><text>Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue, or revise existing, guidance on considerations for the use of real world data and real world evidence to support regulatory decisionmaking, as follows:</text><paragraph id="H80285F210006422FA58F626439BD15C7"><enum>(1)</enum><text>With respect to drugs, such guidance shall address—</text><subparagraph id="H721414BF9E234262B525AE9F25CBEFC2"><enum>(A)</enum><text display-inline="yes-display-inline">the use of such data and evidence to support the approval of a drug application under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or a biological product application under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), or to support an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act or section 351(a)(3) of the Public Health Service Act; and</text></subparagraph><subparagraph id="H0CC6A3E8DFDA49B8B3E0A52115D6A666"><enum>(B)</enum><text display-inline="yes-display-inline">the use of such data and evidence obtained as a result of the use of drugs authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3</external-xref>) in such applications, submissions, or requests; and</text></subparagraph><subparagraph id="H955EE290AADE449389B95E73C32B7BF7"><enum>(C)</enum><text>standards and methodologies which may be used for collection and analysis of real world evidence included in such applications, submissions, or requests, as appropriate.</text></subparagraph></paragraph><paragraph id="H62EC62834E97411AAC1A727AA5C6556F"><enum>(2)</enum><text>With respect to devices, such guidance shall address—</text><subparagraph id="H7AD62820CDDC4EFFBF4C6DA75440868A"><enum>(A)</enum><text>the use of such data and evidence to support the approval, clearance, or classification of a device pursuant to an application or submission submitted under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>, 360c(f)(2), 360e), or to support an investigational use exemption under section 520(g) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(g)</external-xref>);</text></subparagraph><subparagraph id="H4721F13BFCFC46D8B17C9FAFCEB33B9E"><enum>(B)</enum><text display-inline="yes-display-inline">the use of such data and evidence obtained as a result of the use of devices authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3</external-xref>), in such applications, submissions, or requests; and</text></subparagraph><subparagraph id="H8535314468234DD0959435D3F7558B34"><enum>(C)</enum><text display-inline="yes-display-inline">standards and methodologies which may be used for collection and analysis of real world evidence included in such applications, submissions, or requests, as appropriate.</text></subparagraph></paragraph></subsection><subsection id="H11E6537B1D97432FBA7F19C00D58E6DA"><enum>(b)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 2 years after the termination of the public health emergency determination by the Secretary of Health and Human Services under section 564 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3</external-xref>) on February 4, 2020, with respect to the Coronavirus Disease 2019 (COVID–19), the Secretary shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate on—</text><paragraph id="H17B23DCF51434A1A905E71ABC3BEEC25"><enum>(1)</enum><text display-inline="yes-display-inline">the number of applications, submissions, or requests submitted for clearance or approval under section 505, 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), 360c(f)(2), 360e) or section 351 of the Public Health Service Act, for which an authorization under section 564 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3</external-xref>) was previously granted;</text></paragraph><paragraph id="H89678BB0CD8D4F84AC34AEC7ECAC7B59"><enum>(2)</enum><text>of the number of applications so submitted, the number of such applications—</text><subparagraph id="HFE577AA8ABAD44EAA390F8EDD0932081"><enum>(A)</enum><text>for which real world evidence was submitted and used to support a regulatory decision; and</text></subparagraph><subparagraph id="H158B8D3F50644692AF49E35063C36CBF"><enum>(B)</enum><text display-inline="yes-display-inline">for which real world evidence was submitted and determined to be insufficient to support a regulatory decision; and</text></subparagraph></paragraph><paragraph id="H3DA94D2E25214B7C9CEE76894F286385"><enum>(3)</enum><text>a summary explanation of why, in the case of applications described in paragraph (2)(B), real world evidence could not be used to support regulatory decisions.</text></paragraph></subsection><subsection id="H195B071F1C9745B1BBF6CC20822A6CD7"><enum>(c)</enum><header>Information disclosure</header><text display-inline="yes-display-inline">Nothing in this section shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 1905 of title 18, United States Code, or subject to withholding under subsection (b)(4) of section 552 of title 5, United States Code (commonly referred to as the <quote>Freedom of Information Act</quote>).</text></subsection></section><section id="H38E5D9571ADA4A99A921184A9C2246E3" commented="no"><enum>806.</enum><header>Dual Submission for Certain Devices</header><text display-inline="no-display-inline">Section 513 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c</external-xref>) is amended by adding at the end the following: </text><quoted-block style="traditional" id="H90FE75AFF9BB48549A4724BB3F4C995D" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H7E75E8F1F5064F98B5B6946B6AE376E7" commented="no"><enum>(k)</enum><text display-inline="yes-display-inline">For a device authorized for emergency use under section 564 for which, in accordance with section 564(m), the Secretary has deemed a laboratory examination or procedure associated with such device to be in the category of examinations and procedures described in section 353(d)(3) of the Public Health Service Act, the sponsor of such device may, when submitting a request for classification under section 513(f)(2), submit a single submission containing—</text><paragraph id="HB08E2D1E9A2D422E93C380311D50EB07" commented="no"><enum>(1)</enum><text>the information needed for such a request; and </text></paragraph><paragraph id="HED5FCF3E676B4FA5A040A5A3A8FB6778" commented="no"><enum>(2)</enum><text>sufficient information to enable the Secretary to determine whether such laboratory examination or procedure satisfies the criteria to be categorized under section 353(d)(3) of the Public Health Service Act.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H6D4F2FBAF95D4CC5966F53BED0C30064"><enum>807.</enum><header>Medical Devices Advisory Committee meetings</header><subsection id="HC932191BCF624BF9A1912793D438B377"><enum>(a)</enum><header>In general</header><text>The Secretary shall convene one or more panels of the Medical Devices Advisory Committee not less than once per year for the purpose of providing advice to the Secretary on topics related to medical devices used in pandemic preparedness and response, including topics related to in vitro diagnostics.</text></subsection><subsection id="H3FE05AE7170441738EC6DAAA98AF2C94"><enum>(b)</enum><header>Required panel member</header><text>A panel convened under subsection (a) shall include at least 1 population health-specific representative.</text></subsection><subsection id="H0FDFAE147C23491AA5ED13FF9E61331F"><enum>(c)</enum><header>Sunset</header><text>This section shall cease to be effective on October 1, 2027.</text></subsection></section><section id="HF3FE18236476478081B2C7BC2BC7E50E"><enum>808.</enum><header>Ensuring cybersecurity of medical devices</header><subsection id="H1B9B9804967D415397D55B41A65F1509"><enum>(a)</enum><header>In general</header><text>Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>), as amended by section 501, is further amended by adding at the end the following:</text><quoted-block id="HDD415B273C914FCB9F7EFB7C2324FEBF" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><section id="HE0037C4D86DF40279C4B22988C4BC4F7"><enum>524C.</enum><header>Ensuring cybersecurity of devices</header><subsection id="H8A689B31CB104F0BAEF2EAA5D1B856B7"><enum>(a)</enum><header>In general</header><text>For purposes of ensuring cybersecurity throughout the lifecycle of a cyber device, any person who submits a premarket submission for the cyber device shall include such information as the Secretary may require to ensure that the cyber device meets such cybersecurity requirements as the Secretary determines to be appropriate to demonstrate a reasonable assurance of safety and effectiveness, including at a minimum the cybersecurity requirements under subsection (b).</text></subsection><subsection id="HD612FAC8CC1E4B2F9477B1EE5C80F8CA"><enum>(b)</enum><header>Cybersecurity requirements</header><text>At a minimum, the manufacturer of a cyber device shall meet the following cybersecurity requirements:</text><paragraph id="H6FDD915912BA4DBE8FC0C6B022FE7EA2"><enum>(1)</enum><text>The manufacturer shall have a plan to appropriately monitor, identify, and address in a reasonable time postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and procedures.</text></paragraph><paragraph id="H41DFDBD671454B3A8C90B5C54BE9E868"><enum>(2)</enum><text>The manufacturer shall design, develop, and maintain processes and procedures to ensure the device and related systems are cybersecure, and shall make available updates and patches to the cyber device and related systems throughout the lifecycle of the cyber device to address—</text><subparagraph id="H24DA1F0BCEC24DD4BD087C13AE3FCBDE"><enum>(A)</enum><text>on a reasonably justified regular cycle, known unacceptable vulnerabilities; and</text></subparagraph><subparagraph id="H60E5492730E640FD9CDE1BB76549BA81"><enum>(B)</enum><text>as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks.</text></subparagraph></paragraph><paragraph id="HBF20EA541D6242F281826B38BB321BE6"><enum>(3)</enum><text>The manufacturer shall provide in the labeling of the cyber device a software bill of materials, including commercial, open-source, and off-the-shelf software components.</text></paragraph><paragraph id="HE7AE8B6EBEFB4090BECC10DE79E50A52"><enum>(4)</enum><text>The manufacturer shall comply with such other requirements as the Secretary may require to demonstrate reasonable assurance of the safety and effectiveness of the device for purposes of cybersecurity, which the Secretary may require by an order published in the Federal Register.</text></paragraph></subsection><subsection id="H94CA214A75694727BA7C69C96C701811"><enum>(c)</enum><header>Substantial equivalence</header><text>In making a determination of substantial equivalence under section 513(i) for a cyber device, the Secretary may—</text><paragraph id="H77E8A5C4356940DAAC7384F9C06AE934"><enum>(1)</enum><text>find that cybersecurity information for the cyber device described in the relevant premarket submission in the cyber device’s use environment is inadequate; and</text></paragraph><paragraph id="H108DAFFB09274ADE8390E386A56FE709"><enum>(2)</enum><text>issue a nonsubstantial equivalence determination based on this finding.</text></paragraph></subsection><subsection id="H40B84B825CAD4C69A74B98909F6529B6"><enum>(d)</enum><header>Definition</header><text>In this section:</text><paragraph id="H64C59BCD1E8F48408122A31C17D13F3B"><enum>(1)</enum><header>Cyber device</header><text>The term <term>cyber device</term> means a device that—</text><subparagraph id="H2C77ACEB428A4BBABCF9F69380238308"><enum>(A)</enum><text>includes software, including software as or in a device;</text></subparagraph><subparagraph id="H1B4685E9220049C6AEF8239665F9C287"><enum>(B)</enum><text>has the ability to connect to the internet; or</text></subparagraph><subparagraph id="H0D5CE4D4187843D6A2C6AEE7BEC79FAB"><enum>(C)</enum><text>contains any such technological characteristics that could be vulnerable to cybersecurity threats.</text></subparagraph></paragraph><paragraph id="H447C01C28A194318BB19F67094D3B911"><enum>(2)</enum><header>Lifecycle of the cyber device</header><text>The term <term>lifecycle of the cyber device</term> includes the postmarket lifecycle of the cyber device.</text></paragraph><paragraph id="H482618A612FC4DDC992DFA437019B94D"><enum>(3)</enum><header>Premarket submission</header><text>The term <term>premarket submission</term> means any submission under section 510(k), 513, 515(c), 515(f), or 520(m).</text></paragraph></subsection><subsection id="H3D13949BEE6B408B9A3097B08F767954"><enum>(e)</enum><header>Exemption</header><text>The Secretary may identify devices or types of devices that are exempt from meeting the cybersecurity requirements established by this section and regulations promulgated pursuant to this section. The Secretary shall publish in the Federal Register, and update, as appropriate, a list of the devices and types of devices so identified by the Secretary. </text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H058F6AF537C64644B3841CAE18CDC92F"><enum>(b)</enum><header>Prohibited act</header><text>Section 301(q) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331(q)</external-xref>) is amended by adding at the end the following:</text><quoted-block id="HAA75E2E1B8B444869B3107D23B92F9A1" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H2AEF32849B3848218540B3068FEB6611" indent="up1"><enum>(3)</enum><text>The failure to comply with any requirement under section 524C (relating to ensuring device cybersecurity).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H70EB5E24D089401D92DD179C518848B4"><enum>(c)</enum><header>Adulteration</header><text>Section 501 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref>) is amended by inserting after paragraph (j) the following:</text><quoted-block id="HD92CAA1E8DD6455E80835B021CD0F3FE" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H07A94B94C0F340C6BBC2067996BCB888"><enum>(k)</enum><text>If it is a device subject to the requirements set forth in section 524C (relating to ensuring device cybersecurity) and fails to comply with any requirement under that section.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HA3FB73541C6247938586D266C46FA997"><enum>(d)</enum><header>Misbranding</header><text>Section 502(t) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352(t)</external-xref>) is amended—</text><paragraph id="H8B6A19F041C54AE68CBE11FE4ECE02DF"><enum>(1)</enum><text>by striking <quote>or (3)</quote> and inserting <quote>(3)</quote>; and</text></paragraph><paragraph id="HF19AC67B32B241148FD94505830AA48A"><enum>(2)</enum><text>by inserting before the period at the end the following: <quote>, or (4) to furnish a software bill of materials as required under section 524C (relating to ensuring device cybersecurity)</quote>.</text></paragraph></subsection></section><section id="H8DB61ECB6AC946279DA9893C31E8FF01"><enum>809.</enum><header>Public docket on proposed changes to third-party vendors</header><subsection id="H209ADE60E1654D55B0777BD14590025B"><enum>(a)</enum><header>In general</header><paragraph id="H86E98D5D0E8F4DFCB422BD091726BE53"><enum>(1)</enum><header>Opening public docket</header><text>Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services shall open a single public docket to solicit comments on factors that generally should be considered by the Secretary when reviewing requests from sponsors of drugs subject to risk evaluation and mitigation strategies to change third-party vendors engaged by sponsors to aid in implementation and management of the strategies.</text></paragraph><paragraph id="HA6B7354D18184D5EBE8FE9904C3C0867"><enum>(2)</enum><header>Factors</header><text>Such factors include the potential effects of changes in third-party vendors on—</text><subparagraph id="H6208F796EA834FD1BA2B53D85BF3FDFE"><enum>(A)</enum><text>patient access; and</text></subparagraph><subparagraph id="H78A999289D2E453A92DA5237BB9B9DEF"><enum>(B)</enum><text>prescribing and administration of the drugs by health care providers. </text></subparagraph></paragraph><paragraph id="H11BE836A14FA4F70A94506FB2EE9C2D5"><enum>(3)</enum><header>Closing public docket</header><text>The Secretary of Health and Human Services may close such public docket not earlier than 90 days after such docket is opened. </text></paragraph><paragraph id="H1E833BB5870D408B92A152956ACD3DB3"><enum>(4)</enum><header>No delay</header><text>Nothing in this section shall delay agency action on any modification to a risk evaluation and mitigation strategy.</text></paragraph></subsection><subsection id="H3AA37B2F24BE466E886AE7C234DBB129"><enum>(b)</enum><header>GAO report</header><text>Not later than December 31, 2026, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on—</text><paragraph id="H0757E04CA9BB451AA99BC1635664E63A"><enum>(1)</enum><text display-inline="yes-display-inline">the number of changes in third-party vendors (engaged by sponsors to aid implementation and management of risk evaluation and mitigation strategies) for an approved risk evaluation and mitigation strategy the Secretary of Health and Human Services has approved under section 505–1(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(h)</external-xref>);</text></paragraph><paragraph id="H2056843F9EEA4D208031DF4856A00466"><enum>(2)</enum><text display-inline="yes-display-inline">any issues affecting patient access to the drug that is subject to the strategy or considerations with respect to the administration or prescribing of such drug by health care providers that arose as a result of such modifications; and</text></paragraph><paragraph id="H93E0848EC87A4B90A2593210BDADD941"><enum>(3)</enum><text>how such issues were resolved, as applicable.</text></paragraph></subsection></section><section id="H41CF6BEABCA24425BC731014C2E3B022"><enum>810.</enum><header>Facilitating exchange of product information prior to approval</header><subsection id="HAF08296EAF7F4295B31875576461A5C1"><enum>(a)</enum><header>In general</header><text>Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended—</text><paragraph id="HBDE34A3C727F4920B1EEB20B2A044670" commented="no"><enum>(1)</enum><text>in paragraph (a)—</text><subparagraph id="H179560EEDBA44B83979A0F8DC39512DF"><enum>(A)</enum><text>by striking <quote>drugs for coverage</quote> and inserting <quote>drugs or devices for coverage</quote>; and</text></subparagraph><subparagraph id="H7DB17A91686F4B14B0E5F83703162DEB"><enum>(B)</enum><text>by striking <quote>drug</quote> each place it appears and inserting <quote>drug or device</quote>, respectively;</text></subparagraph></paragraph><paragraph id="H05813F14925543D49D1A48ED53802DB2" commented="no"><enum>(2)</enum><text>in paragraphs (a)(1) and (a)(2)(B), by striking <quote>under section 505 or under section 351 of the Public Health Service Act</quote> and inserting <quote>under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>;</text></paragraph><paragraph id="H83F4FAEDD72C48E79163E0AE240E8D3F" commented="no"><enum>(3)</enum><text>in paragraph (a)(1)—</text><subparagraph id="H4E6DD06690F64B6FB6A6922909491C56" commented="no"><enum>(A)</enum><text>by striking <quote>under section 505 or under section 351(a) of the Public Health Service Act</quote> and inserting <quote>under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>; and</text></subparagraph><subparagraph id="H181E1274D4FE44DDB456DD345D5C9474" commented="no"><enum>(B)</enum><text>by striking <quote>in section 505(a) or in subsections (a) and (k) of section 351 of the Public Health Service Act</quote> and inserting <quote>in section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act</quote>; and </text></subparagraph></paragraph><paragraph id="HC20A6402DE884855A159BDC30E47169C"><enum>(4)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="HCB2C341D14194FA783BE4119031646D7" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H58F7B48B418A4BEF8E178589B642ACA1"><enum>(gg)</enum><paragraph commented="no" display-inline="yes-display-inline" id="HCAAF540A15FF433C995A0DEB1F133331"><enum>(1)</enum><text>Unless its labeling bears adequate directions for use in accordance with paragraph (f), except that (in addition to drugs or devices that conform with exemptions pursuant to such paragraph) no drug or device shall be deemed to be misbranded under such paragraph through the provision of product information to a payor, formulary committee, or other similar entity with knowledge and expertise in the area of health care economic analysis carrying out its responsibilities for the selection of drugs or devices for coverage or reimbursement if the product information relates to an investigational drug or device or investigational use of a drug or device that is approved, cleared, granted marketing authorization, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable), provided—</text><subparagraph id="HA0894D7705A249BD8A97E9E7B83911D6" indent="up1"><enum>(A)</enum><text>the product information includes—</text><clause id="H75CF82760D8645DCA67F5E704CEE1A09"><enum>(i)</enum><text>a clear statement that the investigational drug or device or investigational use of a drug or device has not been approved, cleared, granted marketing authorization<italic></italic>, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable) and that the safety and effectiveness of the drug or device or use has not been established; </text></clause><clause id="HE14F8199DFDE44EFAE84479F6A6209DE"><enum>(ii)</enum><text>information related to the stage of development of the drug or device involved, such as—</text><subclause id="H5AB2646A166E41F789C4A98CF76A378B"><enum>(I)</enum><text>the status of any study or studies in which the investigational drug or device or investigational use is being investigated;</text></subclause><subclause id="H3A4F94AE5F0C432B918EB09D407A99AC"><enum>(II)</enum><text>how the study or studies relate to the overall plan for the development of the drug or device; and</text></subclause><subclause id="H76CA32118DF843F0A2B48233D78AF3FF"><enum>(III)</enum><text display-inline="yes-display-inline">whether an application, premarket notification, or request for classification for the investigational drug or device or investigational use has been submitted to the Secretary and when such a submission is planned; </text></subclause></clause><clause id="HD43FAC5AAA044D50B8DAC36108A4697C"><enum>(iii)</enum><text>in the case of information that includes factual presentations of results from studies, which shall not be selectively presented, a description of—</text><subclause id="HECF01D050F9C48E4A1E606D8D46FA47C"><enum>(I)</enum><text>all material aspects of study design, methodology, and results; and</text></subclause><subclause id="H8A6CD447883C4E17B9CA38A496209A9F"><enum>(II)</enum><text>all material limitations related to the study design, methodology, and results;</text></subclause></clause><clause id="HD5CE65E24DB84832B22C45EDA13EA285"><enum>(iv)</enum><text>where applicable, a prominent statement disclosing the indication or indications for which the Secretary has approved, granted marketing authorization<italic></italic>, cleared, or licensed the product pursuant to section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act, and a copy of the most current required labeling; and</text></clause><clause id="HDEFF5A4B909346D39B89F64080B4E5C8"><enum>(v)</enum><text>updated information, if previously communicated information becomes materially outdated as a result of significant changes or as a result of new information regarding the product or its review status; and</text></clause></subparagraph><subparagraph id="HFA8E84F355004A138BE9C12708297A1F" indent="up1"><enum>(B)</enum><text>the product information does not include—</text><clause id="H129A44463BF04542A7E2534F8E511FD8"><enum>(i)</enum><text display-inline="yes-display-inline">information that represents that an unapproved product—</text><subclause id="HAAADA8446962408CB23E930C48E953E1"><enum>(I)</enum><text>has been approved, cleared, granted marketing authorization, or licensed under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act (as applicable); or</text></subclause><subclause id="H269B07F3BF7C4700929431FECC48E5C5"><enum>(II)</enum><text>has otherwise been determined to be safe or effective for the purpose or purposes for which the drug or device is being studied; or</text></subclause></clause><clause id="H1DD4870C2CD348C68CCF81D915ABA82A"><enum>(ii)</enum><text>information that represents that an unapproved use of a drug or device that has been so approved, granted marketing authorization, cleared, or licensed—</text><subclause id="HABF92BC330284CD69D679F48D28F8F5C"><enum>(I)</enum><text>is so approved, granted marketing authorization, cleared, or licensed; or</text></subclause><subclause id="H3A4709B9D1FF4A99A13BED09947CCB82"><enum>(II)</enum><text>that the product is safe or effective for the use or uses for which the drug or device is being studied.</text></subclause></clause></subparagraph></paragraph><paragraph id="H73EC5459F1E74C77A4BCF18BE38495DE" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">For purposes of this paragraph, the term <term>product information</term> includes—</text><subparagraph id="H1928757BE3224ABA8A8DB5306A0FE02B"><enum>(A)</enum><text>information describing the drug or device (such as drug class, device description, and features);</text></subparagraph><subparagraph id="H659EBE5EF41C400B8B43B768DDCE4D22"><enum>(B)</enum><text>information about the indication or indications being investigated;</text></subparagraph><subparagraph id="H4E6C0CED777F4425A7B9A89494EEF979"><enum>(C)</enum><text>the anticipated timeline for a possible approval, clearance, marketing authorization, or licensure pursuant to section 505, 510(k), 513, or 515 of this Act or section 351 of the Public Health Service Act;</text></subparagraph><subparagraph id="H96B1583ACEE441AF89DA4B140E1DB2F6"><enum>(D)</enum><text>drug or device pricing information;</text></subparagraph><subparagraph id="HD7F2164B1FA84BA18AA7D41F5290A851"><enum>(E)</enum><text>patient utilization projections;</text></subparagraph><subparagraph id="HB0D79DB448724201B839F055B390B308"><enum>(F)</enum><text>product-related programs or services; and</text></subparagraph><subparagraph id="H4027B0E70EA448E2AE17665E097464C5"><enum>(G)</enum><text>factual presentations of results from studies that do not characterize or make conclusions regarding safety or efficacy.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H1FC04B0CD03D4E64A76E63285D072FF9"><enum>(b)</enum><header>GAO study and report</header><text>Beginning on the date that is 5 years and 6 months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study on the provision and use of information pursuant to section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by this subsection (a), between manufacturers of drugs and devices (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>)) and entities described in such section 502(gg). Such study shall include an analysis of the following:</text><paragraph id="HA4A01BCADAB749A8B1EFFD2820239659"><enum>(1)</enum><text>The types of information communicated between such manufacturers and payors.</text></paragraph><paragraph id="H494B224545F24BE19C42A3526DA6069E"><enum>(2)</enum><text>The manner of communication between such manufacturers and payors.</text></paragraph><paragraph id="H2D305D9A7FA343319456A4BCE791626A"><enum>(3)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H23E39C34D8F247C2BC60DFCCC8859E26"><enum>(A)</enum><text>Whether such manufacturers file an application for approval, marketing authorization, clearance, or licensing of a new drug or device or the new use of a drug or device that is the subject of communication between such manufacturers and payors under section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a).</text></subparagraph><subparagraph id="H40007409D94242DE9C199C6038B9BBB2" indent="up1"><enum>(B)</enum><text>How frequently the Food and Drug Administration approves, grants marketing authorization, clears, or licenses the new drug or device or new use.</text></subparagraph><subparagraph id="H5EDCC15CCB614E22B011594AE7B91647" indent="up1"><enum>(C)</enum><text>The timeframe between the initial communications permitted under section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), regarding an investigational drug or device or investigational use, and the initial marketing of such drug or device.</text></subparagraph></paragraph></subsection></section><section id="HDD334399F0F84A71980FBDE306A667CE"><enum>811.</enum><header>Bans of devices for one or more intended uses</header><subsection id="H884F2E621B924F29AD452ADD5A3C0469"><enum>(a)</enum><header>In general</header><text>Section 516(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360f">21 U.S.C. 360f(a)</external-xref>) is amended—</text><paragraph id="H876348B377D84C4485CC4D5B3FDDCE81"><enum>(1)</enum><text>in paragraph (1), by inserting <quote>for one or more intended use</quote> before the semicolon at the end; and</text></paragraph><paragraph id="H942582848D82416BB3209AA96D7CB544"><enum>(2)</enum><text>in the matter following paragraph (2), by inserting <quote>for any such intended use or uses. A device that is banned for one or more intended uses is not a legally marketed device under section 1006 when intended for such use or uses</quote> after <quote>banned device</quote>.</text></paragraph></subsection><subsection id="H16C64D6D5F864B9689F5C27CDA93B8B2"><enum>(b)</enum><header>Specific devices deemed banned</header><text>Section 516 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360f">21 U.S.C. 360f</external-xref>) is further amended by adding at the end the following:</text><quoted-block id="H0796D69662AB4CEF83AABED1C7EAAEB8" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="HF0439AEB91324A088FC102692FEE2530"><enum>(c)</enum><header>Specific device banned</header><text>Electrical stimulation devices that apply a noxious electrical stimulus to a person’s skin intended to reduce or cease self-injurious behavior or aggressive behavior are deemed to be banned devices, as described in subsection (a).</text></subsection><subsection id="H563D0239D113412DB2C3A04B36C8F301"><enum>(d)</enum><header>Reversal by regulation</header><text display-inline="yes-display-inline">Devices banned under this section are banned devices unless or until the Secretary promulgates a regulation to make such devices or use of such devices no longer banned based on a finding that such devices or use of such devices does not present substantial deception or an unreasonable and substantial risk of illness or injury, or that such risk can be corrected or eliminated by labeling.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H33CC9FE097634ECEAE2E602951102FEA" section-type="subsequent-section"><enum>812.</enum><header>Clarifying application of exclusive approval, certification, or licensure for drugs designated for rare diseases or conditions</header><subsection id="H37FA40243D2044C8A2E3BD75FAE69CD5"><enum>(a)</enum><header>Application of exclusive approval, certification, or licensure for drugs designated for rare diseases or conditions</header><text display-inline="yes-display-inline">Section 527 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360cc">21 U.S.C. 360cc</external-xref>) is amended—</text><paragraph id="HD3336E065F82418C9A80651E070F3B84"><enum>(1)</enum><text>in subsection (a), in the matter following paragraph (2), by striking <quote>same disease or condition</quote> and inserting <quote>same approved indication or use within such rare disease or condition</quote>;</text></paragraph><paragraph id="HB19DA1779EE248ABBDBCD962068E4C62"><enum>(2)</enum><text>in subsection (b)—</text><subparagraph id="H37BDDDD44D1C4264B183BAC87A963B13"><enum>(A)</enum><text>in the matter preceding paragraph (1), by striking <quote>same rare disease or condition</quote> and inserting <quote>same indication or use for which the Secretary has approved or licensed such drug</quote>; and</text></subparagraph><subparagraph id="HC1AE1D6CCB3449BEB873D53123BCF1AE"><enum>(B)</enum><text>in paragraph (1), by striking <quote>with the disease or condition for which the drug was designated</quote> and inserting <quote>for whom the drug is indicated</quote>; and</text></subparagraph></paragraph><paragraph id="HAB8EC572BC7F4497B1841C3CBBC19C18"><enum>(3)</enum><text>in subsection (c), by striking <quote>same rare disease or condition</quote> and inserting <quote>same indication or use</quote>.</text></paragraph></subsection><subsection id="H14BDEFF6F30045DB95B9B8BA0B07DE3F"><enum>(b)</enum><header>Application of amendments</header><text display-inline="yes-display-inline">The amendments made by subsection (a) shall apply with respect to any drug designated under section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>), regardless of the date on which the drug was so designated, and regardless of the date on which the drug was approved under section 505 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>). </text></subsection></section><section id="H8DAEBA3C1DDB4130919C271E2EEE5599"><enum>813.</enum><header>GAO report on third-party review</header><text display-inline="no-display-inline">Not later than September 30, 2026, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the third-party review program described in section 523 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360m">21 U.S.C. 360m</external-xref>). Such report shall include—</text><paragraph id="H3949184B24A541BBA22CFB260DDEFEC1"><enum>(1)</enum><text>a description of the financial and staffing resources used to carry out such program; </text></paragraph><paragraph id="H1F63DE8E847247268EB586EA84E273F3"><enum>(2)</enum><text display-inline="yes-display-inline">a description of actions taken by the Secretary pursuant section 523(b)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360m">21 U.S.C. 360m(b)(2)(C)</external-xref>); and </text></paragraph><paragraph id="HF5F4CAD8FE1E4E419C9D0855D33BACB6"><enum>(3)</enum><text>the results of an audit of the performance of select persons accredited under such program.</text></paragraph></section><section id="H14DA16CF3AE642FFB9AE628AC6806CCB"><enum>814.</enum><header>Reporting on pending generic drug applications and priority review applications</header><text display-inline="no-display-inline">Section 807 of the FDA Reauthorization Act of 2017 (<external-xref legal-doc="public-law" parsable-cite="pl/115/52">Public Law 115–52</external-xref>) is amended, in the matter preceding paragraph (1), by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></section><section id="H4D5095118BD24C83A7A3288FC3B96454"><enum>815.</enum><header>FDA Workforce Improvements</header><text display-inline="no-display-inline">Section 714A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379d-3a">21 U.S.C. 379d–3a</external-xref>) is amended—</text><paragraph id="HC0A2E4ABE6E84EDB89394A82708C0344"><enum>(1)</enum><text>in subsection (a), by striking <quote>medical products</quote> and inserting <quote>products regulated by the Food and Drug Administration</quote>; and</text></paragraph><paragraph id="H1C11B24EA8214F37915AE5320BAA3F84"><enum>(2)</enum><text>by striking subsection (d) and inserting the following:</text><quoted-block style="OLC" id="HA5C7293EB9BB476CBFCB72466ED5EA49" display-inline="no-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H9CFF1C1809C14BB392910596715BCB15"><enum>(d)</enum><header>Agency-wide strategic workforce plan</header><paragraph id="H03894EB2689945CC9AEBBC8E32B490B4"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of the Food and Drug Amendments of 2022, the Commissioner of Food and Drugs shall develop and begin implementation of an agency-wide strategic workforce plan at the Food and Drug Administration, which shall include—</text><subparagraph id="H78DE8C885949499CB4D8934E768C459E"><enum>(A)</enum><text display-inline="yes-display-inline">agency-wide human capital goals and strategies; </text></subparagraph><subparagraph id="H06031985C45A49478263BF6550F64929"><enum>(B)</enum><text display-inline="yes-display-inline">performance measures, benchmarks, or other elements to facilitate the monitoring and evaluation of the progress made toward such goals and the effectiveness of such strategies; and</text></subparagraph><subparagraph id="H8C561F4A7109443A911FE5BC41B1444D"><enum>(C)</enum><text>a process for updating such plan based on timely and relevant information on an ongoing basis.</text></subparagraph></paragraph><paragraph id="HAB1E3F168BDD44A6BEBDA9E728FAD580"><enum>(2)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of the <short-title>Food and Drug Amendments of 2022</short-title>, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the plan under paragraph (1) and the status of its implementation.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></title></legis-body><endorsement display="yes"><action-date date="20220607">June 7, 2022</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc></endorsement></bill> 

